<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"MT Extra";
	panose-1:5 5 1 2 1 2 5 2 2 2;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Alef;}
@font-face
	{font-family:"Amasis MT Pro";}
@font-face
	{font-family:"Amasis MT Pro Black";}
@font-face
	{font-family:"Amasis MT Pro Light";}
@font-face
	{font-family:"Amasis MT Pro Medium";}
@font-face
	{font-family:"Amatic SC";}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Aref Ruqaa";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:Assistant;}
@font-face
	{font-family:"Assistant ExtraBold";}
@font-face
	{font-family:"Assistant ExtraLight";}
@font-face
	{font-family:"Assistant Light";}
@font-face
	{font-family:"Assistant SemiBold";}
@font-face
	{font-family:Athiti;}
@font-face
	{font-family:"Athiti ExtraLight";}
@font-face
	{font-family:"Athiti Light";}
@font-face
	{font-family:"Athiti Medium";}
@font-face
	{font-family:"Athiti SemiBold";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Demi";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Bierstadt;}
@font-face
	{font-family:"Bierstadt Display";}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Charmonman;}
@font-face
	{font-family:Chonburi;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"EB Garamond";}
@font-face
	{font-family:"EB Garamond ExtraBold";}
@font-face
	{font-family:"EB Garamond Medium";}
@font-face
	{font-family:"EB Garamond SemiBold";}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:Fahkwang;}
@font-face
	{font-family:"Fahkwang ExtraLight";}
@font-face
	{font-family:"Fahkwang Light";}
@font-face
	{font-family:"Fahkwang Medium";}
@font-face
	{font-family:"Fahkwang SemiBold";}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:"Frank Ruhl Libre";}
@font-face
	{font-family:"Frank Ruhl Libre Black";}
@font-face
	{font-family:"Frank Ruhl Libre Light";}
@font-face
	{font-family:"Frank Ruhl Libre Medium";}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:"Goudy Type";}
@font-face
	{font-family:Grandview;}
@font-face
	{font-family:"Grandview Display";}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:Heebo;}
@font-face
	{font-family:"Heebo Black";}
@font-face
	{font-family:"Heebo ExtraBold";}
@font-face
	{font-family:"Heebo Light";}
@font-face
	{font-family:"Heebo Medium";}
@font-face
	{font-family:"Heebo Thin";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:Krub;}
@font-face
	{font-family:"Krub ExtraLight";}
@font-face
	{font-family:"Krub Light";}
@font-face
	{font-family:"Krub Medium";}
@font-face
	{font-family:"Krub SemiBold";}
@font-face
	{font-family:Lalezar;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Miriam Libre";}
@font-face
	{font-family:Mitr;}
@font-face
	{font-family:"Mitr ExtraLight";}
@font-face
	{font-family:"Mitr Light";}
@font-face
	{font-family:"Mitr Medium";}
@font-face
	{font-family:"Mitr SemiBold";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Open Sans";}
@font-face
	{font-family:"Open Sans ExtraBold";}
@font-face
	{font-family:"Open Sans Light";}
@font-face
	{font-family:"Open Sans SemiBold";}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:Pridi;}
@font-face
	{font-family:"Pridi ExtraLight";}
@font-face
	{font-family:"Pridi Light";}
@font-face
	{font-family:"Pridi Medium";}
@font-face
	{font-family:"Pridi SemiBold";}
@font-face
	{font-family:Prompt;}
@font-face
	{font-family:"Prompt Black";}
@font-face
	{font-family:"Prompt ExtraBold";}
@font-face
	{font-family:"Prompt ExtraLight";}
@font-face
	{font-family:"Prompt Light";}
@font-face
	{font-family:"Prompt Medium";}
@font-face
	{font-family:"Prompt SemiBold";}
@font-face
	{font-family:"Prompt Thin";}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Reem Kufi";}
@font-face
	{font-family:Roboto;}
@font-face
	{font-family:"Roboto Black";}
@font-face
	{font-family:"Roboto Condensed";}
@font-face
	{font-family:"Roboto Condensed Light";}
@font-face
	{font-family:"Roboto Condensed Medium";}
@font-face
	{font-family:"Roboto Light";}
@font-face
	{font-family:"Roboto Medium";}
@font-face
	{font-family:"Roboto Thin";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Seaford;}
@font-face
	{font-family:"Seaford Display";}
@font-face
	{font-family:"Secular One";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:Skeena;}
@font-face
	{font-family:"Skeena Display";}
@font-face
	{font-family:"Source Code Pro";}
@font-face
	{font-family:"Source Code Pro Black";}
@font-face
	{font-family:"Source Code Pro ExtraLight";}
@font-face
	{font-family:"Source Code Pro Light";}
@font-face
	{font-family:"Source Code Pro Medium";}
@font-face
	{font-family:"Source Code Pro Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Source Serif Pro";}
@font-face
	{font-family:"Source Serif Pro Black";}
@font-face
	{font-family:"Source Serif Pro ExtraLight";}
@font-face
	{font-family:"Source Serif Pro Light";}
@font-face
	{font-family:"Source Serif Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"Suez One";}
@font-face
	{font-family:Tenorite;}
@font-face
	{font-family:"Tenorite Display";}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:Trirong;}
@font-face
	{font-family:"Trirong Black";}
@font-face
	{font-family:"Trirong ExtraBold";}
@font-face
	{font-family:"Trirong ExtraLight";}
@font-face
	{font-family:"Trirong Light";}
@font-face
	{font-family:"Trirong Medium";}
@font-face
	{font-family:"Trirong SemiBold";}
@font-face
	{font-family:"Trirong Thin";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:9.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.MsoFootnoteReference
	{font-family:"Verdana",sans-serif;
	vertical-align:super;}
span.MsoPageNumber
	{font-family:"Times New Roman",serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{font-family:"Times New Roman",serif;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-weight:bold;
	font-style:italic;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Arial",sans-serif;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Arial",sans-serif;
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Arial",sans-serif;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Arial",sans-serif;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.EMEATableCentered, li.EMEATableCentered, div.EMEATableCentered
	{mso-style-name:"EMEA Table Centered";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATableLeft, li.EMEATableLeft, div.EMEATableLeft
	{mso-style-name:"EMEA Table Left";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEABodyTextIndent, li.EMEABodyTextIndent, div.EMEABodyTextIndent
	{mso-style-name:"EMEA Body Text Indent";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEABodyText, li.EMEABodyText, div.EMEABodyText
	{mso-style-name:"EMEA Body Text";
	mso-style-link:"EMEA Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATitle, li.EMEATitle, div.EMEATitle
	{mso-style-name:"EMEA Title";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAHeading1NoIndent, li.EMEAHeading1NoIndent, div.EMEAHeading1NoIndent
	{mso-style-name:"EMEA Heading 1 No Indent";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading3, li.EMEAHeading3, div.EMEAHeading3
	{mso-style-name:"EMEA Heading 3";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAHeading1, li.EMEAHeading1, div.EMEAHeading1
	{mso-style-name:"EMEA Heading 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading2, li.EMEAHeading2, div.EMEAHeading2
	{mso-style-name:"EMEA Heading 2";
	mso-style-link:"EMEA Heading 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAAddress, li.EMEAAddress, div.EMEAAddress
	{mso-style-name:"EMEA Address";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAComment, li.EMEAComment, div.EMEAComment
	{mso-style-name:"EMEA Comment";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Times New Roman",serif;}
p.EMEAHiddenTitlePIL, li.EMEAHiddenTitlePIL, div.EMEAHiddenTitlePIL
	{mso-style-name:"EMEA Hidden Title PIL";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.EMEAHiddenTitlePAC, li.EMEAHiddenTitlePAC, div.EMEAHiddenTitlePAC
	{mso-style-name:"EMEA Hidden Title PAC";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.BMSInstructionText
	{mso-style-name:"BMS Instruction Text";
	font-family:"Times New Roman",serif;
	color:red;
	display:none;
	font-style:italic;
	text-decoration:none;
	vertical-align:baseline;}
span.EMEASubscript
	{mso-style-name:"EMEA Subscript";
	vertical-align:sub;}
span.EMEASuperscript
	{mso-style-name:"EMEA Superscript";
	vertical-align:super;}
p.EMEATableHeader, li.EMEATableHeader, div.EMEATableHeader
	{mso-style-name:"EMEA Table Header";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Times New Roman",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Times New Roman",serif;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Times New Roman",serif;}
p.EMEATitlePAC, li.EMEATitlePAC, div.EMEATitlePAC
	{mso-style-name:"EMEA Title PAC";
	margin:0in;
	page-break-after:avoid;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.EMEABodyTextChar
	{mso-style-name:"EMEA Body Text Char";
	mso-style-link:"EMEA Body Text";
	font-family:"Times New Roman",serif;}
span.EMEAHeading2Char
	{mso-style-name:"EMEA Heading 2 Char";
	mso-style-link:"EMEA Heading 2";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
p.news-date, li.news-date, div.news-date
	{mso-style-name:news-date;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-weight:bold;}
p.bodytextagency, li.bodytextagency, div.bodytextagency
	{mso-style-name:bodytextagency;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.BodytextAgency0, li.BodytextAgency0, div.BodytextAgency0
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.No-numheading1Agency, li.No-numheading1Agency, div.No-numheading1Agency
	{mso-style-name:"No-num heading 1 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading2Agency, li.No-numheading2Agency, div.No-numheading2Agency
	{mso-style-name:"No-num heading 2 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.BodytextAgencyCarattere, li.BodytextAgencyCarattere, div.BodytextAgencyCarattere
	{mso-style-name:"Body text \(Agency\) Carattere";
	mso-style-link:"Body text \(Agency\) Carattere Carattere";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyCarattereCarattere
	{mso-style-name:"Body text \(Agency\) Carattere Carattere";
	mso-style-link:"Body text \(Agency\) Carattere";
	font-family:"Verdana",sans-serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 841.95pt;
	margin:56.7pt 70.85pt 56.7pt 70.85pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>ANNEX I</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;75&nbsp;mg tablets.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Each tablet contains 75&nbsp;mg of
irbesartan.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Excipient with known effect</span></u><span
lang=EN-GB>: 15.37&nbsp;mg of lactose monohydrate per tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For the full list of excipients, see
section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB>White to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2771 engraved
on the other side.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>4. CLINICAL PARTICULARS</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.1 Therapeutic indications</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Karvea is
indicated in adults for the treatment of essential hypertension.</span></p>

<p class=EMEABodyText><span lang=EN-GB>It is also indicated for the treatment
of renal disease in adult patients with hypertension and type&nbsp;2 diabetes
mellitus as part of an antihypertensive medicinal product regimen (see sections
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.2 Posology and method of
administration</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>The usual
recommended initial and maintenance dose is 150&nbsp;mg once daily, with or
without food. Karvea at a dose of 150&nbsp;mg once daily generally provides a
better 24&nbsp;hour blood pressure control than 75&nbsp;mg. However, initiation
of therapy with 75&nbsp;mg could be considered, particularly in haemodialysed
patients and in the elderly over 75&nbsp;years.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients insufficiently controlled with
150&nbsp;mg once daily, the dose of Karvea can be increased to 300&nbsp;mg, or
other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1).
In particular, the addition of a diuretic such as hydrochlorothiazide has been
shown to have an additive effect with Karvea (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In hypertensive type&nbsp;2 diabetic
patients, therapy should be initiated at 150&nbsp;mg irbesartan once daily and
titrated up to 300&nbsp;mg once daily as the preferred maintenance dose for
treatment of renal disease.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The demonstration of renal benefit of Karvea
in hypertensive type&nbsp;2 diabetic patients is based on studies where
irbesartan was used in addition to other antihypertensive agents, as needed, to
reach target blood pressure (see sections 4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Special Populations</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><span lang=EN-GB>Renal impairment</span></i><span
lang=EN-GB> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No dosage adjustment is necessary in
patients with impaired renal function. A lower starting dose (75&nbsp;mg)
should be considered for patients undergoing haemodialysis (see section 4.4).</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No dosage adjustment is necessary in
patients with mild to moderate hepatic impairment. There is no clinical
experience in patients with severe hepatic impairment.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><i><span lang=EN-GB>Older people</span></i><span
lang=EN-GB> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Although consideration should be given
to initiating therapy with 75&nbsp;mg in patients over 75&nbsp;years of age,
dosage adjustment is not usually necessary for theolder people.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><i><span lang=EN-GB>Paediatric population</span></i><span
lang=EN-GB> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of Karvea in
children aged 0 to 18 has not been established. Currently available data are
described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can
be made.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Method of Administration</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.3 Contraindications</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Second and third trimesters of pregnancy
(see sections&nbsp;4.4 and&nbsp;4.6).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The concomitant use of Karvea with
aliskiren-containing products is contraindicated in patients with diabetes
mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60
ml/min/1.73m<sup>2</sup>) (see sections 4.5 and 5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.4 Special warnings and precautions
for use</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Intravascular
volume depletion</span></u><span lang=EN-GB>: symptomatic hypotension,
especially after the first dose, may occur in patients who are volume and/or
sodium depleted by vigorous diuretic therapy, dietary salt restriction,
diarrhoea or vomiting. Such conditions should be corrected before the
administration of Karvea.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renovascular hypertension</span></u><span
lang=EN-GB>: there is an increased risk of severe hypotension and renal
insufficiency when patients with bilateral renal artery stenosis or stenosis of
the artery to a single functioning kidney are treated with medicinal products
that affect the renin-angiotensin-aldosterone system. While this is not
documented with Karvea, a similar effect should be anticipated with
angiotensin-II receptor antagonists.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renal impairment and kidney
transplantation</span></u><span lang=EN-GB>: when Karvea is used in patients
with impaired renal function, a periodic monitoring of potassium and creatinine
serum levels is recommended. There is no experience regarding the
administration of Karvea in patients with a recent kidney transplantation.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hypertensive patients with
type&nbsp;2 diabetes and renal disease</span></u><span lang=EN-GB>:</span><span
lang=EN-GB style='layout-grid-mode:line'> the effects of irbesartan both on
renal and cardiovascular events were not uniform across all subgroups, in an
analysis carried out in the study with patients with advanced renal disease. In
particular, they appeared less favourable in women and non-white subjects (see
section&nbsp;5.1).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS):</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB>T</span></u><span lang=EN-GB>here is
evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor
blockers or aliskiren increases the risk of hypotension, hyperkalaemia and
decreased renal function (including acute renal failure). Dual blockade of RAAS
through the combined use of ACE-inhibitors, angiotensin II receptor blockers or
aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual
blockade therapy is considered absolutely necessary, this should only occur
under specialist supervision and subject to frequent close monitoring of renal
function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II
receptor blockers should not be used concomitantly in patients with diabetic
nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hyperkalaemia</span></u><span
lang=EN-GB>: as with other medicinal products that affect the
renin-angiotensin-aldosterone system, hyperkalaemia may occur during the
treatment with Karvea, especially in the presence of renal impairment, overt
proteinuria due to diabetic renal disease, and/or heart failure. Close
monitoring of serum potassium in patients at risk is recommended (see
section&nbsp;4.5).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hypoglycaemia: </span></u><span
lang=EN-GB>Karvea may induce hypoglycaemia, particularly in diabetic patients. In
patients treated with insulin or antidiabetics an appropriate blood glucose
monitoring should be considered; a dose adjustment of insulin or antidiabetics may
be required when indicated (see section 4.5).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Lithium</span></u><span lang=EN-GB>:
the combination of lithium and Karvea is not recommended (see
section&nbsp;4.5).</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Aortic and mitral valve stenosis,
obstructive hypertrophic cardiomyopathy</span></u><span lang=EN-GB>: as with
other vasodilators, special caution is indicated in patients suffering from
aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Primary aldosteronism</span></u><span
lang=EN-GB>: patients with primary aldosteronism generally will not respond to
antihypertensive medicinal products acting through inhibition of the renin-angiotensin
system. Therefore, the use of Karvea is not recommended.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>General</span></u><span lang=EN-GB>:
in patients whose vascular tone and renal function depend predominantly on the
activity of the renin-angiotensin-aldosterone system (e.g.&nbsp;patients with
severe congestive heart failure or underlying renal disease, including renal
artery stenosis), treatment with angiotensin<b> </b>converting enzyme
inhibitors or angiotensin-II receptor antagonists that affect this system has
been associated with acute hypotension, azotaemia, oliguria, or rarely acute
renal failure (see section 4.5). As with any antihypertensive agent, excessive
blood pressure decrease in patients with ischaemic cardiopathy or ischaemic
cardiovascular disease could result in a myocardial infarction or stroke.</span></p>

<p class=EMEABodyText><span lang=EN-GB>As observed for angiotensin converting
enzyme inhibitors, irbesartan and the other angiotensin antagonists are
apparently less effective in lowering blood pressure in black people than in
non-blacks, possibly because of higher prevalence of low-renin states in the
black hypertensive population (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Pregnancy:</span></u><span
lang=EN-GB> angiotensin&nbsp;II Receptor Antagonists (AIIRAs) should not be
initiated during pregnancy. </span><span lang=EN-GB>Unless continued AIIRA
therapy is considered essential, patients planning pregnancy should be changed
to alternative antihypertensive treatments which have an established safety
profile for use in pregnancy. When pregnancy is diagnosed, treatment with </span><span
lang=EN-GB>AIIRAs</span><span lang=EN-GB> should be stopped immediately, and,
if appropriate, alternative therapy should be started (see sections&nbsp;4.3
and&nbsp;4.6).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u><span
lang=EN-GB>: irbesartan has been studied in paediatric populations aged 6 to 16
years old but the current data are insufficient to support an extension of the
use in children until further data become available (see sections&nbsp;4.8, 5.1
and&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients</span></u><span lang=FR>:</span></p>

<p class=EMEABodyText><a name="_Hlk37089325"><span lang=FR>Karvea&nbsp;75 mg
tablet contains lactose. </span></a><span lang=EN-GB>Patients with rare
hereditary problems of galactose intolerance, total lactase deficiency or
glucose-galactose malabsorption should not take this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>Karvea&nbsp;75 mg tablet contains sodium. </span><span
lang=EN-GB>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that
is to say essentially sodium-free.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.5 Interaction with other medicinal
products and other forms of interaction</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Diuretics and other antihypertensive
agents</span></u><span lang=EN-GB>: other antihypertensive agents may increase
the hypotensive effects of irbesartan; however Karvea has been safely
administered with other antihypertensive agents, such as beta-blockers, long-acting
calcium channel blockers, and thiazide diuretics. Prior treatment with high
dose diuretics may result in volume depletion and a risk of hypotension when
initiating therapy with Karvea (see section&nbsp;4.4).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Aliskiren-containing products or
ACE-inhibitors</span></u><span lang=EN-GB>: clinical trial data has shown that
dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the
combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren
is associated with a higher frequency of adverse events such as hypotension,
hyperkalaemia and decreased renal function (including acute renal failure)
compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and
5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Potassium supplements and
potassium-sparing diuretics</span></u><span lang=EN-GB>:<i> </i>based on
experience with the use of other medicinal products that affect the renin-angiotensin
system, concomitant use of potassium-sparing diuretics, potassium supplements,
salt substitutes containing potassium or other medicinal products that may
increase serum potassium levels (e.g.&nbsp;heparin) may lead to increases in
serum potassium and is, therefore, not recommended (see section&nbsp;4.4).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Lithium</span></u><span lang=EN-GB>:<i>
</i>reversible increases in serum lithium concentrations and toxicity have been
reported during concomitant administration of lithium with angiotensin
converting enzyme inhibitors. Similar effects have been very rarely reported with
irbesartan so far. Therefore, this combination is not recommended (see
section&nbsp;4.4). If the combination proves necessary, careful monitoring of
serum lithium levels is recommended.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Non-steroidal anti-inflammatory drugs</span></u><span
lang=EN-GB>: w<span style='color:black'>hen angiotensin&nbsp;II antagonists are
administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.
selective COX-2 inhibitors, acetylsalicylic acid (&gt;&nbsp;3&nbsp;g/day) and
non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>As with ACE
inhibitors, concomitant use of angiotensin&nbsp;II antagonists and NSAIDs may
lead to an increased risk of worsening of renal function, including possible
acute renal failure, and an increase in serum potassium, especially in patients
with poor pre-existing renal function. The combination should be administered
with caution, especially in the elderly. Patients should be adequately hydrated
and consideration should be given to monitoring renal function after initiation
of concomitant therapy, and periodically thereafter.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Repaglinide:</span></u><span
lang=EN-GB style='color:black'> irbesartan has the potential to inhibit OATP1B1.
In a clinical study, it was reported that irbesartan increased the C<sub>max</sub>
and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3&#8209;fold,
respectively, when administered 1 hour before repaglinide. In another study, no
relevant pharmacokinetic interaction was reported, when the two drugs were
co-administered. Therefore, dose adjustment of antidiabetic treatment such as
repaglinide may be required (see section 4.4).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Additional information on irbesartan
interactions</span></u><span lang=EN-GB>: <span style='color:black'>in clinical
studies, the pharmacokinetic of irbesartan is not affected by
hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser
extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic
interactions were observed when irbesartan was coadministered with warfarin, a
medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as
rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The
pharmacokinetic of digoxin was not altered by coadministration of irbesartan.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.6 Fertility, pregnancy and
lactation</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEABodyText style='border:none;padding:0in'><span lang=EN-GB>The use
of AIIRAs is not recommended during the first trimester of pregnancy (see
section&nbsp;4.4). The use of AIIRAs is contraindicated during the second and
third trimesters of pregnancy (see sections&nbsp;4.3 and&nbsp;4.4).</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Epidemiological evidence regarding the
risk of teratogenicity following exposure to ACE inhibitors during the first
trimester of pregnancy has not been conclusive; however a small increase in
risk cannot be excluded. Whilst there is no controlled epidemiological data on
the risk with Angiotensin&nbsp;II Receptor Antagonists (AIIRAs), similar risks
may exist for this class of drugs. Unless continued AIIRA therapy is considered
essential, patients planning pregnancy should be changed to alternative
antihypertensive treatments which have an established safety profile for use in
pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped
immediately, and, if appropriate, alternative therapy should be started.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Exposure to AIIRA therapy during the
second and third trimesters is known to induce human foetotoxicity (decreased
renal function, oligohydramnios, skull ossification retardation) and neonatal
toxicity (renal failure, hypotension, hyperkalaemia). (See section&nbsp;5.3).</span></p>

<p class=EMEABodyText><span lang=EN-GB>Should exposure to AIIRAs have occurred
from the second trimester of pregnancy, ultrasound check of renal function and
skull is recommended.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Infants whose mothers have taken AIIRAs
should be closely observed for hypotension (see sections&nbsp;4.3
and&nbsp;4.4).</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Because no information is available
regarding the use of Karvea during breast-feeding, Karvea is not recommended
and alternative treatments with better established safety profiles during
breast-feeding are preferable, especially while nursing a newborn or preterm infant.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>It is unknown whether irbesartan or its metabolites are
excreted in human milk. </p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>Available pharmacodynamic/toxicological data in rats have
shown excretion of irbesartan or its metabolites in milk (for details see 5.3).</p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Fertility</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan had no effect upon fertility
of treated rats and their offspring up to the dose levels inducing the first
signs of parental toxicity (see section 5.3).</span> </p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=EN-GB>4.7 Effects on ability to drive and
use machines</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Based on its pharmacodynamic properties,
irbesartan is unlikely to affect the ability to drive and use machine. When
driving vehicles or operating machines, it should be taken into account that
dizziness or weariness may occur during treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.8 Undesirable effects</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>In
placebo-controlled trials in patients with hypertension, the overall incidence
of adverse events did not differ between the irbesartan (56.2%) and the placebo
groups (56.5%). Discontinuation due to any clinical or laboratory adverse event
was less frequent for irbesartan-treated patients (3.3%) than for
placebo-treated patients (4.5%). The incidence of adverse events was not
related to dose (in the recommended dose range), gender, age, race, or duration
of treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In diabetic hypertensive patients with
microalbuminuria and normal renal function, orthostatic dizziness and
orthostatic hypotension were reported in 0.5% of the patients
(i.e.,&nbsp;uncommon) but in excess of placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The following table presents the adverse
drug reactions that were reported in placebo-controlled trials in which
1,965&nbsp;hypertensive patients received irbesartan. Terms marked with a star
(*) refer to the adverse reactions that were additionally reported in &gt; 2%
of diabetic hypertensive patients with chronic renal insufficiency and overt
proteinuria and in excess of placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The frequency of adverse reactions
listed below is defined using the following convention:</span></p>

<p class=EMEABodyText><span lang=EN-GB>very common (&#8805;&nbsp;1/10); common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare
(&lt;&nbsp;1/10,000). Within each frequency grouping, undesirable effects are
presented in order of decreasing seriousness.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Adverse reactions additionally reported
from postmarketing experience are also listed. These adverse reactions are
derived from spontaneous reports.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Blood
and lymphatic system disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: anaemia, thrombocytopenia</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Immune
system disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hypersensitivity reactions such as angioedema, rash, urticaria,
anaphylactic reaction, anaphylactic shock</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Metabolism
and nutrition disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hyperkalaemia, hypoglycaemia</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Nervous
system disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Common: dizziness, orthostatic
dizziness*</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not known: vertigo, headache</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Ear and
labyrinth disorder</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: tinnitus</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Cardiac
disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: tachycardia</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Vascular
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: orthostatic
hypotension*</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: flushing</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Respiratory,
thoracic and mediastinal disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: cough</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Gastrointestinal
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: nausea/vomiting</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: diarrhoea,
dyspepsia/heartburn</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not known: dysgeusia</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Hepatobiliary
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: jaundice</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hepatitis, abnormal liver function</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Skin
and subcutaneous tissue disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: leukocytoclastic vasculitis</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Musculoskeletal
and connective tissue disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Common: musculoskeletal pain*</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not known: arthralgia, myalgia (in
some cases associated with increased plasma creatine kinase  levels),
muscle cramps</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Renal
and urinary disorders</span></u></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in;page-break-after:
avoid'><span lang=EN-GB>Not known:  impaired renal function including
cases of renal failure in patients at risk (see section&nbsp;4.4)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Reproductive
system and breast disorders</span></u></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB>Uncommon: sexual
dysfunction</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>General
disorders and administration site conditions</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: fatigue</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: chest
pain</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Investigations</span></u></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Very common: Hyperkalaemia* occurred more often in diabetic
patients treated with irbesartan than with placebo. In diabetic hypertensive
patients with microalbuminuria and normal renal function, hyperkalaemia
(&#8805;&nbsp;5.5&nbsp;mEq/L) occurred in 29.4% of the patients in the irbesartan
300&nbsp;mg group and 22% of the patients in the placebo group. In diabetic
hypertensive patients with chronic renal insufficiency and overt proteinuria,
hyperkalaemia (&#8805;&nbsp;5.5&nbsp;mEq/L) occurred in 46.3% of the patients
in the irbesartan group and 26.3% of the patients in the placebo group.</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Common: significant increases in plasma creatine kinase were
commonly observed (1.7%) in irbesartan treated subjects. None of these
increases were associated with identifiable clinical musculoskeletal events.<br>
In 1.7% of hypertensive patients with advanced diabetic renal disease treated
with irbesartan, a decrease in haemoglobin*, which was not clinically
significant, has been observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u><b><span
lang=EN-GB> </span></b></p>

<p class=EMEABodyText><span lang=EN-GB>In a randomised trial of
318&nbsp;hypertensive children and adolescents aged 6 to 16&nbsp;years, the
following adverse reactions occurred in the 3-week double-blind phase: headache
(7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week
open-label period of this trial the most frequent laboratory abnormalities
observed were creatinine increases (6.5%) and elevated CK values in 2% of child
recipients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Reporting of suspected adverse
reactions </span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Reporting suspected adverse reactions
after authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:silver'>the national reporting system listed in Appendix V.</span>
</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.9 Overdose</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Experience in adults exposed to doses of
up to 900&nbsp;mg/day for 8&nbsp;weeks revealed no toxicity. The most likely
manifestations of overdose are expected to be hypotension and tachycardia;
bradycardia might also occur from overdose. No specific information is
available on the treatment of overdose with Karvea. The patient should be
closely monitored, and the treatment should be symptomatic and supportive.
Suggested measures include induction of emesis and/or gastric lavage. Activated
charcoal may be useful in the treatment of overdose. Irbesartan is not removed
by haemodialysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.1 Pharmacodynamic properties</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Pharmacotherapeutic
group: Angiotensin-II antagonists, plain.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>ATC&nbsp;code:
C09C&nbsp;A04.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Mechanism of action</span></u><b><span
lang=EN-GB> </span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan is a potent, orally active,
selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is
expected to block all actions of angiotensin-II mediated by the AT<sub>1</sub>
receptor, regardless of the source or route of synthesis of angiotensin-II. The
selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results in
increases in plasma renin levels and angiotensin-II levels, and a decrease in
plasma aldosterone concentration. Serum potassium levels are not significantly
affected by irbesartan alone at the recommended doses. Irbesartan does not
inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also
degrades bradykinin into inactive metabolites. Irbesartan does not require
metabolic activation for its activity.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><u><span lang=EN-GB style='font-weight:normal'>Clinical
efficacy</span></u></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hypertension</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan lowers blood pressure with minimal
change in heart rate. The decrease in blood pressure is dose-related for once a
day doses with a tendency towards plateau at doses above 300&nbsp;mg. Doses of
150-300&nbsp;mg once daily lower supine or seated blood pressures at trough
(i.e.&nbsp;24&nbsp;hours after dosing) by an average of
8-13/5-8&nbsp;mm&nbsp;Hg (systolic/diastolic) greater than those associated
with placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Peak reduction of blood pressure is
achieved within 3-6&nbsp;hours after administration and the blood pressure
lowering effect is maintained for at least 24&nbsp;hours. At 24&nbsp;hours the
reduction of blood pressure was 60-70% of the corresponding peak diastolic and
systolic responses at the recommended doses. Once daily dosing with 150&nbsp;mg
produced trough and mean 24&nbsp;hour responses similar to twice daily dosing
on the same total dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The blood pressure lowering effect of Karvea
is evident within 1-2&nbsp;weeks, with the maximal effect occurring by
4-6&nbsp;weeks after start of therapy. The antihypertensive effects are
maintained during long term therapy. After withdrawal of therapy, blood pressure
gradually returns toward baseline. Rebound hypertension has not been observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The blood pressure lowering effects of
irbesartan and thiazide-type diuretics are additive. In patients not adequately
controlled by irbesartan alone, the addition of a low dose of
hydrochlorothiazide (12.5&nbsp;mg) to irbesartan once daily results in a
further placebo-adjusted blood pressure reduction at trough of
7-10/3-6&nbsp;mm&nbsp;Hg (systolic/diastolic).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The efficacy of Karvea is not influenced
by age or gender. As is the case with other medicinal products that affect the
renin-angiotensin system, black hypertensive patients have notably less
response to irbesartan monotherapy. When irbesartan is administered
concomitantly with a low dose of hydrochlorothiazide (e.g.&nbsp;12.5&nbsp;mg
daily), the antihypertensive response in black patients approaches that of
white patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>There is no clinically important effect
on serum uric acid or urinary uric acid secretion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Reduction
of blood pressure with 0.5&nbsp;mg/kg (low), 1.5&nbsp;mg/kg (medium) and
4.5&nbsp;mg/kg (high) target titrated doses of irbesartan was evaluated in 318
hypertensive or at risk (diabetic, family history of hypertension) children and
adolescents aged 6 to 16&nbsp;years over a three week period. At the end of the
three weeks the mean reduction from baseline in the primary efficacy variable,
trough seated systolic blood pressure (SeSBP) was 11.7&nbsp;mmHg (low dose),
9.3&nbsp;mmHg (medium dose), 13.2&nbsp;mmHg (high dose). No significant
difference was apparent between these doses. Adjusted mean change of trough
seated diastolic blood pressure (SeDBP) was as follows: 3.8&nbsp;mmHg (low
dose), 3.2&nbsp;mmHg (medium dose), 5.6&nbsp;mmHg (high dose). Over a
subsequent two week period where patients were re-randomized to either active
medicinal product or placebo, patients on placebo had increases of 2.4 and
2.0&nbsp;mmHg in SeSBP and SeDBP compared to +0.1 and -0.3&nbsp;mmHg changes
respectively in those on all doses of irbesartan (see section&nbsp;4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hypertension
and type&nbsp;2 diabetes with renal disease</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>The Irbesartan Diabetic Nephropathy
Trial (IDNT) shows that irbesartan decreases the progression of renal disease
in patients with chronic renal insufficiency and overt proteinuria. IDNT was a
double blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine
and placebo. In 1,715&nbsp;hypertensive patients with type&nbsp;2 diabetes,
proteinuria &#8805;&nbsp;900&nbsp;mg/day and serum creatinine ranging from
1.0-3.0&nbsp;mg/dl, the long-term effects (mean&nbsp;2.6&nbsp;years) of Karvea
on the progression of renal disease and all-cause mortality were examined.
Patients were titrated from 75&nbsp;mg to a maintenance dose of 300&nbsp;mg Karvea</span><span
lang=EN-GB style='font-family:"Times",serif'>, from 2.5&nbsp;mg to 10&nbsp;mg
amlodipine, or placebo</span><span lang=EN-GB> as tolerated. Patients in all
treatment groups typically received between&nbsp;2 and 4&nbsp;antihypertensive
agents (e.g., diuretics, beta&nbsp;blockers, alpha&nbsp;blockers) to reach a
predefined blood pressure goal of &#8804;&nbsp;135/85&nbsp;mmHg or a
10&nbsp;mmHg reduction in systolic pressure if baseline was
&gt;&nbsp;160&nbsp;mmHg. Sixty per cent (60%) of patients in the placebo group
reached this target blood pressure whereas this figure was 76% and 78% in the
irbesartan and amlodipine groups respectively. Irbesartan significantly reduced
the relative risk in the primary combined endpoint of doubling serum
creatinine, end-stage renal disease (ESRD) or all-cause mortality.
Approximately 33% of patients in the irbesartan group reached the primary renal
composite endpoint compared to 39% and 41% in the placebo and amlodipine groups
[20% relative risk reduction versus placebo (p&nbsp;=&nbsp;0.024) and 23%
relative risk reduction compared to amlodipine (p&nbsp;=&nbsp;0.006)]. When the
individual components of the primary endpoint were analysed, no effect in all
cause mortality was observed, while a positive trend in the reduction in ESRD
and a significant reduction in doubling of serum creatinine were observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>Subgroups
consisting of gender, race, age, duration of diabetes, baseline blood pressure,
serum creatinine, and albumin excretion rate were assessed for treatment
effect. In the female and black subgroups which represented 32% and 26% of the
overall study population respectively, a renal benefit was not evident, </span>although
the confidence intervals do not exclude it. As for the secondary endpoint of
fatal and non-fatal cardiovascular events, there was no difference among the
three groups in the overall population, although an increased incidence of
non-fatal MI was seen for women and a decreased incidence of non-fatal MI was
seen in males in the irbesartan group versus the placebo-based regimen. An
increased incidence of non-fatal MI and stroke was seen in females in the
irbesartan-based regimen versus the amlodipine-based regimen, while
hospitalization due to heart failure was reduced in the overall population.
However, no proper explanation for these findings in women has been identified.</p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The study of the Effects of Irbesartan
on Microalbuminuria in Hypertensive Patients with type&nbsp;2 Diabetes Mellitus
(IRMA&nbsp;2) shows that irbesartan 300&nbsp;mg delays progression to overt
proteinuria in patients with microalbuminuria. IRMA&nbsp;2 was a
placebo-controlled double blind morbidity study in 590&nbsp;patients with type&nbsp;2
diabetes, microalbuminuria (30-300&nbsp;mg/day) and normal renal function
(serum creatinine&nbsp;&#8804;&nbsp;1.5&nbsp;mg/dl in males and
&lt;&nbsp;1.1&nbsp;mg/dl in females). The study examined the long-term effects
(2&nbsp;years) of Karvea on the progression to clinical (overt) proteinuria
(urinary albumin excretion rate (UAER) &gt;&nbsp;300&nbsp;mg/day, and an
increase in UAER of at least 30% from baseline). The predefined blood pressure
goal was &#8804;&nbsp;135/85&nbsp;mmHg. Additional antihypertensive agents
(excluding ACE inhibitors, angiotensin&nbsp;II receptor antagonists and
dihydropyridine calcium blockers) were added as needed to help achieve the
blood pressure goal. While similar blood pressure was achieved in all treatment
groups, fewer subjects in the irbesartan 300&nbsp;mg group (5.2%) than in the
placebo (14.9%) or in the irbesartan 150&nbsp;mg group (9.7%) reached the
endpoint of overt proteinuria, demonstrating a 70% relative risk reduction
versus placebo (p&nbsp;=&nbsp;0.0004) for the higher dose. An accompanying
improvement in the glomerular filtration rate (GFR) was not observed during the
first three months of treatment. The slowing in the progression to clinical
proteinuria was evident as early as three months and continued over the
2&nbsp;year period. Regression to normoalbuminuria (&lt;&nbsp;30&nbsp;mg/day)
was more frequent in the Karvea&nbsp;300&nbsp;mg group (34%) than in the placebo
group (21%).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS)</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Two large randomised, controlled trials (ONTARGET
(ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint
Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have
examined the use of the combination of an ACE-inhibitor with an angiotensin II
receptor blocker. ONTARGET was a study conducted in patients with a history of
cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus
accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in
patients with type 2 diabetes mellitus and diabetic nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>These studies have shown no significant
beneficial effect on renal and/or cardiovascular outcomes and mortality, while
an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as
compared to monotherapy was observed. Given their similar pharmacodynamic
properties, these results are also relevant for other ACE-inhibitors and
angiotensin II receptor blockers.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ACE-inhibitors and angiotensin II
receptor blockers should therefore not be used concomitantly in patients with
diabetic nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ALTITUDE (Aliskiren Trial in Type 2
Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed
to test the benefit of adding aliskiren to a standard therapy of an
ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2
diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
The study was terminated early because of an increased risk of adverse
outcomes. Cardiovascular death and stroke were both numerically more frequent
in the aliskiren group than in the placebo group and adverse events and serious
adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)
were more frequently reported in the aliskiren group than in the placebo group.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.2 Pharmacokinetic properties</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>After
oral administration, irbesartan is well absorbed: studies of absolute
bioavailability gave values of approximately 60-80%. Concomitant food intake
does not significantly influence the bioavailability of irbesartan. </span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Plasma
protein binding is approximately 96%, with negligible binding to cellular blood
components. The volume of distribution is 53-93&nbsp;litres. </span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Following
oral or intravenous administration of <sup><span style='position:relative;
top:-1.0pt'>14</span></sup>C irbesartan, 80-85% of the circulating plasma
radioactivity is attributable to unchanged irbesartan. Irbesartan is
metabolised by the liver via glucuronide conjugation and oxidation. The major
circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In&nbsp;vitro</i>
studies indicate that irbesartan is primarily oxidised by the
cytochrome&nbsp;P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Linearity / non-linearity</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan exhibits linear and dose
proportional pharmacokinetics over the dose range of 10&nbsp;to 600&nbsp;mg. A
less than proportional increase in oral absorption at doses beyond 600&nbsp;mg
(twice the maximal recommended dose) was observed; the mechanism for this is
unknown. Peak plasma concentrations are attained at 1.5-2&nbsp;hours after oral
administration. The total body and renal clearance are 157&#8209;176&nbsp;and
3-3.5&nbsp;ml/min, respectively. The terminal elimination half-life of
irbesartan is 11-15&nbsp;hours. Steady-state plasma concentrations are attained
within 3&nbsp;days after initiation of a once-daily dosing regimen. Limited
accumulation of irbesartan (&lt;&nbsp;20%) is observed in plasma upon repeated
once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan
were observed in female hypertensive patients. However, there was no difference
in the half-life and accumulation of irbesartan. No dosage adjustment is
necessary in female patients. Irbesartan AUC and C<span class=EMEASubscript>max</span>
values were also somewhat greater in oldersubjects (&#8805;&nbsp;65&nbsp;years)
than those of young subjects (18-40&nbsp;years). However the terminal half-life
was not significantly altered. No dosage adjustment is necessary in older
people.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Elimination</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan and its metabolites are
eliminated by both biliary and renal pathways. After either oral or IV
administration of <sup><span style='position:relative;top:-1.0pt'>14</span></sup>C
irbesartan, about 20% of the radioactivity is recovered in the urine, and the
remainder in the faeces. Less than 2% of the dose is excreted in the urine as
unchanged irbesartan.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>The pharmacokinetics of irbesartan were
evaluated in 23&nbsp;hypertensive children after the administration of single
and multiple daily doses of irbesartan (2&nbsp;mg/kg) up to a maximum daily
dose of 150&nbsp;mg for four weeks. Of those 23 children, 21 were evaluable for
comparison of pharmacokinetics with adults (twelve children over 12&nbsp;years,
nine children between 6 and 12 years). Results showed that C<span
class=EMEASubscript>max</span>, AUC and clearance rates were comparable to
those observed in adult patients receiving 150&nbsp;mg irbesartan daily. A
limited accumulation of irbesartan (18%) in plasma was observed upon repeated
once daily dosing.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients with renal impairment or
those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan
are not significantly altered. Irbesartan is not removed by haemodialysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hepatic impairment</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients with mild to moderate
cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly
altered.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Studies have not been performed in
patients with severe hepatic impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.3<i> </i>Preclinical safety data</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>There was
no evidence of abnormal systemic or target organ toxicity at clinically relevant
doses. In non-clinical safety studies, high doses of irbesartan
(&#8805;&nbsp;250&nbsp;mg/kg/day in rats and &#8805;&nbsp;100&nbsp;mg/kg/day in
macaques) caused a reduction of red blood cell parameters (erythrocytes,
haemoglobin, haematocrit). At very high doses (&#8805;&nbsp;500&nbsp;mg/kg/day)
degenerative changes in the kidney (such as interstitial nephritis, tubular
distension, basophilic tubules, increased plasma concentrations of urea and
creatinine) were induced by irbesartan in the rat and the macaque and are
considered secondary to the hypotensive effects of the medicinal product which
led to decreased renal perfusion. Furthermore, irbesartan induced
hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at
&#8805;&nbsp;90&nbsp;mg/kg/day, in macaques at &#8805;&nbsp;10&nbsp;mg/kg/day).
All of these changes were considered to be caused by the pharmacological action
of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/
hypertrophy of the renal juxtaglomerular cells does not appear to have any
relevance.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>There was no evidence of mutagenicity,
clastogenicity or carcinogenicity.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Fertility and reproductive performance
were not affected in studies of male and female rats even at oral doses of
irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including
mortality at the highest dose. No significant effects on the number of corpora
lutea, implants, or live foetuses were observed. Irbesartan did not affect
survival, development, or reproduction of offspring. Studies in animals
indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.
Irbesartan is excreted in the milk of lactating rats.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Animal studies with irbesartan showed
transient toxic effects (increased renal pelvic cavitation, hydroureter or
subcutaneous oedema) in rat foetuses, which were resolved after birth. In
rabbits, abortion or early resorption were noted at doses causing significant
maternal toxicity, including mortality. No teratogenic effects were observed in
the rat or rabbit.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.1 List of excipients</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Microcrystalline
cellulose</span></p>

<p class=EMEABodyText><span lang=EN-GB>Croscarmellose sodium</span></p>

<p class=EMEABodyText><span lang=EN-GB>Lactose monohydrate</span></p>

<p class=EMEABodyText><span lang=EN-GB>Magnesium stearate</span></p>

<p class=EMEABodyText><span lang=EN-GB>Colloidal hydrated silica</span></p>

<p class=EMEABodyText><span lang=EN-GB>Pregelatinised maize starch</span></p>

<p class=EMEABodyText><span lang=EN-GB>Poloxamer&nbsp;188</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.2 Incompatibilities</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
applicable.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.3 Shelf life</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>3&nbsp;years.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.4 Special precautions for storage</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Do not store
above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>6.5 Nature
and contents of container</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 14&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 28&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 56&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 98&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 56&nbsp;x&nbsp;1&nbsp;tablet
in PVC/PVDC/Aluminium perforated unit dose blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.6 Special precautions for disposal</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Any
unused medicinal product or waste material should be disposed of in accordance
with local requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=FR>7. MARKETING AUTHORISATION HOLDER</span></p>

<p class=EMEAHeading1><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=FR>8. MARKETING AUTHORISATION NUMBERS</span></p>

<p class=EMEAHeading1><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=NO-BOK>EU/1/97/049/001-003<br>
EU/1/97/049/010<br>
EU/1/97/049/013</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>9. DATE OF FIRST AUTHORISATION /
RENEWAL OF THE AUTHORISATION</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Date of first authorisation: 27 August
1997<br>
Date of latest renewal: 27 August 2007</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency http://www.ema.europa.eu</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;150&nbsp;mg tablets.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Each tablet contains 150&nbsp;mg of
irbesartan.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Excipient with known effect</span></u><span
lang=EN-GB>: 30.75&nbsp;mg of lactose monohydrate per tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For the full list of excipients, see
section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB>White to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2772 engraved
on the other side.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>4. CLINICAL PARTICULARS</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.1 Therapeutic indications</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Karvea is
indicated in adults for the treatment of essential hypertension.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>It is also indicated for the treatment
of renal disease in adult patients with hypertension and type&nbsp;2 diabetes
mellitus as part of an antihypertensive medicinal product regimen (see sections
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.2 Posology and method of
administration</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>The usual
recommended initial and maintenance dose is 150&nbsp;mg once daily, with or
without food. Karvea at a dose of 150&nbsp;mg once daily generally provides a
better 24&nbsp;hour blood pressure control than 75&nbsp;mg. However, initiation
of therapy with 75&nbsp;mg could be considered, particularly in haemodialysed
patients and in the elderly over 75&nbsp;years.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients insufficiently controlled
with 150&nbsp;mg once daily, the dose of Karvea can be increased to
300&nbsp;mg, or other antihypertensive agents can be added (see sections 4.3,
4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as
hydrochlorothiazide has been shown to have an additive effect with Karvea (see
section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In hypertensive type&nbsp;2 diabetic
patients, therapy should be initiated at 150&nbsp;mg irbesartan once daily and
titrated up to 300&nbsp;mg once daily as the preferred maintenance dose for
treatment of renal disease.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The demonstration of renal benefit of Karvea
in hypertensive type&nbsp;2 diabetic patients is based on studies where
irbesartan was used in addition to other antihypertensive agents, as needed, to
reach target blood pressure (see sections 4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Special Populations</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><span lang=EN-GB>Renal impairment</span></i><span
lang=EN-GB> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No dosage adjustment is necessary in
patients with impaired renal function. A lower starting dose (75&nbsp;mg)
should be considered for patients undergoing haemodialysis (see section 4.4).</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><i><span lang=EN-GB>Hepatic impairment</span></i><span
lang=EN-GB> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No dosage adjustment is necessary in
patients with mild to moderate hepatic impairment. There is no clinical
experience in patients with severe hepatic impairment.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><i><span lang=EN-GB>Older people</span></i><span
lang=EN-GB> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Although consideration should be given
to initiating therapy with 75&nbsp;mg in patients over 75&nbsp;years of age,
dosage adjustment is not usually necessary for older people.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><i><span lang=EN-GB>Paediatric population</span></i><span
lang=EN-GB> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of Karvea in
children aged 0 to 18 has not been established. Currently available data are
described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can
be made.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Method of Administration</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.3 Contraindications</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Second and third trimesters of pregnancy
(see sections&nbsp;4.4 and&nbsp;4.6).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The concomitant use of Karvea with
aliskiren-containing products is contraindicated in patients with diabetes
mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60
ml/min/1.73m<sup>2</sup>) (see sections 4.5 and 5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.4 Special warnings and precautions
for use</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Intravascular
volume depletion</span></u><span lang=EN-GB>: symptomatic hypotension,
especially after the first dose, may occur in patients who are volume and/or
sodium depleted by vigorous diuretic therapy, dietary salt restriction,
diarrhoea or vomiting. Such conditions should be corrected before the
administration of Karvea.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renovascular hypertension</span></u><span
lang=EN-GB>: there is an increased risk of severe hypotension and renal
insufficiency when patients with bilateral renal artery stenosis or stenosis of
the artery to a single functioning kidney are treated with medicinal products
that affect the renin-angiotensin-aldosterone system. While this is not
documented with Karvea, a similar effect should be anticipated with
angiotensin-II receptor antagonists.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renal impairment and kidney
transplantation</span></u><span lang=EN-GB>: when Karvea is used in patients
with impaired renal function, a periodic monitoring of potassium and creatinine
serum levels is recommended. There is no experience regarding the
administration of Karvea in patients with a recent kidney transplantation.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hypertensive patients with
type&nbsp;2 diabetes and renal disease</span></u><span lang=EN-GB>:</span><span
lang=EN-GB style='layout-grid-mode:line'> the effects of irbesartan both on
renal and cardiovascular events were not uniform across all subgroups, in an
analysis carried out in the study with patients with advanced renal disease. In
particular, they appeared less favourable in women and non-white subjects (see
section&nbsp;5.1).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS</span></u><span lang=EN-GB>): <u>t</u>here
is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor
blockers or aliskiren increases the risk of hypotension, hyperkalaemia and
decreased renal function (including acute renal failure). Dual blockade of RAAS
through the combined use of ACE-inhibitors, angiotensin II receptor blockers or
aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual
blockade therapy is considered absolutely necessary, this should only occur
under specialist supervision and subject to frequent close monitoring of renal
function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II
receptor blockers should not be used concomitantly in patients with diabetic
nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hyperkalaemia</span></u><span
lang=EN-GB>: as with other medicinal products that affect the
renin-angiotensin-aldosterone system, hyperkalaemia may occur during the
treatment with Karvea, especially in the presence of renal impairment, overt
proteinuria due to diabetic renal disease, and/or heart failure. Close
monitoring of serum potassium in patients at risk is recommended (see
section&nbsp;4.5).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hypoglycaemia: </span></u><span
lang=EN-GB>Karvea may induce hypoglycaemia, particularly in diabetic patients. In
patients treated with insulin or antidiabetics an appropriate blood glucose
monitoring should be considered; a dose adjustment of insulin or antidiabetics may
be required when indicated (see section 4.5).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Lithium</span></u><span lang=EN-GB>:
the combination of lithium and Karvea is not recommended (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Aortic and mitral valve stenosis,
obstructive hypertrophic cardiomyopathy</span></u><span lang=EN-GB>: as with
other vasodilators, special caution is indicated in patients suffering from
aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Primary aldosteronism</span></u><span
lang=EN-GB>: patients with primary aldosteronism generally will not respond to
antihypertensive medicinal products acting through inhibition of the
renin-angiotensin system. Therefore, the use of Karvea is not recommended.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>General</span></u><span lang=EN-GB>:
in patients whose vascular tone and renal function depend predominantly on the
activity of the renin-angiotensin-aldosterone system (e.g.&nbsp;patients with
severe congestive heart failure or underlying renal disease, including renal
artery stenosis), treatment with angiotensin<b> </b>converting enzyme inhibitors
or angiotensin-II receptor antagonists that affect this system has been
associated with acute hypotension, azotaemia, oliguria, or rarely acute renal
failure (see section 4.5). As with any antihypertensive agent, excessive blood
pressure decrease in patients with ischaemic cardiopathy or ischaemic
cardiovascular disease could result in a myocardial infarction or stroke.</span></p>

<p class=EMEABodyText><span lang=EN-GB>As observed for angiotensin converting
enzyme inhibitors, irbesartan and the other angiotensin antagonists are
apparently less effective in lowering blood pressure in black people than in
non-blacks, possibly because of higher prevalence of low-renin states in the
black hypertensive population (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Pregnancy:</span></u><span
lang=EN-GB> angiotensin&nbsp;II Receptor Antagonists (AIIRAs) should not be
initiated during pregnancy. </span><span lang=EN-GB>Unless continued AIIRA
therapy is considered essential, patients planning pregnancy should be changed
to alternative antihypertensive treatments which have an established safety
profile for use in pregnancy. When pregnancy is diagnosed, treatment with </span><span
lang=EN-GB>AIIRAs</span><span lang=EN-GB> should be stopped immediately, and,
if appropriate, alternative therapy should be started (see sections&nbsp;4.3
and&nbsp;4.6).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u><span
lang=EN-GB>: irbesartan has been studied in paediatric populations aged 6 to 16
years old but the current data are insufficient to support an extension of the
use in children until further data become available (see sections&nbsp;4.8, 5.1
and&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients</span></u><span lang=FR>:</span></p>

<p class=EMEABodyText><span lang=FR>Karvea&nbsp;150 mg tablet contains lactose.
</span><span lang=EN-GB>Patients with rare hereditary problems of galactose
intolerance, total lactase deficiency or glucose-galactose malabsorption should
not take this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>Karvea&nbsp;150 mg tablet contains sodium. </span><span
lang=EN-GB>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that
is to say essentially sodium-free.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.5 Interaction with other medicinal
products and other forms of interaction</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Diuretics and other antihypertensive
agents</span></u><span lang=EN-GB>: other antihypertensive agents may increase
the hypotensive effects of irbesartan; however Karvea has been safely administered
with other antihypertensive agents, such as beta-blockers, long-acting calcium
channel blockers, and thiazide diuretics. Prior treatment with high dose
diuretics may result in volume depletion and a risk of hypotension when
initiating therapy with Karvea (see section&nbsp;4.4).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Aliskiren-containing productsand
ACE-inhibitors</span></u><span lang=EN-GB>:.clinical trial data has shown that
dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the
combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren
is associated with a higher frequency of adverse events such as hypotension,
hyperkalaemia and decreased renal function (including acute renal failure)
compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and
5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Potassium supplements and potassium-sparing
diuretics</span></u><span lang=EN-GB>:<i> </i>based on experience with the use
of other medicinal products that affect the renin-angiotensin system,
concomitant use of potassium-sparing diuretics, potassium supplements, salt
substitutes containing potassium or other medicinal products that may increase
serum potassium levels (e.g.&nbsp;heparin) may lead to increases in serum
potassium and is, therefore, not recommended (see section&nbsp;4.4).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Lithium</span></u><span lang=EN-GB>:<i>
</i>reversible increases in serum lithium concentrations and toxicity have been
reported during concomitant administration of lithium with angiotensin
converting enzyme inhibitors. Similar effects have been very rarely reported
with irbesartan so far. Therefore, this combination is not recommended (see
section&nbsp;4.4). If the combination proves necessary, careful monitoring of
serum lithium levels is recommended.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Non-steroidal anti-inflammatory drugs</span></u><span
lang=EN-GB>: w<span style='color:black'>hen angiotensin&nbsp;II antagonists are
administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.
selective COX-2 inhibitors, acetylsalicylic acid (&gt;&nbsp;3&nbsp;g/day) and
non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>As with ACE
inhibitors, concomitant use of angiotensin&nbsp;II antagonists and NSAIDs may
lead to an increased risk of worsening of renal function, including possible
acute renal failure, and an increase in serum potassium, especially in patients
with poor pre-existing renal function. The combination should be administered
with caution, especially in the elderly. Patients should be adequately hydrated
and consideration should be given to monitoring renal function after initiation
of concomitant therapy, and periodically thereafter.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Repaglinide:</span></u><span
lang=EN-GB style='color:black'> irbesartan has the potential to inhibit OATP1B1.
In a clinical study, it was reported that irbesartan increased the C<sub>max</sub>
and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3&#8209;fold,
respectively, when administered 1 hour before repaglinide. In another study, no
relevant pharmacokinetic interaction was reported, when the two drugs were
co-administered. Therefore, dose adjustment of antidiabetic treatment such as
repaglinide may be required (see section 4.4).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Additional information on irbesartan
interactions</span></u><span lang=EN-GB>: <span style='color:black'>in clinical
studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.
Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by
glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions
were observed when irbesartan was coadministered with warfarin, a medicinal
product metabolised by CYP2C9. The effects of CYP2C9 inducers such as
rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The
pharmacokinetic of digoxin was not altered by coadministration of irbesartan.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.6 Fertility, pregnancy and
lactation</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEABodyText style='border:none;padding:0in'><span lang=EN-GB>The use
of AIIRAs is not recommended during the first trimester of pregnancy (see
section&nbsp;4.4). The use of AIIRAs is contraindicated during the second and
third trimesters of pregnancy (see sections&nbsp;4.3 and&nbsp;4.4).</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Epidemiological evidence regarding the
risk of teratogenicity following exposure to ACE inhibitors during the first
trimester of pregnancy has not been conclusive; however a small increase in
risk cannot be excluded. Whilst there is no controlled epidemiological data on
the risk with Angiotensin&nbsp;II Receptor Antagonists (AIIRAs), similar risks
may exist for this class of drugs. Unless continued AIIRA therapy is considered
essential, patients planning pregnancy should be changed to alternative antihypertensive
treatments which have an established safety profile for use in pregnancy. When
pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and,
if appropriate, alternative therapy should be started.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Exposure to AIIRA therapy during the
second and third trimesters is known to induce human foetotoxicity (decreased
renal function, oligohydramnios, skull ossification retardation) and neonatal
toxicity (renal failure, hypotension, hyperkalaemia). (See section&nbsp;5.3).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Should exposure to AIIRAs have occurred
from the second trimester of pregnancy, ultrasound check of renal function and
skull is recommended.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Infants whose mothers have taken AIIRAs
should be closely observed for hypotension (see sections&nbsp;4.3
and&nbsp;4.4).</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Because no information is available
regarding the use of Karvea during breast-feeding, Karvea is not recommended
and alternative treatments with better established safety profiles during
breast-feeding are preferable, especially while nursing a newborn or preterm
infant.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>It is unknown whether irbesartan or its metabolites are
excreted in human milk. </p>

<p class=EMEABodyText>Available pharmacodynamic/toxicological data in rats have
shown excretion of irbesartan or its metabolites in milk (for details see 5.3).</p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Fertility</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan had no effect upon fertility
of treated rats and their offspring up to the dose levels inducing the first
signs of parental toxicity (see section 5.3).</span> </p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=EN-GB>4.7 Effects on ability to drive and
use machines</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Based on its pharmacodynamic properties,
irbesartan is unlikely to affect the ability to drive and use machnes. When driving
vehicles or operating machines, it should be taken into account that dizziness
or weariness may occur during treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.8 Undesirable effects</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>In
placebo-controlled trials in patients with hypertension, the overall incidence
of adverse events did not differ between the irbesartan (56.2%) and the placebo
groups (56.5%). Discontinuation due to any clinical or laboratory adverse event
was less frequent for irbesartan-treated patients (3.3%) than for
placebo-treated patients (4.5%). The incidence of adverse events was not
related to dose (in the recommended dose range), gender, age, race, or duration
of treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In diabetic hypertensive patients with
microalbuminuria and normal renal function, orthostatic dizziness and
orthostatic hypotension were reported in 0.5% of the patients
(i.e.,&nbsp;uncommon) but in excess of placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The following table presents the adverse
drug reactions that were reported in placebo-controlled trials in which
1,965&nbsp;hypertensive patients received irbesartan. Terms marked with a star
(*) refer to the adverse reactions that were additionally reported in &gt; 2%
of diabetic hypertensive patients with chronic renal insufficiency and overt
proteinuria and in excess of placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The frequency of adverse reactions
listed below is defined using the following convention:</span></p>

<p class=EMEABodyText><span lang=EN-GB>very common (&#8805;&nbsp;1/10); common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare
(&lt;&nbsp;1/10,000). Within each frequency grouping, undesirable effects are
presented in order of decreasing seriousness.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Adverse reactions additionally reported
from postmarketing experience are also listed. These adverse reactions are
derived from spontaneous reports.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Blood
and lymphatic system disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: anaemia, thrombocytopenia </span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Immune
system disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hypersensitivity reactions such as angioedema, rash, urticaria,
anaphylactic reaction, anaphylactic shock</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Metabolism
and nutrition disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hyperkalaemia, hypoglycaemia</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Nervous
system disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Common: dizziness, orthostatic
dizziness*</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not known: vertigo, headache</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Ear and
labyrinth disorder</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: tinnitus</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Cardiac
disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: tachycardia</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Vascular
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: orthostatic
hypotension*</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: flushing</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Respiratory,
thoracic and mediastinal disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: cough</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Gastrointestinal
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: nausea/vomiting</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: diarrhoea,
dyspepsia/heartburn</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not known: dysgeusia</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Hepatobiliary
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: jaundice</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hepatitis, abnormal liver function</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Skin
and subcutaneous tissue disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: leukocytoclastic vasculitis</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Musculoskeletal
and connective tissue disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Common: musculoskeletal pain*</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Not known: arthralgia, myalgia (in some cases associated with
increased plasma creatine kinase levels), muscle cramps</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Renal
and urinary disorders</span></u></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in;page-break-after:
avoid'><span lang=EN-GB>Not known:  impaired renal function including
cases of renal failure in patients at risk (see section&nbsp;4.4)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Reproductive
system and breast disorders</span></u></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB>Uncommon: sexual
dysfunction</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>General
disorders and administration site conditions</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: fatigue</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: chest
pain</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Investigations</span></u></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Very common: Hyperkalaemia* occurred more often in diabetic
patients treated with irbesartan than with placebo. In diabetic hypertensive
patients with microalbuminuria and normal renal function, hyperkalaemia
(&#8805;&nbsp;5.5&nbsp;mEq/L) occurred in 29.4% of the patients in the irbesartan
300&nbsp;mg group and 22% of the patients in the placebo group. In diabetic
hypertensive patients with chronic renal insufficiency and overt proteinuria,
hyperkalaemia (&#8805;&nbsp;5.5&nbsp;mEq/L) occurred in 46.3% of the patients
in the irbesartan group and 26.3% of the patients in the placebo group.</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Common: significant increases in plasma creatine kinase were
commonly observed (1.7%) in irbesartan treated subjects. None of these
increases were associated with identifiable clinical musculoskeletal events.<br>
In 1.7% of hypertensive patients with advanced diabetic renal disease treated
with irbesartan, a decrease in haemoglobin*, which was not clinically
significant, has been observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u><b><span
lang=EN-GB> </span></b></p>

<p class=EMEABodyText><span lang=EN-GB>In a randomised trial of
318&nbsp;hypertensive children and adolescents aged 6 to 16&nbsp;years, the
following adverse reactions occurred in the 3-week double-blind phase: headache
(7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week
open-label period of this trial the most frequent laboratory abnormalities
observed were creatinine increases (6.5%) and elevated CK values in 2% of child
recipients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Reporting of suspected adverse
reactions </span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Reporting suspected adverse reactions
after authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:silver'>the national reporting system listed in Appendix V.</span>
</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.9 Overdose</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Experience in adults exposed to doses of
up to 900&nbsp;mg/day for 8&nbsp;weeks revealed no toxicity. The most likely
manifestations of overdose are expected to be hypotension and tachycardia;
bradycardia might also occur from overdose. No specific information is
available on the treatment of overdose with Karvea. The patient should be
closely monitored, and the treatment should be symptomatic and supportive.
Suggested measures include induction of emesis and/or gastric lavage. Activated
charcoal may be useful in the treatment of overdose. Irbesartan is not removed
by haemodialysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.1 Pharmacodynamic properties</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Pharmacotherapeutic
group: Angiotensin-II antagonists, plain.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>ATC&nbsp;code:
C09C&nbsp;A04.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Mechanism of action</span></u><b><span
lang=EN-GB> </span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan is a potent, orally active, selective
angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is expected to
block all actions of angiotensin-II mediated by the AT<sub>1</sub> receptor,
regardless of the source or route of synthesis of angiotensin-II. The selective
antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results in
increases in plasma renin levels and angiotensin-II levels, and a decrease in
plasma aldosterone concentration. Serum potassium levels are not significantly
affected by irbesartan alone at the recommended doses. Irbesartan does not
inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also
degrades bradykinin into inactive metabolites. Irbesartan does not require
metabolic activation for its activity.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><u><span lang=EN-GB style='font-weight:normal'>Clinical
efficacy</span></u></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hypertension</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan lowers blood pressure with minimal
change in heart rate. The decrease in blood pressure is dose-related for once a
day doses with a tendency towards plateau at doses above 300&nbsp;mg. Doses of
150-300&nbsp;mg once daily lower supine or seated blood pressures at trough
(i.e.&nbsp;24&nbsp;hours after dosing) by an average of
8-13/5-8&nbsp;mm&nbsp;Hg (systolic/diastolic) greater than those associated
with placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Peak reduction of blood pressure is
achieved within 3-6&nbsp;hours after administration and the blood pressure
lowering effect is maintained for at least 24&nbsp;hours. At 24&nbsp;hours the
reduction of blood pressure was 60-70% of the corresponding peak diastolic and
systolic responses at the recommended doses. Once daily dosing with 150&nbsp;mg
produced trough and mean 24&nbsp;hour responses similar to twice daily dosing on
the same total dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The blood pressure lowering effect of Karvea
is evident within 1-2&nbsp;weeks, with the maximal effect occurring by
4-6&nbsp;weeks after start of therapy. The antihypertensive effects are
maintained during long term therapy. After withdrawal of therapy, blood pressure
gradually returns toward baseline. Rebound hypertension has not been observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The blood pressure lowering effects of
irbesartan and thiazide-type diuretics are additive. In patients not adequately
controlled by irbesartan alone, the addition of a low dose of
hydrochlorothiazide (12.5&nbsp;mg) to irbesartan once daily results in a
further placebo-adjusted blood pressure reduction at trough of
7-10/3-6&nbsp;mm&nbsp;Hg (systolic/diastolic).</span></p>

<p class=EMEABodyText><span lang=EN-GB>The efficacy of Karvea is not influenced
by age or gender. As is the case with other medicinal products that affect the
renin-angiotensin system, black hypertensive patients have notably less
response to irbesartan monotherapy. When irbesartan is administered
concomitantly with a low dose of hydrochlorothiazide (e.g.&nbsp;12.5&nbsp;mg
daily), the antihypertensive response in black patients approaches that of
white patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>There is no clinically important effect
on serum uric acid or urinary uric acid secretion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Reduction
of blood pressure with 0.5&nbsp;mg/kg (low), 1.5&nbsp;mg/kg (medium) and
4.5&nbsp;mg/kg (high) target titrated doses of irbesartan was evaluated in 318
hypertensive or at risk (diabetic, family history of hypertension) children and
adolescents aged 6 to 16&nbsp;years over a three week period. At the end of the
three weeks the mean reduction from baseline in the primary efficacy variable,
trough seated systolic blood pressure (SeSBP) was 11.7&nbsp;mmHg (low dose),
9.3&nbsp;mmHg (medium dose), 13.2&nbsp;mmHg (high dose). No significant
difference was apparent between these doses. Adjusted mean change of trough
seated diastolic blood pressure (SeDBP) was as follows: 3.8&nbsp;mmHg (low
dose), 3.2&nbsp;mmHg (medium dose), 5.6&nbsp;mmHg (high dose). Over a
subsequent two week period where patients were re-randomized to either active
medicinal product or placebo, patients on placebo had increases of 2.4 and
2.0&nbsp;mmHg in SeSBP and SeDBP compared to +0.1 and -0.3&nbsp;mmHg changes
respectively in those on all doses of irbesartan (see section&nbsp;4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hypertension
and type&nbsp;2 diabetes with renal disease</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>The Irbesartan Diabetic Nephropathy
Trial (IDNT) shows that irbesartan decreases the progression of renal disease
in patients with chronic renal insufficiency and overt proteinuria. IDNT was a
double blind, controlled, morbidity and mortality trial comparing Karvea,
amlodipine and placebo. In 1,715&nbsp;hypertensive patients with type&nbsp;2
diabetes, proteinuria &#8805;&nbsp;900&nbsp;mg/day and serum creatinine ranging
from 1.0-3.0&nbsp;mg/dl, the long-term effects (mean&nbsp;2.6&nbsp;years) of Karvea
on the progression of renal disease and all-cause mortality were examined.
Patients were titrated from 75&nbsp;mg to a maintenance dose of 300&nbsp;mg Karvea</span><span
lang=EN-GB style='font-family:"Times",serif'>, from 2.5&nbsp;mg to 10&nbsp;mg
amlodipine, or placebo</span><span lang=EN-GB> as tolerated. Patients in all
treatment groups typically received between&nbsp;2 and 4&nbsp;antihypertensive
agents (e.g., diuretics, beta&nbsp;blockers, alpha&nbsp;blockers) to reach a
predefined blood pressure goal of &#8804;&nbsp;135/85&nbsp;mmHg or a
10&nbsp;mmHg reduction in systolic pressure if baseline was
&gt;&nbsp;160&nbsp;mmHg. Sixty per cent (60%) of patients in the placebo group
reached this target blood pressure whereas this figure was 76% and 78% in the
irbesartan and amlodipine groups respectively. Irbesartan significantly reduced
the relative risk in the primary combined endpoint of doubling serum
creatinine, end-stage renal disease (ESRD) or all-cause mortality.
Approximately 33% of patients in the irbesartan group reached the primary renal
composite endpoint compared to 39% and 41% in the placebo and amlodipine groups
[20% relative risk reduction versus placebo (p&nbsp;=&nbsp;0.024) and 23%
relative risk reduction compared to amlodipine (p&nbsp;=&nbsp;0.006)]. When the
individual components of the primary endpoint were analysed, no effect in all
cause mortality was observed, while a positive trend in the reduction in ESRD
and a significant reduction in doubling of serum creatinine were observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>Subgroups
consisting of gender, race, age, duration of diabetes, baseline blood pressure,
serum creatinine, and albumin excretion rate were assessed for treatment
effect. In the female and black subgroups which represented 32% and 26% of the
overall study population respectively, a renal benefit was not evident, </span>although
the confidence intervals do not exclude it. As for the secondary endpoint of
fatal and non-fatal cardiovascular events, there was no difference among the
three groups in the overall population, although an increased incidence of
non-fatal MI was seen for women and a decreased incidence of non-fatal MI was
seen in males in the irbesartan group versus the placebo-based regimen. An
increased incidence of non-fatal MI and stroke was seen in females in the
irbesartan-based regimen versus the amlodipine-based regimen, while
hospitalization due to heart failure was reduced in the overall population.
However, no proper explanation for these findings in women has been identified.</p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The study of the Effects of Irbesartan
on Microalbuminuria in Hypertensive Patients with type&nbsp;2 Diabetes Mellitus
(IRMA&nbsp;2) shows that irbesartan 300&nbsp;mg delays progression to overt
proteinuria in patients with microalbuminuria. IRMA&nbsp;2 was a
placebo-controlled double blind morbidity study in 590&nbsp;patients with
type&nbsp;2 diabetes, microalbuminuria (30-300&nbsp;mg/day) and normal renal
function (serum creatinine&nbsp;&#8804;&nbsp;1.5&nbsp;mg/dl in males and
&lt;&nbsp;1.1&nbsp;mg/dl in females). The study examined the long-term effects
(2&nbsp;years) of Karvea on the progression to clinical (overt) proteinuria
(urinary albumin excretion rate (UAER) &gt;&nbsp;300&nbsp;mg/day, and an
increase in UAER of at least 30% from baseline). The predefined blood pressure
goal was &#8804;&nbsp;135/85&nbsp;mmHg. Additional antihypertensive agents
(excluding ACE inhibitors, angiotensin&nbsp;II receptor antagonists and
dihydropyridine calcium blockers) were added as needed to help achieve the
blood pressure goal. While similar blood pressure was achieved in all treatment
groups, fewer subjects in the irbesartan 300&nbsp;mg group (5.2%) than in the placebo
(14.9%) or in the irbesartan 150&nbsp;mg group (9.7%) reached the endpoint of
overt proteinuria, demonstrating a 70% relative risk reduction versus placebo
(p&nbsp;=&nbsp;0.0004) for the higher dose. An accompanying improvement in the
glomerular filtration rate (GFR) was not observed during the first three months
of treatment. The slowing in the progression to clinical proteinuria was
evident as early as three months and continued over the 2&nbsp;year period.
Regression to normoalbuminuria (&lt;&nbsp;30&nbsp;mg/day) was more frequent in
the Karvea&nbsp;300&nbsp;mg group (34%) than in the placebo group (21%).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS)</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Two large randomised, controlled trials
(ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global
Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))
have examined the use of the combination of an ACE-inhibitor with an
angiotensin II receptor blocker. ONTARGET was a study conducted in patients
with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes
mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study
in patients with type 2 diabetes mellitus and diabetic nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>These studies have shown no significant
beneficial effect on renal and/or cardiovascular outcomes and mortality, while
an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as
compared to monotherapy was observed. Given their similar pharmacodynamic
properties, these results are also relevant for other ACE-inhibitors and
angiotensin II receptor blockers.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ACE-inhibitors and angiotensin II
receptor blockers should therefore not be used concomitantly in patients with
diabetic nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ALTITUDE (Aliskiren Trial in Type 2
Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed
to test the benefit of adding aliskiren to a standard therapy of an
ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2
diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
The study was terminated early because of an increased risk of adverse
outcomes. Cardiovascular death and stroke were both numerically more frequent
in the aliskiren group than in the placebo group and adverse events and serious
adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)
were more frequently reported in the aliskiren group than in the placebo group.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.2 Pharmacokinetic properties</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>After
oral administration, irbesartan is well absorbed: studies of absolute
bioavailability gave values of approximately 60-80%. Concomitant food intake
does not significantly influence the bioavailability of irbesartan. </span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Plasma
protein binding is approximately 96%, with negligible binding to cellular blood
components. The volume of distribution is 53-93&nbsp;litres. </span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Following
oral or intravenous administration of <sup><span style='position:relative;
top:-1.0pt'>14</span></sup>C irbesartan, 80-85% of the circulating plasma
radioactivity is attributable to unchanged irbesartan. Irbesartan is
metabolised by the liver via glucuronide conjugation and oxidation. The major
circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In&nbsp;vitro</i>
studies indicate that irbesartan is primarily oxidised by the
cytochrome&nbsp;P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Linearity/ non-linearity</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan exhibits linear and dose
proportional pharmacokinetics over the dose range of 10&nbsp;to 600&nbsp;mg. A
less than proportional increase in oral absorption at doses beyond 600&nbsp;mg
(twice the maximal recommended dose) was observed; the mechanism for this is
unknown. Peak plasma concentrations are attained at 1.5-2&nbsp;hours after oral
administration. The total body and renal clearance are 157-176&nbsp;and
3-3.5&nbsp;ml/min, respectively. The terminal elimination half-life of irbesartan
is 11-15&nbsp;hours. Steady-state plasma concentrations are attained within
3&nbsp;days after initiation of a once-daily dosing regimen. Limited
accumulation of irbesartan (&lt;&nbsp;20%) is observed in plasma upon repeated
once-daily dosing. In a study, somewhat higher plasma concentrations of
irbesartan were observed in female hypertensive patients. However, there was no
difference in the half-life and accumulation of irbesartan. No dosage
adjustment is necessary in female patients. Irbesartan AUC and C<span
class=EMEASubscript>max</span> values were also somewhat greater in oldersubjects
(&#8805;&nbsp;65&nbsp;years) than those of young subjects (18-40&nbsp;years).
However the terminal half-life was not significantly altered. No dosage
adjustment is necessary in older people.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Elimination</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan and its metabolites are
eliminated by both biliary and renal pathways. After either oral or IV
administration of <sup><span style='position:relative;top:-1.0pt'>14</span></sup>C
irbesartan, about 20% of the radioactivity is recovered in the urine, and the
remainder in the faeces. Less than 2% of the dose is excreted in the urine as
unchanged irbesartan.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>The pharmacokinetics of irbesartan were
evaluated in 23&nbsp;hypertensive children after the administration of single
and multiple daily doses of irbesartan (2&nbsp;mg/kg) up to a maximum daily
dose of 150&nbsp;mg for four weeks. Of those 23 children, 21 were evaluable for
comparison of pharmacokinetics with adults (twelve children over 12&nbsp;years,
nine children between 6 and 12 years). Results showed that C<span
class=EMEASubscript>max</span>, AUC and clearance rates were comparable to
those observed in adult patients receiving 150&nbsp;mg irbesartan daily. A
limited accumulation of irbesartan (18%) in plasma was observed upon repeated
once daily dosing.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients with renal impairment or
those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan
are not significantly altered. Irbesartan is not removed by haemodialysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hepatic impairment</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients with mild to moderate
cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly
altered.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Studies have not been performed in
patients with severe hepatic impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.3<i> </i>Preclinical safety data</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>There was
no evidence of abnormal systemic or target organ toxicity at clinically
relevant doses. In non-clinical safety studies, high doses of irbesartan
(&#8805;&nbsp;250&nbsp;mg/kg/day in rats and &#8805;&nbsp;100&nbsp;mg/kg/day in
macaques) caused a reduction of red blood cell parameters (erythrocytes,
haemoglobin, haematocrit). At very high doses (&#8805;&nbsp;500&nbsp;mg/kg/day)
degenerative changes in the kidney (such as interstitial nephritis, tubular
distension, basophilic tubules, increased plasma concentrations of urea and
creatinine) were induced by irbesartan in the rat and the macaque and are
considered secondary to the hypotensive effects of the medicinal product which
led to decreased renal perfusion. Furthermore, irbesartan induced
hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at
&#8805;&nbsp;90&nbsp;mg/kg/day, in macaques at &#8805;&nbsp;10&nbsp;mg/kg/day).
All of these changes were considered to be caused by the pharmacological action
of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/
hypertrophy of the renal juxtaglomerular cells does not appear to have any
relevance.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>There was no evidence of mutagenicity,
clastogenicity or carcinogenicity.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Fertility and reproductive performance
were not affected in studies of male and female rats even at oral doses of
irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including
mortality at the highest dose. No significant effects on the number of corpora
lutea, implants, or live foetuses were observed. Irbesartan did not affect
survival, development, or reproduction of offspring. Studies in animals
indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.
Irbesartan is excreted in the milk of lactating rats.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Animal studies with irbesartan showed
transient toxic effects (increased renal pelvic cavitation, hydroureter or
subcutaneous oedema) in rat foetuses, which were resolved after birth. In
rabbits, abortion or early resorption were noted at doses causing significant
maternal toxicity, including mortality. No teratogenic effects were observed in
the rat or rabbit.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.1 List of excipients</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Microcrystalline
cellulose</span></p>

<p class=EMEABodyText><span lang=EN-GB>Croscarmellose sodium</span></p>

<p class=EMEABodyText><span lang=EN-GB>Lactose monohydrate</span></p>

<p class=EMEABodyText><span lang=EN-GB>Magnesium stearate</span></p>

<p class=EMEABodyText><span lang=EN-GB>Colloidal hydrated silica</span></p>

<p class=EMEABodyText><span lang=EN-GB>Pregelatinised maize starch</span></p>

<p class=EMEABodyText><span lang=EN-GB>Poloxamer&nbsp;188</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.2 Incompatibilities</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
applicable.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.3 Shelf life</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>3&nbsp;years.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.4 Special precautions for storage</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Do not
store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>6.5 Nature
and contents of container</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 14&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 28&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 56&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 98&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 56&nbsp;x&nbsp;1&nbsp;tablet
in PVC/PVDC/Aluminium perforated unit dose blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.6 Special precautions for disposal</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Any
unused medicinal product or waste material should be disposed of in accordance
with local requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=FR>7. MARKETING AUTHORISATION HOLDER</span></p>

<p class=EMEAHeading1><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=FR>8. MARKETING AUTHORISATION NUMBERS</span></p>

<p class=EMEAHeading1><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=NO-BOK>EU/1/97/049/004-006<br>
EU/1/97/049/011<br>
EU/1/97/049/014</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>9. DATE OF FIRST AUTHORISATION /
RENEWAL OF THE AUTHORISATION</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Date of first authorisation: 27 August
1997<br>
Date of latest renewal: 27 August 2007</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency
http://www.ema.europa.eu</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;300&nbsp;mg tablets.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Each tablet contains 300&nbsp;mg of
irbesartan.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Excipient with known effect</span></u><span
lang=EN-GB>: 61.50&nbsp;mg of lactose monohydrate per tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For the full list of excipients, see
section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB>White to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2773 engraved
on the other side.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>4. CLINICAL PARTICULARS</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.1 Therapeutic indications</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Karvea is
indicated in adults for the treatment of essential hypertension.</span></p>

<p class=EMEABodyText><span lang=EN-GB>It is also indicated for the treatment
of renal disease in adult patients with hypertension and type&nbsp;2 diabetes
mellitus as part of an antihypertensive medicinal product regimen (see sections
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.2 Posology and method of
administration</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>The usual
recommended initial and maintenance dose is 150&nbsp;mg once daily, with or
without food. Karvea at a dose of 150&nbsp;mg once daily generally provides a
better 24&nbsp;hour blood pressure control than 75&nbsp;mg. However, initiation
of therapy with 75&nbsp;mg could be considered, particularly in haemodialysed
patients and in the elderly over 75&nbsp;years.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients insufficiently controlled
with 150&nbsp;mg once daily, the dose of Karvea can be increased to
300&nbsp;mg, or other antihypertensive agents can be added (see sections 4.3,
4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as
hydrochlorothiazide has been shown to have an additive effect with Karvea (see
section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In hypertensive type&nbsp;2 diabetic
patients, therapy should be initiated at 150&nbsp;mg irbesartan once daily and
titrated up to 300&nbsp;mg once daily as the preferred maintenance dose for
treatment of renal disease.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The demonstration of renal benefit of Karvea
in hypertensive type&nbsp;2 diabetic patients is based on studies where
irbesartan was used in addition to other antihypertensive agents, as needed, to
reach target blood pressure (see sections 4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Special Populations</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><span lang=EN-GB>Renal impairment</span></i><span
lang=EN-GB> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No dosage adjustment is necessary in
patients with impaired renal function. A lower starting dose (75&nbsp;mg)
should be considered for patients undergoing haemodialysis (see section 4.4).</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><i><span lang=EN-GB>Hepatic impairment</span></i><span
lang=EN-GB> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No dosage adjustment is necessary in
patients with mild to moderate hepatic impairment. There is no clinical
experience in patients with severe hepatic impairment.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><i><span lang=EN-GB>Older people</span></i><span
lang=EN-GB> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Although consideration should be given
to initiating therapy with 75&nbsp;mg in patients over 75&nbsp;years of age,
dosage adjustment is not usually necessary for older people.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><i><span lang=EN-GB>Paediatric population</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of Karvea in
children aged 0 to 18 has not been established. Currently available data are
described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can
be made.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Method of Administration</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.3 Contraindications</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Second and third trimesters of pregnancy
(see sections&nbsp;4.4 and&nbsp;4.6).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The concomitant use of Karvea with
aliskiren-containing products is contraindicated in patients with diabetes
mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60
ml/min/1.73m<sup>2</sup>) (see sections 4.5 and 5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.4 Special warnings and precautions
for use</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Intravascular
volume depletion</span></u><span lang=EN-GB>: symptomatic hypotension,
especially after the first dose, may occur in patients who are volume and/or
sodium depleted by vigorous diuretic therapy, dietary salt restriction,
diarrhoea or vomiting. Such conditions should be corrected before the
administration of Karvea.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renovascular hypertension</span></u><span
lang=EN-GB>: there is an increased risk of severe hypotension and renal
insufficiency when patients with bilateral renal artery stenosis or stenosis of
the artery to a single functioning kidney are treated with medicinal products
that affect the renin-angiotensin-aldosterone system. While this is not
documented with Karvea, a similar effect should be anticipated with
angiotensin-II receptor antagonists.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renal impairment and kidney
transplantation</span></u><span lang=EN-GB>: when Karvea is used in patients
with impaired renal function, a periodic monitoring of potassium and creatinine
serum levels is recommended. There is no experience regarding the
administration of Karvea in patients with a recent kidney transplantation.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hypertensive patients with
type&nbsp;2 diabetes and renal disease</span></u><span lang=EN-GB>:</span><span
lang=EN-GB style='layout-grid-mode:line'> the effects of irbesartan both on
renal and cardiovascular events were not uniform across all subgroups, in an
analysis carried out in the study with patients with advanced renal disease. In
particular, they appeared less favourable in women and non-white subjects (see
section&nbsp;5.1).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS):</span></u><span lang=EN-GB> there
is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor
blockers or aliskiren increases the risk of hypotension, hyperkalaemia and
decreased renal function (including acute renal failure). Dual blockade of RAAS
through the combined use of ACE-inhibitors, angiotensin II receptor blockers or
aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual
blockade therapy is considered absolutely necessary, this should only occur
under specialist supervision and subject to frequent close monitoring of renal
function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II
receptor blockers should not be used concomitantly in patients with diabetic
nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hyperkalaemia</span></u><span
lang=EN-GB>: as with other medicinal products that affect the
renin-angiotensin-aldosterone system, hyperkalaemia may occur during the
treatment with Karvea, especially in the presence of renal impairment, overt
proteinuria due to diabetic renal disease, and/or heart failure. Close
monitoring of serum potassium in patients at risk is recommended (see
section&nbsp;4.5).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hypoglycaemia</span></u><span
lang=EN-GB>: Karvea may induce hypoglycaemia, particularly in diabetic patients.
In patients treated with insulin or antidiabetics an appropriate blood glucose
monitoring should be considered; a dose adjustment of insulin or antidiabetics may
be required when indicated (see section 4.5).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Lithium</span></u><span lang=EN-GB>:
the combination of lithium and Karvea is not recommended (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Aortic and mitral valve stenosis, obstructive
hypertrophic cardiomyopathy</span></u><span lang=EN-GB>: as with other
vasodilators, special caution is indicated in patients suffering from aortic or
mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Primary aldosteronism</span></u><span
lang=EN-GB>: patients with primary aldosteronism generally will not respond to
antihypertensive medicinal products acting through inhibition of the renin-angiotensin
system. Therefore, the use of Karvea is not recommended.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>General</span></u><span lang=EN-GB>:
in patients whose vascular tone and renal function depend predominantly on the
activity of the renin-angiotensin-aldosterone system (e.g.&nbsp;patients with
severe congestive heart failure or underlying renal disease, including renal
artery stenosis), treatment with angiotensin<b> </b>converting enzyme
inhibitors or angiotensin-II receptor antagonists that affect this system has
been associated with acute hypotension, azotaemia, oliguria, or rarely acute
renal failure (see section 4.5). As with any antihypertensive agent, excessive
blood pressure decrease in patients with ischaemic cardiopathy or ischaemic
cardiovascular disease could result in a myocardial infarction or stroke.</span></p>

<p class=EMEABodyText><span lang=EN-GB>As observed for angiotensin converting
enzyme inhibitors, irbesartan and the other angiotensin antagonists are
apparently less effective in lowering blood pressure in black people than in
non-blacks, possibly because of higher prevalence of low-renin states in the
black hypertensive population (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Pregnancy:</span></u><span
lang=EN-GB> angiotensin&nbsp;II Receptor Antagonists (AIIRAs) should not be
initiated during pregnancy. </span><span lang=EN-GB>Unless continued AIIRA
therapy is considered essential, patients planning pregnancy should be changed
to alternative antihypertensive treatments which have an established safety
profile for use in pregnancy. When pregnancy is diagnosed, treatment with </span><span
lang=EN-GB>AIIRAs</span><span lang=EN-GB> should be stopped immediately, and,
if appropriate, alternative therapy should be started (see sections&nbsp;4.3
and&nbsp;4.6).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u><span
lang=EN-GB>: irbesartan has been studied in paediatric populations aged 6 to 16
years old but the current data are insufficient to support an extension of the
use in children until further data become available (see sections&nbsp;4.8, 5.1
and&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients</span></u><span lang=FR>:</span></p>

<p class=EMEABodyText><span lang=FR>Karvea&nbsp;300 mg tablet contains lactose.
</span><span lang=EN-GB>Patients with rare hereditary problems of galactose
intolerance, total lactase deficiency or glucose-galactose malabsorption should
not take this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>Karvea&nbsp;300 mg tablet contains sodium. </span><span
lang=EN-GB>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that
is to say essentially sodium-free.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.5 Interaction with other medicinal
products and other forms of interaction</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Diuretics and other antihypertensive
agents</span></u><span lang=EN-GB>: other antihypertensive agents may increase
the hypotensive effects of irbesartan; however Karvea has been safely
administered with other antihypertensive agents, such as beta-blockers,
long-acting calcium channel blockers, and thiazide diuretics. Prior treatment
with high dose diuretics may result in volume depletion and a risk of
hypotension when initiating therapy with Karvea (see section&nbsp;4.4).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Aliskiren-containing products or
ACE-inhibitors</span></u><span lang=EN-GB>: clinical trial data has shown that
dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the
combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren
is associated with a higher frequency of adverse events such as hypotension,
hyperkalaemia and decreased renal function (including acute renal failure)
compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Potassium supplements and
potassium-sparing diuretics</span></u><span lang=EN-GB>:<i> </i>based on
experience with the use of other medicinal products that affect the
renin-angiotensin system, concomitant use of potassium-sparing diuretics,
potassium supplements, salt substitutes containing potassium or other medicinal
products that may increase serum potassium levels (e.g.&nbsp;heparin) may lead
to increases in serum potassium and is, therefore, not recommended (see
section&nbsp;4.4).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Lithium</span></u><span lang=EN-GB>:<i>
</i>reversible increases in serum lithium concentrations and toxicity have been
reported during concomitant administration of lithium with angiotensin
converting enzyme inhibitors. Similar effects have been very rarely reported
with irbesartan so far. Therefore, this combination is not recommended (see
section&nbsp;4.4). If the combination proves necessary, careful monitoring of
serum lithium levels is recommended.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Non-steroidal anti-inflammatory drugs</span></u><span
lang=EN-GB>: w<span style='color:black'>hen angiotensin&nbsp;II antagonists are
administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.
selective COX-2 inhibitors, acetylsalicylic acid (&gt;&nbsp;3&nbsp;g/day) and
non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>As with ACE
inhibitors, concomitant use of angiotensin&nbsp;II antagonists and NSAIDs may
lead to an increased risk of worsening of renal function, including possible
acute renal failure, and an increase in serum potassium, especially in patients
with poor pre-existing renal function. The combination should be administered
with caution, especially in the elderly. Patients should be adequately hydrated
and consideration should be given to monitoring renal function after initiation
of concomitant therapy, and periodically thereafter.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Repaglinide:</span></u><span
lang=EN-GB style='color:black'> irbesartan has the potential to inhibit OATP1B1.
In a clinical study, it was reported that irbesartan increased the C<sub>max</sub>
and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3&#8209;fold,
respectively, when administered 1 hour before repaglinide. In another study, no
relevant pharmacokinetic interaction was reported, when the two drugs were
co-administered. Therefore, dose adjustment of antidiabetic treatment such as
repaglinide may be required (see section 4.4).</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText><u><span lang=EN-GB>Additional information on irbesartan
interactions</span></u><span lang=EN-GB>: <span style='color:black'>in clinical
studies, the pharmacokinetic of irbesartan is not affected by
hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser
extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic
interactions were observed when irbesartan was coadministered with warfarin, a
medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as
rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The
pharmacokinetic of digoxin was not altered by coadministration of irbesartan.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.6 Fertility, pregnancy and lactation</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEABodyText style='border:none;padding:0in'><span lang=EN-GB>The use
of AIIRAs is not recommended during the first trimester of pregnancy (see
section&nbsp;4.4). The use of AIIRAs is contraindicated during the second and
third trimesters of pregnancy (see sections&nbsp;4.3 and&nbsp;4.4).</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Epidemiological evidence regarding the
risk of teratogenicity following exposure to ACE inhibitors during the first
trimester of pregnancy has not been conclusive; however a small increase in risk
cannot be excluded. Whilst there is no controlled epidemiological data on the
risk with Angiotensin&nbsp;II Receptor Antagonists (AIIRAs), similar risks may
exist for this class of drugs. Unless continued AIIRA therapy is considered
essential, patients planning pregnancy should be changed to alternative
antihypertensive treatments which have an established safety profile for use in
pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped
immediately, and, if appropriate, alternative therapy should be started.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Exposure to AIIRA therapy during the
second and third trimesters is known to induce human foetotoxicity (decreased
renal function, oligohydramnios, skull ossification retardation) and neonatal
toxicity (renal failure, hypotension, hyperkalaemia). (See section&nbsp;5.3).</span></p>

<p class=EMEABodyText><span lang=EN-GB>Should exposure to AIIRAs have occurred
from the second trimester of pregnancy, ultrasound check of renal function and
skull is recommended.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Infants whose mothers have taken AIIRAs
should be closely observed for hypotension (see sections&nbsp;4.3 and&nbsp;4.4).</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Because no information is available regarding
the use of Karvea during breast-feeding, Karvea is not recommended and
alternative treatments with better established safety profiles during
breast-feeding are preferable, especially while nursing a newborn or preterm
infant.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>It is unknown whether irbesartan or its metabolites are
excreted in human milk. </p>

<p class=EMEABodyText>Available pharmacodynamic/toxicological data in rats have
shown excretion of irbesartan or its metabolites in milk (for details see 5.3).</p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Fertility</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan had no effect upon fertility
of treated rats and their offspring up to the dose levels inducing the first
signs of parental toxicity (see section 5.3).</span> </p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=EN-GB>4.7 Effects on ability to drive and
use machines</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Based on its pharmacodynamic properties,
irbesartan is unlikely to affect the abilityto drive and use machine. When
driving vehicles or operating machines, it should be taken into account that
dizziness or weariness may occur during treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.8 Undesirable effects</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>In
placebo-controlled trials in patients with hypertension, the overall incidence
of adverse events did not differ between the irbesartan (56.2%) and the placebo
groups (56.5%). Discontinuation due to any clinical or laboratory adverse event
was less frequent for irbesartan-treated patients (3.3%) than for
placebo-treated patients (4.5%). The incidence of adverse events was not
related to dose (in the recommended dose range), gender, age, race, or duration
of treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In diabetic hypertensive patients with
microalbuminuria and normal renal function, orthostatic dizziness and
orthostatic hypotension were reported in 0.5% of the patients (i.e.,&nbsp;uncommon)
but in excess of placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The following table presents the adverse
drug reactions that were reported in placebo-controlled trials in which
1,965&nbsp;hypertensive patients received irbesartan. Terms marked with a star
(*) refer to the adverse reactions that were additionally reported in &gt; 2%
of diabetic hypertensive patients with chronic renal insufficiency and overt
proteinuria and in excess of placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The frequency of adverse reactions
listed below is defined using the following convention:</span></p>

<p class=EMEABodyText><span lang=EN-GB>very common (&#8805;&nbsp;1/10); common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare
(&lt;&nbsp;1/10,000). Within each frequency grouping, undesirable effects are
presented in order of decreasing seriousness.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Adverse reactions additionally reported
from postmarketing experience are also listed. These adverse reactions are
derived from spontaneous reports.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Blood
and lymphatic system disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: anaemia, thrombocytopenia</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Immune
system disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hypersensitivity reactions such as angioedema, rash, urticaria,
anaphylactic reaction, anaphylactic shock</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Metabolism
and nutrition disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hyperkalaemia, hypoglycaemia</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Nervous
system disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Common: dizziness, orthostatic
dizziness*</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not known: vertigo, headache</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Ear and
labyrinth disorder</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: tinnitus</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Cardiac
disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: tachycardia</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Vascular
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: orthostatic
hypotension*</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: flushing</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Respiratory,
thoracic and mediastinal disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: cough</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Gastrointestinal
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: nausea/vomiting</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: diarrhoea,
dyspepsia/heartburn</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not known: dysgeusia</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Hepatobiliary
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: jaundice</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hepatitis, abnormal liver function</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Skin
and subcutaneous tissue disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: leukocytoclastic vasculitis</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Musculoskeletal
and connective tissue disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Common: musculoskeletal pain*</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Not known: arthralgia, myalgia (in some cases associated with
increased plasma creatine kinase levels), muscle cramps</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Renal
and urinary disorders</span></u></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in;page-break-after:
avoid'><span lang=EN-GB>Not known:  impaired renal function including
cases of renal failure in patients at risk (see section&nbsp;4.4)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Reproductive
system and breast disorders</span></u></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB>Uncommon: sexual
dysfunction</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>General
disorders and administration site conditions</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: fatigue</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: chest
pain</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Investigations</span></u></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Very common: Hyperkalaemia* occurred more often in diabetic
patients treated with irbesartan than with placebo. In diabetic hypertensive
patients with microalbuminuria and normal renal function, hyperkalaemia
(&#8805;&nbsp;5.5&nbsp;mEq/L) occurred in 29.4% of the patients in the irbesartan
300&nbsp;mg group and 22% of the patients in the placebo group. In diabetic
hypertensive patients with chronic renal insufficiency and overt proteinuria,
hyperkalaemia (&#8805;&nbsp;5.5&nbsp;mEq/L) occurred in 46.3% of the patients
in the irbesartan group and 26.3% of the patients in the placebo group.</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Common: significant increases in plasma creatine kinase were
commonly observed (1.7%) in irbesartan treated subjects. None of these
increases were associated with identifiable clinical musculoskeletal events.<br>
In 1.7% of hypertensive patients with advanced diabetic renal disease treated
with irbesartan, a decrease in haemoglobin*, which was not clinically
significant, has been observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u><b><span
lang=EN-GB> </span></b></p>

<p class=EMEABodyText><span lang=EN-GB>In a randomised trial of
318&nbsp;hypertensive children and adolescents aged 6 to 16&nbsp;years, the
following adverse reactions occurred in the 3-week double-blind phase: headache
(7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week
open-label period of this trial the most frequent laboratory abnormalities
observed were creatinine increases (6.5%) and elevated CK values in 2% of child
recipients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Reporting of suspected adverse
reactions </span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Reporting suspected adverse reactions
after authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:silver'>the national reporting system listed in Appendix V.</span>
</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.9 Overdose</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Experience in adults exposed to doses of
up to 900&nbsp;mg/day for 8&nbsp;weeks revealed no toxicity. The most likely
manifestations of overdose are expected to be hypotension and tachycardia;
bradycardia might also occur from overdose. No specific information is
available on the treatment of overdose with Karvea. The patient should be
closely monitored, and the treatment should be symptomatic and supportive.
Suggested measures include induction of emesis and/or gastric lavage. Activated
charcoal may be useful in the treatment of overdose. Irbesartan is not removed
by haemodialysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.1 Pharmacodynamic properties</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Pharmacotherapeutic
group: Angiotensin-II antagonists, plain.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>ATC&nbsp;code:
C09C&nbsp;A04.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Mechanism of action</span></u><b><span
lang=EN-GB> </span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan is a potent, orally active,
selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is
expected to block all actions of angiotensin-II mediated by the AT<sub>1</sub>
receptor, regardless of the source or route of synthesis of angiotensin-II. The
selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results
in increases in plasma renin levels and angiotensin-II levels, and a decrease
in plasma aldosterone concentration. Serum potassium levels are not
significantly affected by irbesartan alone at the recommended doses. Irbesartan
does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II
and also degrades bradykinin into inactive metabolites. Irbesartan does not
require metabolic activation for its activity.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><u><span lang=EN-GB style='font-weight:normal'>Clinical
efficacy</span></u></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hypertension</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan lowers blood pressure with minimal
change in heart rate. The decrease in blood pressure is dose-related for once a
day doses with a tendency towards plateau at doses above 300&nbsp;mg. Doses of
150-300&nbsp;mg once daily lower supine or seated blood pressures at trough
(i.e.&nbsp;24&nbsp;hours after dosing) by an average of
8-13/5-8&nbsp;mm&nbsp;Hg (systolic/diastolic) greater than those associated
with placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Peak reduction of blood pressure is
achieved within 3-6&nbsp;hours after administration and the blood pressure
lowering effect is maintained for at least 24&nbsp;hours. At 24&nbsp;hours the
reduction of blood pressure was 60-70% of the corresponding peak diastolic and
systolic responses at the recommended doses. Once daily dosing with 150&nbsp;mg
produced trough and mean 24&nbsp;hour responses similar to twice daily dosing
on the same total dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The blood pressure lowering effect of Karvea
is evident within 1-2&nbsp;weeks, with the maximal effect occurring by
4-6&nbsp;weeks after start of therapy. The antihypertensive effects are
maintained during long term therapy. After withdrawal of therapy, blood pressure
gradually returns toward baseline. Rebound hypertension has not been observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The blood pressure lowering effects of
irbesartan and thiazide-type diuretics are additive. In patients not adequately
controlled by irbesartan alone, the addition of a low dose of
hydrochlorothiazide (12.5&nbsp;mg) to irbesartan once daily results in a
further placebo-adjusted blood pressure reduction at trough of
7-10/3-6&nbsp;mm&nbsp;Hg (systolic/diastolic).</span></p>

<p class=EMEABodyText><span lang=EN-GB>The efficacy of Karvea is not influenced
by age or gender. As is the case with other medicinal products that affect the
renin-angiotensin system, black hypertensive patients have notably less
response to irbesartan monotherapy. When irbesartan is administered
concomitantly with a low dose of hydrochlorothiazide (e.g.&nbsp;12.5&nbsp;mg
daily), the antihypertensive response in black patients approaches that of
white patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>There is no clinically important effect
on serum uric acid or urinary uric acid secretion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Reduction
of blood pressure with 0.5&nbsp;mg/kg (low), 1.5&nbsp;mg/kg (medium) and
4.5&nbsp;mg/kg (high) target titrated doses of irbesartan was evaluated in 318
hypertensive or at risk (diabetic, family history of hypertension) children and
adolescents aged 6 to 16&nbsp;years over a three week period. At the end of the
three weeks the mean reduction from baseline in the primary efficacy variable,
trough seated systolic blood pressure (SeSBP) was 11.7&nbsp;mmHg (low dose),
9.3&nbsp;mmHg (medium dose), 13.2&nbsp;mmHg (high dose). No significant
difference was apparent between these doses. Adjusted mean change of trough
seated diastolic blood pressure (SeDBP) was as follows: 3.8&nbsp;mmHg (low
dose), 3.2&nbsp;mmHg (medium dose), 5.6&nbsp;mmHg (high dose). Over a
subsequent two week period where patients were re-randomized to either active
medicinal product or placebo, patients on placebo had increases of 2.4 and
2.0&nbsp;mmHg in SeSBP and SeDBP compared to +0.1 and -0.3&nbsp;mmHg changes
respectively in those on all doses of irbesartan (see section&nbsp;4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hypertension
and type&nbsp;2 diabetes with renal disease</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>The Irbesartan Diabetic Nephropathy
Trial (IDNT) shows that irbesartan decreases the progression of renal disease
in patients with chronic renal insufficiency and overt proteinuria. IDNT was a
double blind, controlled, morbidity and mortality trial comparing Karvea,
amlodipine and placebo. In 1,715&nbsp;hypertensive patients with type&nbsp;2
diabetes, proteinuria &#8805;&nbsp;900&nbsp;mg/day and serum creatinine ranging
from 1.0-3.0&nbsp;mg/dl, the long-term effects (mean&nbsp;2.6&nbsp;years) of Karvea
on the progression of renal disease and all-cause mortality were examined.
Patients were titrated from 75&nbsp;mg to a maintenance dose of 300&nbsp;mg Karvea</span><span
lang=EN-GB style='font-family:"Times",serif'>, from 2.5&nbsp;mg to 10&nbsp;mg
amlodipine, or placebo</span><span lang=EN-GB> as tolerated. Patients in all
treatment groups typically received between&nbsp;2 and 4&nbsp;antihypertensive
agents (e.g., diuretics, beta&nbsp;blockers, alpha&nbsp;blockers) to reach a
predefined blood pressure goal of &#8804;&nbsp;135/85&nbsp;mmHg or a
10&nbsp;mmHg reduction in systolic pressure if baseline was
&gt;&nbsp;160&nbsp;mmHg. Sixty per cent (60%) of patients in the placebo group
reached this target blood pressure whereas this figure was 76% and 78% in the
irbesartan and amlodipine groups respectively. Irbesartan significantly reduced
the relative risk in the primary combined endpoint of doubling serum
creatinine, end-stage renal disease (ESRD) or all-cause mortality.
Approximately 33% of patients in the irbesartan group reached the primary renal
composite endpoint compared to 39% and 41% in the placebo and amlodipine groups
[20% relative risk reduction versus placebo (p&nbsp;=&nbsp;0.024) and 23%
relative risk reduction compared to amlodipine (p&nbsp;=&nbsp;0.006)]. When the
individual components of the primary endpoint were analysed, no effect in all
cause mortality was observed, while a positive trend in the reduction in ESRD
and a significant reduction in doubling of serum creatinine were observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>Subgroups
consisting of gender, race, age, duration of diabetes, baseline blood pressure,
serum creatinine, and albumin excretion rate were assessed for treatment
effect. In the female and black subgroups which represented 32% and 26% of the
overall study population respectively, a renal benefit was not evident, </span>although
the confidence intervals do not exclude it. As for the secondary endpoint of
fatal and non-fatal cardiovascular events, there was no difference among the
three groups in the overall population, although an increased incidence of
non-fatal MI was seen for women and a decreased incidence of non-fatal MI was
seen in males in the irbesartan group versus the placebo-based regimen. An
increased incidence of non-fatal MI and stroke was seen in females in the
irbesartan-based regimen versus the amlodipine-based regimen, while
hospitalization due to heart failure was reduced in the overall population.
However, no proper explanation for these findings in women has been identified.</p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The study of the Effects of Irbesartan
on Microalbuminuria in Hypertensive Patients with type&nbsp;2 Diabetes Mellitus
(IRMA&nbsp;2) shows that irbesartan 300&nbsp;mg delays progression to overt
proteinuria in patients with microalbuminuria. IRMA&nbsp;2 was a
placebo-controlled double blind morbidity study in 590&nbsp;patients with
type&nbsp;2 diabetes, microalbuminuria (30-300&nbsp;mg/day) and normal renal
function (serum creatinine&nbsp;&#8804;&nbsp;1.5&nbsp;mg/dl in males and
&lt;&nbsp;1.1&nbsp;mg/dl in females). The study examined the long-term effects
(2&nbsp;years) of Karvea on the progression to clinical (overt) proteinuria
(urinary albumin excretion rate (UAER) &gt;&nbsp;300&nbsp;mg/day, and an
increase in UAER of at least 30% from baseline). The predefined blood pressure
goal was &#8804;&nbsp;135/85&nbsp;mmHg. Additional antihypertensive agents
(excluding ACE inhibitors, angiotensin&nbsp;II receptor antagonists and
dihydropyridine calcium blockers) were added as needed to help achieve the
blood pressure goal. While similar blood pressure was achieved in all treatment
groups, fewer subjects in the irbesartan 300&nbsp;mg group (5.2%) than in the
placebo (14.9%) or in the irbesartan 150&nbsp;mg group (9.7%) reached the
endpoint of overt proteinuria, demonstrating a 70% relative risk reduction
versus placebo (p&nbsp;=&nbsp;0.0004) for the higher dose. An accompanying
improvement in the glomerular filtration rate (GFR) was not observed during the
first three months of treatment. The slowing in the progression to clinical
proteinuria was evident as early as three months and continued over the
2&nbsp;year period. Regression to normoalbuminuria (&lt;&nbsp;30&nbsp;mg/day)
was more frequent in the Karvea&nbsp;300&nbsp;mg group (34%) than in the
placebo group (21%).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS)</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Two large randomised, controlled trials (ONTARGET
(ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint
Trial) and NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have
examined the use of the combination of an ACE-inhibitor with an angiotensin II
receptor blocker. ONTARGET was a study conducted in patients with a history of
cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus
accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in
patients with type 2 diabetes mellitus and diabetic nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>These studies have shown no significant
beneficial effect on renal and/or cardiovascular outcomes and mortality, while
an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as
compared to monotherapy was observed. Given their similar pharmacodynamic
properties, these results are also relevant for other ACE-inhibitors and
angiotensin II receptor blockers.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ACE-inhibitors and angiotensin II
receptor blockers should therefore not be used concomitantly in patients with
diabetic nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ALTITUDE (Aliskiren Trial in Type 2
Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed
to test the benefit of adding aliskiren to a standard therapy of an
ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2
diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
The study was terminated early because of an increased risk of adverse
outcomes. Cardiovascular death and stroke were both numerically more frequent
in the aliskiren group than in the placebo group and adverse events and serious
adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)
were more frequently reported in the aliskiren group than in the placebo group.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.2 Pharmacokinetic properties</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>After
oral administration, irbesartan is well absorbed: studies of absolute
bioavailability gave values of approximately 60-80%. Concomitant food intake
does not significantly influence the bioavailability of irbesartan. </span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Plasma
protein binding is approximately 96%, with negligible binding to cellular blood
components. The volume of distribution is 53-93&nbsp;litres. </span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Following
oral or intravenous administration of <sup><span style='position:relative;
top:-1.0pt'>14</span></sup>C irbesartan, 80-85% of the circulating plasma
radioactivity is attributable to unchanged irbesartan. Irbesartan is
metabolised by the liver via glucuronide conjugation and oxidation. The major
circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In&nbsp;vitro</i>
studies indicate that irbesartan is primarily oxidised by the
cytochrome&nbsp;P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Linearity / non-linearity</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan exhibits linear and dose
proportional pharmacokinetics over the dose range of 10&nbsp;to 600&nbsp;mg. A
less than proportional increase in oral absorption at doses beyond 600&nbsp;mg
(twice the maximal recommended dose) was observed; the mechanism for this is
unknown. Peak plasma concentrations are attained at 1.5-2&nbsp;hours after oral
administration. The total body and renal clearance are 157-176&nbsp;and
3-3.5&nbsp;ml/min, respectively. The terminal elimination half-life of
irbesartan is 11-15&nbsp;hours. Steady-state plasma concentrations are attained
within 3&nbsp;days after initiation of a once-daily dosing regimen. Limited
accumulation of irbesartan (&lt;&nbsp;20%) is observed in plasma upon repeated
once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan
were observed in female hypertensive patients. However, there was no difference
in the half-life and accumulation of irbesartan. No dosage adjustment is
necessary in female patients. Irbesartan AUC and C<span class=EMEASubscript>max</span>
values were also somewhat greater in oldersubjects (&#8805;&nbsp;65&nbsp;years)
than those of young subjects (18-40&nbsp;years). However the terminal half-life
was not significantly altered. No dosage adjustment is necessary in older
people.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Elimination</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan and its metabolites are
eliminated by both biliary and renal pathways. After either oral or IV
administration of <sup><span style='position:relative;top:-1.0pt'>14</span></sup>C
irbesartan, about 20% of the radioactivity is recovered in the urine, and the
remainder in the faeces. Less than 2% of the dose is excreted in the urine as
unchanged irbesartan.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>The pharmacokinetics of irbesartan were
evaluated in 23&nbsp;hypertensive children after the administration of single
and multiple daily doses of irbesartan (2&nbsp;mg/kg) up to a maximum daily
dose of 150&nbsp;mg for four weeks. Of those 23 children, 21 were evaluable for
comparison of pharmacokinetics with adults (twelve children over 12&nbsp;years,
nine children between 6 and 12 years). Results showed that C<span
class=EMEASubscript>max</span>, AUC and clearance rates were comparable to
those observed in adult patients receiving 150&nbsp;mg irbesartan daily. A
limited accumulation of irbesartan (18%) in plasma was observed upon repeated
once daily dosing.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients with renal impairment or
those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan
are not significantly altered. Irbesartan is not removed by haemodialysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hepatic impairment</span></u><span
lang=EN-GB>:</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients with mild to moderate
cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly
altered.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Studies have not been performed in
patients with severe hepatic impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.3<i> </i>Preclinical safety data</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>There was
no evidence of abnormal systemic or target organ toxicity at clinically
relevant doses. In non-clinical safety studies, high doses of irbesartan
(&#8805;&nbsp;250&nbsp;mg/kg/day in rats and &#8805;&nbsp;100&nbsp;mg/kg/day in
macaques) caused a reduction of red blood cell parameters (erythrocytes,
haemoglobin, haematocrit). At very high doses (&#8805;&nbsp;500&nbsp;mg/kg/day)
degenerative changes in the kidney (such as interstitial nephritis, tubular
distension, basophilic tubules, increased plasma concentrations of urea and
creatinine) were induced by irbesartan in the rat and the macaque and are
considered secondary to the hypotensive effects of the medicinal product which
led to decreased renal perfusion. Furthermore, irbesartan induced
hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at
&#8805;&nbsp;90&nbsp;mg/kg/day, in macaques at &#8805;&nbsp;10&nbsp;mg/kg/day).
All of these changes were considered to be caused by the pharmacological action
of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/
hypertrophy of the renal juxtaglomerular cells does not appear to have any
relevance.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>There was no evidence of mutagenicity,
clastogenicity or carcinogenicity.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Fertility and reproductive performance
were not affected in studies of male and female rats even at oral doses of
irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including
mortality at the highest dose. No significant effects on the number of corpora
lutea, implants, or live foetuses were observed. Irbesartan did not affect
survival, development, or reproduction of offspring. Studies in animals
indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.
Irbesartan is excreted in the milk of lactating rats.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Animal studies with irbesartan showed
transient toxic effects (increased renal pelvic cavitation, hydroureter or
subcutaneous oedema) in rat foetuses, which were resolved after birth. In
rabbits, abortion or early resorption were noted at doses causing significant
maternal toxicity, including mortality. No teratogenic effects were observed in
the rat or rabbit.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.1 List of excipients</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Microcrystalline
cellulose</span></p>

<p class=EMEABodyText><span lang=EN-GB>Croscarmellose sodium</span></p>

<p class=EMEABodyText><span lang=EN-GB>Lactose monohydrate</span></p>

<p class=EMEABodyText><span lang=EN-GB>Magnesium stearate</span></p>

<p class=EMEABodyText><span lang=EN-GB>Colloidal hydrated silica</span></p>

<p class=EMEABodyText><span lang=EN-GB>Pregelatinised maize starch</span></p>

<p class=EMEABodyText><span lang=EN-GB>Poloxamer&nbsp;188</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.2 Incompatibilities</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
applicable.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.3 Shelf life</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>3&nbsp;years.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.4 Special precautions for storage</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Do not
store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>6.5 Nature
and contents of container</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 14&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 28&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 56&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 98&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 56&nbsp;x&nbsp;1&nbsp;tablet
in PVC/PVDC/Aluminium perforated unit dose blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.6 Special precautions for disposal</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Any
unused medicinal product or waste material should be disposed of in accordance
with local requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=FR>7. MARKETING AUTHORISATION HOLDER</span></p>

<p class=EMEAHeading1><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=FR>8. MARKETING AUTHORISATION NUMBERS</span></p>

<p class=EMEAHeading1><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=NO-BOK>EU/1/97/049/007-009<br>
EU/1/97/049/012<br>
EU/1/97/049/015</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>9. DATE OF FIRST AUTHORISATION /
RENEWAL OF THE AUTHORISATION</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Date of first authorisation: 27 August
1997<br>
Date of latest renewal: 27 August 2007</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency
http://www.ema.europa.eu</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;75&nbsp;mg film-coated
tablets.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Each film-coated tablet contains 75&nbsp;mg
of irbesartan.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Excipient with known effect</span></u><span
lang=EN-GB>: 25.50&nbsp;mg of lactose monohydrate per film-coated tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For the full list of excipients, see
section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Film-coated
tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB>White to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2871 engraved
on the other side.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>4. CLINICAL PARTICULARS</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.1 Therapeutic indications</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Karvea is
indicated in adults for the treatment of essential hypertension.</span></p>

<p class=EMEABodyText><span lang=EN-GB>It is also indicated for the treatment
of renal disease in adult patients with hypertension and type&nbsp;2 diabetes
mellitus as part of an antihypertensive medicinal product regimen (see sections
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.2 Posology and method of
administration</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>The usual
recommended initial and maintenance dose is 150&nbsp;mg once daily, with or
without food. Karvea at a dose of 150&nbsp;mg once daily generally provides a
better 24&nbsp;hour blood pressure control than 75&nbsp;mg. However, initiation
of therapy with 75&nbsp;mg could be considered, particularly in haemodialysed
patients and in the elderly over 75&nbsp;years.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients insufficiently controlled
with 150&nbsp;mg once daily, the dose of Karvea can be increased to
300&nbsp;mg, or other antihypertensive agents can be added (see sections 4.3,
4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as
hydrochlorothiazide has been shown to have an additive effect with Karvea (see
section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In hypertensive type&nbsp;2 diabetic
patients, therapy should be initiated at 150&nbsp;mg irbesartan once daily and
titrated up to 300&nbsp;mg once daily as the preferred maintenance dose for
treatment of renal disease.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The demonstration of renal benefit of Karvea
in hypertensive type&nbsp;2 diabetic patients is based on studies where
irbesartan was used in addition to other antihypertensive agents, as needed, to
reach target blood pressure (see sections 4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Special Populations</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No dosage adjustment is necessary in
patients with impaired renal function. A lower starting dose (75&nbsp;mg)
should be considered for patients undergoing haemodialysis (see section 4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No dosage adjustment is necessary in
patients with mild to moderate hepatic impairment. There is no clinical
experience in patients with severe hepatic impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Older people</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Although consideration should be given
to initiating therapy with 75&nbsp;mg in patients over 75&nbsp;years of age,
dosage adjustment is not usually necessary for older people.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Paediatric population</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of Karvea in
children aged 0 to 18 has not been established. Currently available data are
described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can be
made.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Method of Administration</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.3 Contraindications</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Second and third trimesters of pregnancy
(see sections&nbsp;4.4 and&nbsp;4.6).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The concomitant use of Karvea with
aliskiren-containing products is contraindicated in patients with diabetes
mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60
ml/min/1.73m<sup>2</sup>) (see sections 4.5 and 5.1).</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.4 Special warnings and precautions
for use</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Intravascular
volume depletion</span></u><span lang=EN-GB>: symptomatic hypotension,
especially after the first dose, may occur in patients who are volume and/or
sodium depleted by vigorous diuretic therapy, dietary salt restriction,
diarrhoea or vomiting. Such conditions should be corrected before the
administration of Karvea.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renovascular hypertension</span></u><span
lang=EN-GB>: there is an increased risk of severe hypotension and renal
insufficiency when patients with bilateral renal artery stenosis or stenosis of
the artery to a single functioning kidney are treated with medicinal products
that affect the renin-angiotensin-aldosterone system. While this is not
documented with Karvea, a similar effect should be anticipated with
angiotensin-II receptor antagonists.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renal impairment and kidney
transplantation</span></u><span lang=EN-GB>: when Karvea is used in patients
with impaired renal function, a periodic monitoring of potassium and creatinine
serum levels is recommended. There is no experience regarding the
administration of Karvea in patients with a recent kidney transplantation.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hypertensive patients with
type&nbsp;2 diabetes and renal disease</span></u><span lang=EN-GB>:</span><span
lang=EN-GB style='layout-grid-mode:line'> the effects of irbesartan both on
renal and cardiovascular events were not uniform across all subgroups, in an
analysis carried out in the study with patients with advanced renal disease. In
particular, they appeared less favourable in women and non-white subjects (see
section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS):</span></u><span lang=EN-GB> there
is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor
blockers or aliskiren increases the risk of hypotension, hyperkalaemia and
decreased renal function (including acute renal failure). Dual blockade of RAAS
through the combined use of ACE-inhibitors, angiotensin II receptor blockers or
aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual
blockade therapy is considered absolutely necessary, this should only occur
under specialist supervision and subject to frequent close monitoring of renal
function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II
receptor blockers should not be used concomitantly in patients with diabetic
nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hyperkalaemia</span></u><span
lang=EN-GB>: as with other medicinal products that affect the
renin-angiotensin-aldosterone system, hyperkalaemia may occur during the
treatment with Karvea, especially in the presence of renal impairment, overt
proteinuria due to diabetic renal disease, and/or heart failure. Close
monitoring of serum potassium in patients at risk is recommended (see
section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hypoglycaemia: </span></u><span
lang=EN-GB>Karvea may induce hypoglycaemia, particularly in diabetic patients. In
patients treated with insulin or antidiabetics an appropriate blood glucose
monitoring should be considered; a dose adjustment of insulin or antidiabetics may
be required when indicated (see section 4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Lithium</span></u><span lang=EN-GB>:
the combination of lithium and Karvea is not recommended (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Aortic and mitral valve stenosis,
obstructive hypertrophic cardiomyopathy</span></u><span lang=EN-GB>: as with
other vasodilators, special caution is indicated in patients suffering from
aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Primary aldosteronism</span></u><span
lang=EN-GB>: patients with primary aldosteronism generally will not respond to
antihypertensive medicinal products acting through inhibition of the
renin-angiotensin system. Therefore, the use of Karvea is not recommended.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>General</span></u><span lang=EN-GB>:
in patients whose vascular tone and renal function depend predominantly on the
activity of the renin-angiotensin-aldosterone system (e.g.&nbsp;patients with
severe congestive heart failure or underlying renal disease, including renal
artery stenosis), treatment with angiotensin<b> </b>converting enzyme
inhibitors or angiotensin-II receptor antagonists that affect this system has
been associated with acute hypotension, azotaemia, oliguria, or rarely acute
renal failure (see section 4.5). As with any antihypertensive agent, excessive
blood pressure decrease in patients with ischaemic cardiopathy or ischaemic
cardiovascular disease could result in a myocardial infarction or stroke.</span></p>

<p class=EMEABodyText><span lang=EN-GB>As observed for angiotensin converting
enzyme inhibitors, irbesartan and the other angiotensin antagonists are apparently
less effective in lowering blood pressure in black people than in non-blacks,
possibly because of higher prevalence of low-renin states in the black
hypertensive population (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Pregnancy:</span></u><span
lang=EN-GB> angiotensin&nbsp;II Receptor Antagonists (AIIRAs) should not be
initiated during pregnancy. </span><span lang=EN-GB>Unless continued AIIRA
therapy is considered essential, patients planning pregnancy should be changed
to alternative antihypertensive treatments which have an established safety
profile for use in pregnancy. When pregnancy is diagnosed, treatment with </span><span
lang=EN-GB>AIIRAs</span><span lang=EN-GB> should be stopped immediately, and,
if appropriate, alternative therapy should be started (see sections&nbsp;4.3
and&nbsp;4.6).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u><span
lang=EN-GB>: irbesartan has been studied in paediatric populations aged 6 to 16
years old but the current data are insufficient to support an extension of the
use in children until further data become available (see sections&nbsp;4.8, 5.1
and&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients</span></u><span lang=FR>:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;75 mg film-coated tablet contains
lactose. Patients with rare hereditary problems of galactose intolerance, total
lactase deficiency or glucose-galactose malabsorption should not take this
medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;75 mg film-coated tablet contains
sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that
is to say essentially sodium-free.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.5 Interaction with other medicinal
products and other forms of interaction</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Diuretics and other antihypertensive
agents</span></u><span lang=EN-GB>: other antihypertensive agents may increase
the hypotensive effects of irbesartan; however Karvea has been safely
administered with other antihypertensive agents, such as beta-blockers,
long-acting calcium channel blockers, and thiazide diuretics. Prior treatment
with high dose diuretics may result in volume depletion and a risk of
hypotension when initiating therapy with Karvea (see section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Aliskiren-containing products or
ACE-inhibitors</span></u><span lang=EN-GB>: clinical trial data has shown that
dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the
combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is
associated with a higher frequency of adverse events such as hypotension, hyperkalaemia
and decreased renal function (including acute renal failure) compared to the
use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Potassium supplements and
potassium-sparing diuretics</span></u><span lang=EN-GB>:<i> </i>based on
experience with the use of other medicinal products that affect the
renin-angiotensin system, concomitant use of potassium-sparing diuretics,
potassium supplements, salt substitutes containing potassium or other medicinal
products that may increase serum potassium levels (e.g.&nbsp;heparin) may lead
to increases in serum potassium and is, therefore, not recommended (see section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Lithium</span></u><span lang=EN-GB>:<i>
</i>reversible increases in serum lithium concentrations and toxicity have been
reported during concomitant administration of lithium with angiotensin
converting enzyme inhibitors. Similar effects have been very rarely reported
with irbesartan so far. Therefore, this combination is not recommended (see
section&nbsp;4.4). If the combination proves necessary, careful monitoring of
serum lithium levels is recommended.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><u><span lang=EN-GB>Non-steroidal anti-inflammatory drugs</span></u><span
lang=EN-GB>: <span style='color:black'>when angiotensin&nbsp;II antagonists are
administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective
COX-2 inhibitors, acetylsalicylic acid (&gt;&nbsp;3&nbsp;g/day) and
non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>As with ACE
inhibitors, concomitant use of angiotensin&nbsp;II antagonists and NSAIDs may
lead to an increased risk of worsening of renal function, including possible
acute renal failure, and an increase in serum potassium, especially in patients
with poor pre-existing renal function. The combination should be administered
with caution, especially in the elderly. Patients should be adequately hydrated
and consideration should be given to monitoring renal function after initiation
of concomitant therapy, and periodically thereafter.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Repaglinide:</span></u><span
lang=EN-GB style='color:black'> irbesartan has the potential to inhibit OATP1B1.
In a clinical study, it was reported that irbesartan increased the C<sub>max</sub>
and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3&#8209;fold,
respectively, when administered 1 hour before repaglinide. In another study, no
relevant pharmacokinetic interaction was reported, when the two drugs were
co-administered. Therefore, dose adjustment of antidiabetic treatment such as
repaglinide may be required (see section 4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Additional information on irbesartan
interactions</span></u><span lang=EN-GB>: <span style='color:black'>in clinical
studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.
Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation.
No significant pharmacokinetic or pharmacodynamic interactions were observed
when irbesartan was coadministered with warfarin, a medicinal product
metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the
pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of
digoxin was not altered by coadministration of irbesartan.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.6 Fertility, pregnancy and lactation</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEABodyText style='border:none;padding:0in'><span lang=EN-GB>The use
of AIIRAs is not recommended during the first trimester of pregnancy (see section&nbsp;4.4).
The use of AIIRAs is contraindicated during the second and third trimesters of
pregnancy (see sections&nbsp;4.3 and&nbsp;4.4).</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Epidemiological evidence regarding the
risk of teratogenicity following exposure to ACE inhibitors during the first
trimester of pregnancy has not been conclusive; however a small increase in
risk cannot be excluded. Whilst there is no controlled epidemiological data on
the risk with Angiotensin&nbsp;II Receptor Antagonists (AIIRAs), similar risks
may exist for this class of drugs. Unless continued AIIRA therapy is considered
essential, patients planning pregnancy should be changed to alternative
antihypertensive treatments which have an established safety profile for use in
pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped
immediately, and, if appropriate, alternative therapy should be started.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Exposure to AIIRA therapy during the
second and third trimesters is known to induce human foetotoxicity (decreased
renal function, oligohydramnios, skull ossification retardation) and neonatal
toxicity (renal failure, hypotension, hyperkalaemia). (See section&nbsp;5.3).</span></p>

<p class=EMEABodyText><span lang=EN-GB>Should exposure to AIIRAs have occurred from
the second trimester of pregnancy, ultrasound check of renal function and skull
is recommended.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Infants whose mothers have taken AIIRAs
should be closely observed for hypotension (see sections&nbsp;4.3
and&nbsp;4.4).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Because no information is available regarding
the use of Karvea during breast-feeding, Karvea is not recommended and
alternative treatments with better established safety profiles during breast-feeding
are preferable, especially while nursing a newborn or preterm infant.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>It is unknown whether irbesartan or its
metabolites are excreted in human milk. </span></p>

<p class=EMEABodyText><span lang=EN-GB>Available pharmacodynamic/toxicological
data in rats have shown excretion of irbesartan or its metabolites in milk (for
details see 5.3).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=EN-GB>Fertility</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText>Irbesartan had no effect upon fertility of treated rats
and their offspring up to the dose levels inducing the first signs of parental
toxicity (see section 5.3). </p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.7 Effects on ability to drive and
use machines</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Based on
its pharmacodynamic properties, irbesartan is unlikely to affect the ability to
drive and use machines. When driving vehicles or operating machines, it should
be taken into account that dizziness or weariness may occur during treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.8 Undesirable effects</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In placebo-controlled trials in patients
with hypertension, the overall incidence of adverse events did not differ
between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation
due to any clinical or laboratory adverse event was less frequent for
irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%).
The incidence of adverse events was not related to dose (in the recommended
dose range), gender, age, race, or duration of treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In diabetic hypertensive patients with microalbuminuria
and normal renal function, orthostatic dizziness and orthostatic hypotension
were reported in 0.5% of the patients (i.e.,&nbsp;uncommon) but in excess of
placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The following table presents the adverse
drug reactions that were reported in placebo-controlled trials in which
1,965&nbsp;hypertensive patients received irbesartan. Terms marked with a star
(*) refer to the adverse reactions that were additionally reported in &gt; 2%
of diabetic hypertensive patients with chronic renal insufficiency and overt
proteinuria and in excess of placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The frequency of adverse reactions
listed below is defined using the following convention:</span></p>

<p class=EMEABodyText><span lang=EN-GB>very common (&#8805;&nbsp;1/10); common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare
(&lt;&nbsp;1/10,000). Within each frequency grouping, undesirable effects are
presented in order of decreasing seriousness.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Adverse reactions additionally reported
from postmarketing experience are also listed. These adverse reactions are
derived from spontaneous reports.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Blood
and lymphatic system disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: anaemia, thrombocytopenia</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Immune
system disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hypersensitivity reactions such as angioedema, rash, urticaria,
anaphylactic reaction, anaphylactic shock</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Metabolism
and nutrition disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hyperkalaemia, hypoglycaemia</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Nervous
system disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Common: dizziness, orthostatic
dizziness*</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not known: vertigo, headache</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Ear
and labyrinth disorder</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: tinnitus</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Cardiac
disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: tachycardia</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Vascular
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: orthostatic
hypotension*</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: flushing</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Respiratory,
thoracic and mediastinal disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: cough</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Gastrointestinal
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: nausea/vomiting</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: diarrhoea,
dyspepsia/heartburn</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not known: dysgeusia</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Hepatobiliary
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: jaundice</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hepatitis, abnormal liver function</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Skin
and subcutaneous tissue disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: leukocytoclastic vasculitis</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Musculoskeletal
and connective tissue disorders </span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Common: musculoskeletal pain*</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Not known: arthralgia, myalgia (in some cases associated with
increased plasma creatine kinase levels), muscle cramps</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Renal
and urinary disorders</span></u></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in;page-break-after:
avoid'><span lang=EN-GB>Not known:  impaired renal function including
cases of renal failure in patients at risk (see section&nbsp;4.4)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='text-align:justify;page-break-after:avoid'><u><span
lang=EN-GB>Reproductive system and breast disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: sexual dysfunction</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>General
disorders and administration site conditions</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: fatigue</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: chest
pain</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Investigations</span></u></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Very common: Hyperkalaemia* occurred more often in diabetic
patients treated with irbesartan than with placebo. In diabetic hypertensive
patients with microalbuminuria and normal renal function, hyperkalaemia
(&#8805;&nbsp;5.5&nbsp;mEq/L) occurred in 29.4% of the patients in the irbesartan
300&nbsp;mg group and 22% of the patients in the placebo group. In diabetic
hypertensive patients with chronic renal insufficiency and overt proteinuria,
hyperkalaemia (&#8805;&nbsp;5.5&nbsp;mEq/L) occurred in 46.3% of the patients
in the irbesartan group and 26.3% of the patients in the placebo group.</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Common: significant increases in plasma creatine kinase were
commonly observed (1.7%) in irbesartan treated subjects. None of these
increases were associated with identifiable clinical musculoskeletal events.<br>
In 1.7% of hypertensive patients with advanced diabetic renal disease treated
with irbesartan, a decrease in haemoglobin*, which was not clinically
significant, has been observed.</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>I</span><span lang=EN-GB>n a randomised
trial of 318&nbsp;hypertensive children and adolescents aged 6 to
16&nbsp;years, the following adverse reactions occurred in the 3-week
double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%),
cough (0.9%). In the 26-week open-label period of this trial the most frequent
laboratory abnormalities observed were creatinine increases (6.5%) and elevated
CK values in 2% of child recipients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Reporting of suspected adverse
reactions </span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Reporting suspected adverse reactions
after authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:silver'>the national reporting system listed in Appendix V.</span>
</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.9 Overdose</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Experience
in adults exposed to doses of up to 900&nbsp;mg/day for 8&nbsp;weeks revealed
no toxicity. The most likely manifestations of overdose are expected to be
hypotension and tachycardia; bradycardia might also occur from overdose. No
specific information is available on the treatment of overdose with Karvea. The
patient should be closely monitored, and the treatment should be symptomatic
and supportive. Suggested measures include induction of emesis and/or gastric
lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan
is not removed by haemodialysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.1 Pharmacodynamic properties</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Pharmacotherapeutic group:
Angiotensin-II antagonists, plain.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ATC&nbsp;code: C09C&nbsp;A04.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan is a potent, orally active,
selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is
expected to block all actions of angiotensin-II mediated by the AT<sub>1</sub>
receptor, regardless of the source or route of synthesis of angiotensin-II. The
selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results
in increases in plasma renin levels and angiotensin-II levels, and a decrease
in plasma aldosterone concentration. Serum potassium levels are not
significantly affected by irbesartan alone at the recommended doses. Irbesartan
does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II
and also degrades bradykinin into inactive metabolites. Irbesartan does not
require metabolic activation for its activity.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><u><span lang=EN-GB style='font-weight:normal'>Clinical
efficacy</span></u></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hypertension</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan lowers blood pressure with
minimal change in heart rate. The decrease in blood pressure is dose-related
for once a day doses with a tendency towards plateau at doses above
300&nbsp;mg. Doses of 150-300&nbsp;mg once daily lower supine or seated blood
pressures at trough (i.e.&nbsp;24&nbsp;hours after dosing) by an average of
8-13/5-8&nbsp;mm&nbsp;Hg (systolic/diastolic) greater than those associated
with placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Peak reduction of blood pressure is
achieved within 3-6&nbsp;hours after administration and the blood pressure
lowering effect is maintained for at least 24&nbsp;hours. At 24&nbsp;hours the
reduction of blood pressure was 60-70% of the corresponding peak diastolic and
systolic responses at the recommended doses. Once daily dosing with 150&nbsp;mg
produced trough and mean 24&nbsp;hour responses similar to twice daily dosing
on the same total dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The blood pressure lowering effect of Karvea
is evident within 1-2&nbsp;weeks, with the maximal effect occurring by
4-6&nbsp;weeks after start of therapy. The antihypertensive effects are
maintained during long term therapy. After withdrawal of therapy, blood
pressure gradually returns toward baseline. Rebound hypertension has not been
observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The blood pressure lowering effects of
irbesartan and thiazide-type diuretics are additive. In patients not adequately
controlled by irbesartan alone, the addition of a low dose of
hydrochlorothiazide (12.5&nbsp;mg) to irbesartan once daily results in a
further placebo-adjusted blood pressure reduction at trough of
7-10/3-6&nbsp;mm&nbsp;Hg (systolic/diastolic).</span></p>

<p class=EMEABodyText><span lang=EN-GB>The efficacy of Karvea is not influenced
by age or gender. As is the case with other medicinal products that affect the
renin-angiotensin system, black hypertensive patients have notably less
response to irbesartan monotherapy. When irbesartan is administered
concomitantly with a low dose of hydrochlorothiazide (e.g.&nbsp;12.5&nbsp;mg
daily), the antihypertensive response in black patients approaches that of
white patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>There is no clinically important effect
on serum uric acid or urinary uric acid secretion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Reduction of blood pressure with
0.5&nbsp;mg/kg (low), 1.5&nbsp;mg/kg (medium) and 4.5&nbsp;mg/kg (high) target
titrated doses of irbesartan was evaluated in 318&nbsp;hypertensive or at risk
(diabetic, family history of hypertension) children and adolescents aged 6 to
16&nbsp;years over a three week period. At the end of the three weeks the mean
reduction from baseline in the primary efficacy variable, trough seated
systolic blood pressure (SeSBP) was 11.7&nbsp;mmHg (low dose), 9.3&nbsp;mmHg
(medium dose), 13.2&nbsp;mmHg (high dose). No significant difference was
apparent between these doses. Adjusted mean change of trough seated diastolic
blood pressure (SeDBP) was as follows: 3.8&nbsp;mmHg (low dose), 3.2&nbsp;mmHg
(medium dose), 5.6&nbsp;mmHg (high dose). Over a subsequent two week period
where patients were re-randomized to either active medicinal product or
placebo, patients on placebo had increases of 2.4 and 2.0&nbsp;mmHg in SeSBP
and SeDBP compared to +0.1 and -0.3&nbsp;mmHg changes respectively in those on
all doses of irbesartan (see section&nbsp;4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hypertension
and type&nbsp;2 diabetes with renal disease</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>The Irbesartan Diabetic Nephropathy
Trial (IDNT) shows that irbesartan decreases the progression of renal disease
in patients with chronic renal insufficiency and overt proteinuria. IDNT was a
double blind, controlled, morbidity and mortality trial comparing Karvea,
amlodipine and placebo. In 1,715&nbsp;hypertensive patients with type&nbsp;2
diabetes, proteinuria &#8805;&nbsp;900&nbsp;mg/day and serum creatinine ranging
from 1.0-3.0&nbsp;mg/dl, the long-term effects (mean&nbsp;2.6&nbsp;years) of Karvea
on the progression of renal disease and all-cause mortality were examined.
Patients were titrated from 75&nbsp;mg to a maintenance dose of 300&nbsp;mg Karvea</span><span
lang=EN-GB style='font-family:"Times",serif'>, from 2.5&nbsp;mg to 10&nbsp;mg
amlodipine, or placebo</span><span lang=EN-GB> as tolerated. Patients in all
treatment groups typically received between&nbsp;2 and 4&nbsp;antihypertensive
agents (e.g., diuretics, beta&nbsp;blockers, alpha&nbsp;blockers) to reach a
predefined blood pressure goal of &#8804;&nbsp;135/85&nbsp;mmHg or a
10&nbsp;mmHg reduction in systolic pressure if baseline was
&gt;&nbsp;160&nbsp;mmHg. Sixty per cent (60%) of patients in the placebo group
reached this target blood pressure whereas this figure was 76% and 78% in the
irbesartan and amlodipine groups respectively. Irbesartan significantly reduced
the relative risk in the primary combined endpoint of doubling serum
creatinine, end-stage renal disease (ESRD) or all-cause mortality.
Approximately 33% of patients in the irbesartan group reached the primary renal
composite endpoint compared to 39% and 41% in the placebo and amlodipine groups
[20% relative risk reduction versus placebo (p&nbsp;=&nbsp;0.024) and 23%
relative risk reduction compared to amlodipine (p&nbsp;=&nbsp;0.006)]. When the
individual components of the primary endpoint were analysed, no effect in all
cause mortality was observed, while a positive trend in the reduction in ESRD
and a significant reduction in doubling of serum creatinine were observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>Subgroups
consisting of gender, race, age, duration of diabetes, baseline blood pressure,
serum creatinine, and albumin excretion rate were assessed for treatment
effect. In the female and black subgroups which represented 32% and 26% of the
overall study population respectively, a renal benefit was not evident, </span>although
the confidence intervals do not exclude it. As for the secondary endpoint of
fatal and non-fatal cardiovascular events, there was no difference among the
three groups in the overall population, although an increased incidence of
non-fatal MI was seen for women and a decreased incidence of non-fatal MI was
seen in males in the irbesartan group versus the placebo-based regimen. An
increased incidence of non-fatal MI and stroke was seen in females in the
irbesartan-based regimen versus the amlodipine-based regimen, while
hospitalization due to heart failure was reduced in the overall population.
However, no proper explanation for these findings in women has been identified.</p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The study of the Effects of Irbesartan
on Microalbuminuria in Hypertensive Patients with type&nbsp;2 Diabetes Mellitus
(IRMA&nbsp;2) shows that irbesartan 300&nbsp;mg delays progression to overt
proteinuria in patients with microalbuminuria. IRMA&nbsp;2 was a
placebo-controlled double blind morbidity study in 590&nbsp;patients with type&nbsp;2
diabetes, microalbuminuria (30-300&nbsp;mg/day) and normal renal function
(serum creatinine&nbsp;&#8804;&nbsp;1.5&nbsp;mg/dl in males and
&lt;&nbsp;1.1&nbsp;mg/dl in females). The study examined the long-term effects
(2&nbsp;years) of Karvea on the progression to clinical (overt) proteinuria
(urinary albumin excretion rate (UAER) &gt;&nbsp;300&nbsp;mg/day, and an
increase in UAER of at least 30% from baseline). The predefined blood pressure
goal was &#8804;&nbsp;135/85&nbsp;mmHg. Additional antihypertensive agents
(excluding ACE inhibitors, angiotensin&nbsp;II receptor antagonists and
dihydropyridine calcium blockers) were added as needed to help achieve the
blood pressure goal. While similar blood pressure was achieved in all treatment
groups, fewer subjects in the irbesartan 300&nbsp;mg group (5.2%) than in the
placebo (14.9%) or in the irbesartan 150&nbsp;mg group (9.7%) reached the
endpoint of overt proteinuria, demonstrating a 70% relative risk reduction
versus placebo (p&nbsp;=&nbsp;0.0004) for the higher dose. An accompanying
improvement in the glomerular filtration rate (GFR) was not observed during the
first three months of treatment. The slowing in the progression to clinical
proteinuria was evident as early as three months and continued over the
2&nbsp;year period. Regression to normoalbuminuria (&lt;&nbsp;30&nbsp;mg/day)
was more frequent in the Karvea&nbsp;300&nbsp;mg group (34%) than in the
placebo group (21%).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS)</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Two large randomised, controlled trials
(ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global
Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))
have examined the use of the combination of an ACE-inhibitor with an
angiotensin II receptor blocker. ONTARGET was a study conducted in patients
with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes
mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study
in patients with type 2 diabetes mellitus and diabetic nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>These studies have shown no significant
beneficial effect on renal and/or cardiovascular outcomes and mortality, while
an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as
compared to monotherapy was observed. Given their similar pharmacodynamic
properties, these results are also relevant for other ACE-inhibitors and
angiotensin II receptor blockers.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ACE-inhibitors and angiotensin II
receptor blockers should therefore not be used concomitantly in patients with
diabetic nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>ALTITUDE (Aliskiren Trial in Type 2
Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed
to test the benefit of adding aliskiren to a standard therapy of an
ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2
diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
The study was terminated early because of an increased risk of adverse
outcomes. Cardiovascular death and stroke were both numerically more frequent
in the aliskiren group that in the placebo group and adverse events and serious
adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)
were more frequently reported in the aliskiren group than in the placebo group.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.2 Pharmacokinetic properties</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>After
oral administration, irbesartan is well absorbed: studies of absolute
bioavailability gave values of approximately 60-80%. Concomitant food intake
does not significantly influence the bioavailability of irbesartan. </span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Plasma
protein binding is approximately 96%, with negligible binding to cellular blood
components. The volume of distribution is 53&nbsp;-&nbsp;93&nbsp;litres. </span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Following
oral or intravenous administration of <sup><span style='position:relative;
top:-1.0pt'>14</span></sup>C irbesartan, 80-85% of the circulating plasma
radioactivity is attributable to unchanged irbesartan. Irbesartan is
metabolised by the liver via glucuronide conjugation and oxidation. The major
circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In&nbsp;vitro</i>
studies indicate that irbesartan is primarily oxidised by the
cytochrome&nbsp;P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Linearity/non-linearity</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan exhibits linear and dose
proportional pharmacokinetics over the dose range of 10&nbsp;to 600&nbsp;mg. A
less than proportional increase in oral absorption at doses beyond 600&nbsp;mg
(twice the maximal recommended dose) was observed; the mechanism for this is
unknown. Peak plasma concentrations are attained at
1.5&nbsp;-&nbsp;2&nbsp;hours after oral administration. The total body and
renal clearance are 157&nbsp;-&nbsp;176&nbsp;and 3&nbsp;-&nbsp;3.5&nbsp;ml/min,
respectively. The terminal elimination half-life of irbesartan is
11&nbsp;-&nbsp;15&nbsp;hours. Steady-state plasma concentrations are attained
within 3&nbsp;days after initiation of a once-daily dosing regimen. Limited
accumulation of irbesartan (&lt;&nbsp;20%) is observed in plasma upon repeated
once-daily dosing. In a study, somewhat higher plasma concentrations of
irbesartan were observed in female hypertensive patients. However, there was no
difference in the half-life and accumulation of irbesartan. No dosage
adjustment is necessary in female patients. Irbesartan AUC and C<span
class=EMEASubscript>max</span> values were also somewhat greater in older subjects
(&#8805;&nbsp;65&nbsp;years) than those of young subjects
(18&nbsp;-&nbsp;40&nbsp;years). However the terminal half-life was not
significantly altered. No dosage adjustment is necessary in older people.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Elimination</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan and its metabolites are
eliminated by both biliary and renal pathways. After either oral or IV
administration of <sup><span style='position:relative;top:-1.0pt'>14</span></sup>C
irbesartan, about 20% of the radioactivity is recovered in the urine, and the
remainder in the faeces. Less than 2% of the dose is excreted in the urine as
unchanged irbesartan.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>The pharmacokinetics of irbesartan were
evaluated in 23&nbsp;hypertensive children after the administration of single
and multiple daily doses of irbesartan (2&nbsp;mg/kg) up to a maximum daily
dose of 150&nbsp;mg for four weeks. Of those 23 children, 21 were evaluable for
comparison of pharmacokinetics with adults (twelve children over 12&nbsp;years,
nine children between 6 and 12 years). Results showed that C<span
class=EMEASubscript>max</span>, AUC and clearance rates were comparable to
those observed in adult patients receiving 150&nbsp;mg irbesartan daily. A
limited accumulation of irbesartan (18%) in plasma was observed upon repeated
once daily dosing.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients with renal impairment or
those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are
not significantly altered. Irbesartan is not removed by haemodialysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hepatic impairment</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients with mild to moderate
cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly
altered. </span></p>

<p class=EMEABodyText><span lang=EN-GB>Studies have not been performed in patients
with severe hepatic impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.3<i> </i>Preclinical safety data</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>There was
no evidence of abnormal systemic or target organ toxicity at clinically
relevant doses. In non-clinical safety studies, high doses of irbesartan
(&#8805;&nbsp;250&nbsp;mg/kg/day in rats and &#8805;&nbsp;100&nbsp;mg/kg/day in
macaques) caused a reduction of red blood cell parameters (erythrocytes,
haemoglobin, haematocrit). At very high doses (&#8805;&nbsp;500&nbsp;mg/kg/day)
degenerative changes in the kidney (such as interstitial nephritis, tubular
distension, basophilic tubules, increased plasma concentrations of urea and
creatinine) were induced by irbesartan in the rat and the macaque and are
considered secondary to the hypotensive effects of the medicinal product which
led to decreased renal perfusion. Furthermore, irbesartan induced
hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at
&#8805;&nbsp;90&nbsp;mg/kg/day, in macaques at &#8805;&nbsp;10&nbsp;mg/kg/day).
All of these changes were considered to be caused by the pharmacological action
of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/
hypertrophy of the renal juxtaglomerular cells does not appear to have any
relevance.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>There was no evidence of mutagenicity,
clastogenicity or carcinogenicity.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Fertility and reproductive performance
were not affected in studies of male and female rats even at oral doses of
irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including
mortality at the highest dose. No significant effects on the number of corpora
lutea, implants, or live foetuses were observed. Irbesartan did not affect
survival, development, or reproduction of offspring. Studies in animals
indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.
Irbesartan is excreted in the milk of lactating rats.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Animal studies with irbesartan showed
transient toxic effects (increased renal pelvic cavitation, hydroureter or
subcutaneous oedema) in rat foetuses, which were resolved after birth. In
rabbits, abortion or early resorption were noted at doses causing significant
maternal toxicity, including mortality. No teratogenic effects were observed in
the rat or rabbit.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.1 List of excipients</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Tablet
core:</span></p>

<p class=EMEABodyText><span lang=IT>Lactose monohydrate</span></p>

<p class=EMEABodyText><span lang=IT>Microcrystalline cellulose</span></p>

<p class=EMEABodyText><span lang=IT>Croscarmellose sodium</span></p>

<p class=EMEABodyText><span lang=IT>Hypromellose</span></p>

<p class=EMEABodyText><span lang=IT>Silicon dioxide</span></p>

<p class=EMEABodyText><span lang=IT>Magnesium stearate.</span></p>

<p class=EMEABodyText><span lang=IT>&nbsp;</span></p>

<p class=EMEABodyText><span lang=IT>Film-coating:</span></p>

<p class=EMEABodyText><span lang=IT>Lactose monohydrate</span></p>

<p class=EMEABodyText><span lang=IT>Hypromellose</span></p>

<p class=EMEABodyText><span lang=IT>Titanium dioxide</span></p>

<p class=EMEABodyText><span lang=IT>Macrogol 3000</span></p>

<p class=EMEABodyText><span lang=IT>Carnauba wax.</span></p>

<p class=EMEABodyText><span lang=IT>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.2 Incompatibilities</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not applicable.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.3 Shelf life</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>3&nbsp;years.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.4 Special precautions for storage</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>6.5 Nature
and contents of container</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 14&nbsp;film-coated tablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 28&nbsp;film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 30</span><span lang=EN-GB>
film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 56&nbsp;film-coated tablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 84&nbsp;film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 90</span><span lang=EN-GB>
film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 98&nbsp;film-coated tablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 56&nbsp;x&nbsp;1&nbsp;film-coated tablet in PVC/PVDC/Aluminium
perforated unit dose blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.6 Special precautions for disposal</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=FR>7. MARKETING AUTHORISATION HOLDER</span></p>

<p class=EMEAHeading1><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=FR>8. MARKETING AUTHORISATION NUMBERS</span></p>

<p class=EMEAHeading1><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=SL>EU/1/97/049/016-020<br>
EU/1/97/049/031<br>
EU/1/97/049/034<br>
EU/1/97/049/037</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>9. DATE OF FIRST AUTHORISATION /
RENEWAL OF THE AUTHORISATION</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Date of first authorisation: 27 August
1997<br>
Date of latest renewal: 27 August 2007</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency
http://www.ema.europa.eu</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;150&nbsp;mg film-coated
tablets.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Each film-coated tablet contains 150&nbsp;mg
of irbesartan.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Excipient with known effect</span></u><span
lang=EN-GB>: 51.00&nbsp;mg of lactose monohydrate per film-coated tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For the full list of excipients, see
section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Film-coated
tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB>White to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2872 engraved
on the other side.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>4. CLINICAL PARTICULARS</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.1 Therapeutic indications</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Karvea is
indicated in adults for the treatment of essential hypertension.</span></p>

<p class=EMEABodyText><span lang=EN-GB>It is also indicated for the treatment
of renal disease in adult patients with hypertension and type&nbsp;2 diabetes
mellitus as part of an antihypertensive medicinal product regimen (see sections
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.2 Posology and method of
administration</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>The usual
recommended initial and maintenance dose is 150&nbsp;mg once daily, with or
without food. Karvea at a dose of 150&nbsp;mg once daily generally provides a
better 24&nbsp;hour blood pressure control than 75&nbsp;mg. However, initiation
of therapy with 75&nbsp;mg could be considered, particularly in haemodialysed
patients and in the elderly over 75&nbsp;years.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients insufficiently controlled
with 150&nbsp;mg once daily, the dose of Karvea can be increased to
300&nbsp;mg, or other antihypertensive agents can be added (see sections 4.3,
4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as
hydrochlorothiazide has been shown to have an additive effect with Karvea (see
section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In hypertensive type&nbsp;2 diabetic
patients, therapy should be initiated at 150&nbsp;mg irbesartan once daily and
titrated up to 300&nbsp;mg once daily as the preferred maintenance dose for
treatment of renal disease.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The demonstration of renal benefit of Karvea
in hypertensive type&nbsp;2 diabetic patients is based on studies where
irbesartan was used in addition to other antihypertensive agents, as needed, to
reach target blood pressure (see sections 4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Special Populations</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No dosage adjustment is necessary in
patients with impaired renal function. A lower starting dose (75&nbsp;mg)
should be considered for patients undergoing haemodialysis (see section 4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No dosage adjustment is necessary in
patients with mild to moderate hepatic impairment. There is no clinical
experience in patients with severe hepatic impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Older people</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Although consideration should be given
to initiating therapy with 75&nbsp;mg in patients over 75&nbsp;years of age,
dosage adjustment is not usually necessary forolder people.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Paediatric population</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of Karvea in
children aged 0 to 18 has not been established. Currently available data are
described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can
be made.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Method of Administration</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.3 Contraindications</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Second and third trimesters of pregnancy
(see sections&nbsp;4.4 and&nbsp;4.6).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The concomitant use of Karvea with
aliskiren-containing products is contraindicated in patients with diabetes
mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60
ml/min/1.73m<sup>2</sup>) (see sections 4.5 and 5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.4 Special warnings and precautions
for use</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Intravascular
volume depletion</span></u><span lang=EN-GB>: symptomatic hypotension,
especially after the first dose, may occur in patients who are volume and/or
sodium depleted by vigorous diuretic therapy, dietary salt restriction,
diarrhoea or vomiting. Such conditions should be corrected before the
administration of Karvea.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renovascular hypertension</span></u><span
lang=EN-GB>: there is an increased risk of severe hypotension and renal
insufficiency when patients with bilateral renal artery stenosis or stenosis of
the artery to a single functioning kidney are treated with medicinal products
that affect the renin-angiotensin-aldosterone system. While this is not
documented with Karvea, a similar effect should be anticipated with
angiotensin-II receptor antagonists.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renal impairment and kidney
transplantation</span></u><span lang=EN-GB>: when Karvea is used in patients
with impaired renal function, a periodic monitoring of potassium and creatinine
serum levels is recommended. There is no experience regarding the
administration of Karvea in patients with a recent kidney transplantation.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hypertensive patients with
type&nbsp;2 diabetes and renal disease</span></u><span lang=EN-GB>:</span><span
lang=EN-GB style='layout-grid-mode:line'> the effects of irbesartan both on
renal and cardiovascular events were not uniform across all subgroups, in an
analysis carried out in the study with patients with advanced renal disease. In
particular, they appeared less favourable in women and non-white subjects (see
section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS): t</span></u><span lang=EN-GB>here
is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor
blockers or aliskiren increases the risk of hypotension, hyperkalaemia and
decreased renal function (including acute renal failure). Dual blockade of RAAS
through the combined use of ACE-inhibitors, angiotensin II receptor blockers or
aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual
blockade therapy is considered absolutely necessary, this should only occur
under specialist supervision and subject to frequent close monitoring of renal
function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II
receptor blockers should not be used concomitantly in patients with diabetic
nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hyperkalaemia</span></u><span
lang=EN-GB>: as with other medicinal products that affect the
renin-angiotensin-aldosterone system, hyperkalaemia may occur during the
treatment with Karvea, especially in the presence of renal impairment, overt
proteinuria due to diabetic renal disease, and/or heart failure. Close
monitoring of serum potassium in patients at risk is recommended (see
section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hypoglycaemia</span></u><span
lang=EN-GB>: Karvea may induce hypoglycaemia, particularly in diabetic patients.
In patients treated with insulin or antidiabetics an appropriate blood glucose
monitoring should be considered; a dose adjustment of insulin or antidiabetics may
be required when indicated (see section 4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Lithium</span></u><span lang=EN-GB>:
the combination of lithium and Karvea is not recommended (see
section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Aortic and mitral valve stenosis,
obstructive hypertrophic cardiomyopathy</span></u><span lang=EN-GB>: as with
other vasodilators, special caution is indicated in patients suffering from
aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Primary aldosteronism</span></u><span
lang=EN-GB>: patients with primary aldosteronism generally will not respond to
antihypertensive medicinal products acting through inhibition of the
renin-angiotensin system. Therefore, the use of Karvea is not recommended.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>General</span></u><span lang=EN-GB>:
in patients whose vascular tone and renal function depend predominantly on the
activity of the renin-angiotensin-aldosterone system (e.g.&nbsp;patients with
severe congestive heart failure or underlying renal disease, including renal
artery stenosis), treatment with angiotensin<b> </b>converting enzyme inhibitors
or angiotensin-II receptor antagonists that affect this system has been
associated with acute hypotension, azotaemia, oliguria, or rarely acute renal
failure (see section 4.5). As with any antihypertensive agent, excessive blood
pressure decrease in patients with ischaemic cardiopathy or ischaemic
cardiovascular disease could result in a myocardial infarction or stroke.</span></p>

<p class=EMEABodyText><span lang=EN-GB>As observed for angiotensin converting
enzyme inhibitors, irbesartan and the other angiotensin antagonists are
apparently less effective in lowering blood pressure in black people than in
non-blacks, possibly because of higher prevalence of low-renin states in the
black hypertensive population (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Pregnancy:</span></u><span
lang=EN-GB> angiotensin&nbsp;II Receptor Antagonists (AIIRAs) should not be
initiated during pregnancy. </span><span lang=EN-GB>Unless continued AIIRA
therapy is considered essential, patients planning pregnancy should be changed
to alternative antihypertensive treatments which have an established safety
profile for use in pregnancy. When pregnancy is diagnosed, treatment with </span><span
lang=EN-GB>AIIRAs</span><span lang=EN-GB> should be stopped immediately, and,
if appropriate, alternative therapy should be started (see sections&nbsp;4.3
and&nbsp;4.6).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u><span
lang=EN-GB>: irbesartan has been studied in paediatric populations aged 6 to 16
years old but the current data are insufficient to support an extension of the
use in children until further data become available (see sections&nbsp;4.8, 5.1
and&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients</span></u><span lang=FR>:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;150 mg film-coated tablet contains
lactose. Patients with rare hereditary problems of galactose intolerance, total
lactase deficiency or glucose-galactose malabsorption should not take this
medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>Karvea&nbsp;150 mg fil -coated tablet contains
sodium. </span><span lang=EN-GB>This medicine contains less than 1 mmol sodium
(23 mg) per tablet, that is to say essentially sodium-free.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.5 Interaction with other medicinal
products and other forms of interaction</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Diuretics and other antihypertensive
agents</span></u><span lang=EN-GB>: other antihypertensive agents may increase
the hypotensive effects of irbesartan; however Karvea has been safely
administered with other antihypertensive agents, such as beta-blockers, long-acting
calcium channel blockers, and thiazide diuretics. Prior treatment with high
dose diuretics may result in volume depletion and a risk of hypotension when
initiating therapy with Karvea (see section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Aliskiren-containing products or
ACE-inhibitors</span></u><span lang=EN-GB>: clinical trial data has shown that
dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the
combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren
is associated with a higher frequency of adverse events such as hypotension,
hyperkalaemia and decreased renal function (including acute renal failure) compared
to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Potassium supplements and
potassium-sparing diuretics</span></u><span lang=EN-GB>:<i> </i>based on
experience with the use of other medicinal products that affect the renin-angiotensin
system, concomitant use of potassium-sparing diuretics, potassium supplements,
salt substitutes containing potassium or other medicinal products that may
increase serum potassium levels (e.g.&nbsp;heparin) may lead to increases in
serum potassium and is, therefore, not recommended (see section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Lithium</span></u><span lang=EN-GB>:<i>
</i>reversible increases in serum lithium concentrations and toxicity have been
reported during concomitant administration of lithium with angiotensin
converting enzyme inhibitors. Similar effects have been very rarely reported
with irbesartan so far. Therefore, this combination is not recommended (see
section&nbsp;4.4). If the combination proves necessary, careful monitoring of
serum lithium levels is recommended.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><u><span lang=EN-GB>Non-steroidal anti-inflammatory drugs</span></u><span
lang=EN-GB>: <span style='color:black'>when angiotensin&nbsp;II antagonists are
administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.
selective COX-2 inhibitors, acetylsalicylic acid (&gt;&nbsp;3&nbsp;g/day) and
non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>As with ACE inhibitors,
concomitant use of angiotensin&nbsp;II antagonists and NSAIDs may lead to an
increased risk of worsening of renal function, including possible acute renal
failure, and an increase in serum potassium, especially in patients with poor
pre-existing renal function. The combination should be administered with
caution, especially in the elderly. Patients should be adequately hydrated and
consideration should be given to monitoring renal function after initiation of
concomitant therapy, and periodically thereafter.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Repaglinide:</span></u><span
lang=EN-GB style='color:black'> irbesartan has the potential to inhibit OATP1B1.
In a clinical study, it was reported that irbesartan increased the C<sub>max</sub>
and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3&#8209;fold,
respectively, when administered 1 hour before repaglinide. In another study, no
relevant pharmacokinetic interaction was reported, when the two drugs were
co-administered. Therefore, dose adjustment of antidiabetic treatment such as
repaglinide may be required (see section 4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Additional information on irbesartan
interactions</span></u><span lang=EN-GB>: <span style='color:black'>in clinical
studies, the pharmacokinetic of irbesartan is not affected by
hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser
extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic
interactions were observed when irbesartan was coadministered with warfarin, a
medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as
rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The
pharmacokinetic of digoxin was not altered by coadministration of irbesartan.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.6 Fertility, pregnancy and lactation</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEABodyText style='border:none;padding:0in'><span lang=EN-GB>The use
of AIIRAs is not recommended during the first trimester of pregnancy (see
section&nbsp;4.4). The use of AIIRAs is contraindicated during the second and
third trimesters of pregnancy (see sections&nbsp;4.3 and&nbsp;4.4).</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Epidemiological evidence regarding the
risk of teratogenicity following exposure to ACE inhibitors during the first
trimester of pregnancy has not been conclusive; however a small increase in
risk cannot be excluded. Whilst there is no controlled epidemiological data on
the risk with Angiotensin&nbsp;II Receptor Antagonists (AIIRAs), similar risks
may exist for this class of drugs. Unless continued AIIRA therapy is considered
essential, patients planning pregnancy should be changed to alternative
antihypertensive treatments which have an established safety profile for use in
pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped
immediately, and, if appropriate, alternative therapy should be started.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Exposure to AIIRA therapy during the
second and third trimesters is known to induce human foetotoxicity (decreased
renal function, oligohydramnios, skull ossification retardation) and neonatal
toxicity (renal failure, hypotension, hyperkalaemia). (See section&nbsp;5.3).</span></p>

<p class=EMEABodyText><span lang=EN-GB>Should exposure to AIIRAs have occurred
from the second trimester of pregnancy, ultrasound check of renal function and
skull is recommended.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Infants whose mothers have taken AIIRAs
should be closely observed for hypotension (see sections&nbsp;4.3
and&nbsp;4.4).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Because no information is available
regarding the use of Karvea during breast-feeding, Karvea is not recommended
and alternative treatments with better established safety profiles during breast-feeding
are preferable, especially while nursing a newborn or preterm infant.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>It is unknown whether irbesartan or its
metabolites are excreted in human milk. </span></p>

<p class=EMEABodyText><span lang=EN-GB>Available pharmacodynamic/toxicological
data in rats have shown excretion of irbesartan or its metabolites in milk (for
details see 5.3).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=EN-GB>Fertility</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText>Irbesartan had no effect upon fertility of treated rats
and their offspring up to the dose levels inducing the first signs of parental
toxicity (see section 5.3). </p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.7 Effects on ability to drive and
use machines</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Based on its
pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive
and use machines. When driving vehicles or operating machines, it should be
taken into account that dizziness or weariness may occur during treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.8 Undesirable effects</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In placebo-controlled trials in patients
with hypertension, the overall incidence of adverse events did not differ
between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation
due to any clinical or laboratory adverse event was less frequent for
irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%).
The incidence of adverse events was not related to dose (in the recommended
dose range), gender, age, race, or duration of treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In diabetic hypertensive patients with
microalbuminuria and normal renal function, orthostatic dizziness and orthostatic
hypotension were reported in 0.5% of the patients (i.e.,&nbsp;uncommon) but in excess
of placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The following table presents the adverse
drug reactions that were reported in placebo-controlled trials in which
1,965&nbsp;hypertensive patients received irbesartan. Terms marked with a star
(*) refer to the adverse reactions that were additionally reported in &gt; 2%
of diabetic hypertensive patients with chronic renal insufficiency and overt
proteinuria and in excess of placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The frequency of adverse reactions
listed below is defined using the following convention:</span></p>

<p class=EMEABodyText><span lang=EN-GB>very common (&#8805;&nbsp;1/10); common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare
(&lt;&nbsp;1/10,000). Within each frequency grouping, undesirable effects are
presented in order of decreasing seriousness.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Adverse reactions additionally reported
from postmarketing experience are also listed. These adverse reactions are
derived from spontaneous reports.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Blood
and lymphatic system disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: anaemia, thrombocytopenia</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Immune
system disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hypersensitivity reactions such as angioedema, rash, urticaria,
anaphylactic reaction, anaphylactic shock</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Metabolism
and nutrition disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hyperkalaemia, hypoglycaemia</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Nervous
system disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Common: dizziness, orthostatic
dizziness*</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not known: vertigo, headache</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Ear and
labyrinth disorder</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: tinnitus</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Cardiac
disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: tachycardia</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Vascular
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: orthostatic
hypotension*</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: flushing</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Respiratory,
thoracic and mediastinal disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: cough</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Gastrointestinal
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: nausea/vomiting</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: diarrhoea,
dyspepsia/heartburn</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not known: dysgeusia</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Hepatobiliary
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: jaundice</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hepatitis, abnormal liver function</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Skin
and subcutaneous tissue disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: leukocytoclastic vasculitis</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Musculoskeletal
and connective tissue disorders </span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Common: musculoskeletal pain*</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Not known: arthralgia, myalgia (in some cases associated with
increased plasma creatine kinase levels), muscle cramps</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Renal
and urinary disorders</span></u></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in;page-break-after:
avoid'><span lang=EN-GB>Not known: impaired renal function including cases
of renal failure in patients at risk (see section&nbsp;4.4)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='text-align:justify;page-break-after:avoid'><u><span
lang=EN-GB>Reproductive system and breast disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: sexual dysfunction</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>General
disorders and administration site conditions</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: fatigue</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: chest
pain</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Investigations</span></u></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Very common: Hyperkalaemia* occurred more often in diabetic
patients treated with irbesartan than with placebo. In diabetic hypertensive
patients with microalbuminuria and normal renal function, hyperkalaemia
(&#8805;&nbsp;5.5&nbsp;mEq/L) occurred in 29.4% of the patients in the irbesartan
300&nbsp;mg group and 22% of the patients in the placebo group. In diabetic
hypertensive patients with chronic renal insufficiency and overt proteinuria,
hyperkalaemia (&#8805;&nbsp;5.5&nbsp;mEq/L) occurred in 46.3% of the patients
in the irbesartan group and 26.3% of the patients in the placebo group.</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Common: significant increases in plasma creatine kinase were
commonly observed (1.7%) in irbesartan treated subjects. None of these
increases were associated with identifiable clinical musculoskeletal events.<br>
In 1.7% of hypertensive patients with advanced diabetic renal disease treated
with irbesartan, a decrease in haemoglobin*, which was not clinically
significant, has been observed.</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>I</span><span lang=EN-GB>n a randomised
trial of 318&nbsp;hypertensive children and adolescents aged 6 to
16&nbsp;years, the following adverse reactions occurred in the 3-week
double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%),
cough (0.9%). In the 26-week open-label period of this trial the most frequent
laboratory abnormalities observed were creatinine increases (6.5%) and elevated
CK values in 2% of child recipients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Reporting of suspected adverse
reactions </span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Reporting suspected adverse reactions
after authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:silver'>the national reporting system listed in Appendix V.</span>
</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.9 Overdose</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Experience
in adults exposed to doses of up to 900&nbsp;mg/day for 8&nbsp;weeks revealed
no toxicity. The most likely manifestations of overdose are expected to be
hypotension and tachycardia; bradycardia might also occur from overdose. No
specific information is available on the treatment of overdose with Karvea. The
patient should be closely monitored, and the treatment should be symptomatic
and supportive. Suggested measures include induction of emesis and/or gastric
lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan
is not removed by haemodialysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.1 Pharmacodynamic properties</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Pharmacotherapeutic group:
Angiotensin-II antagonists, plain.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ATC&nbsp;code: C09C&nbsp;A04.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Mechanism of action</span></u><b><span
lang=EN-GB> </span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan is a potent, orally active,
selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is
expected to block all actions of angiotensin-II mediated by the AT<sub>1</sub>
receptor, regardless of the source or route of synthesis of angiotensin-II. The
selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results in
increases in plasma renin levels and angiotensin-II levels, and a decrease in
plasma aldosterone concentration. Serum potassium levels are not significantly
affected by irbesartan alone at the recommended doses. Irbesartan does not
inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also
degrades bradykinin into inactive metabolites. Irbesartan does not require
metabolic activation for its activity.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><u><span lang=EN-GB style='font-weight:normal'>Clinical
efficacy</span></u></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hypertension</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan lowers blood pressure with minimal
change in heart rate. The decrease in blood pressure is dose-related for once a
day doses with a tendency towards plateau at doses above 300&nbsp;mg. Doses of
150-300&nbsp;mg once daily lower supine or seated blood pressures at trough
(i.e.&nbsp;24&nbsp;hours after dosing) by an average of 8-13/5-8&nbsp;mm&nbsp;Hg
(systolic/diastolic) greater than those associated with placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Peak reduction of blood pressure is
achieved within 3-6&nbsp;hours after administration and the blood pressure
lowering effect is maintained for at least 24&nbsp;hours. At 24&nbsp;hours the
reduction of blood pressure was 60-70% of the corresponding peak diastolic and
systolic responses at the recommended doses. Once daily dosing with 150&nbsp;mg
produced trough and mean 24&nbsp;hour responses similar to twice daily dosing
on the same total dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The blood pressure lowering effect of Karvea
is evident within 1-2&nbsp;weeks, with the maximal effect occurring by
4-6&nbsp;weeks after start of therapy. The antihypertensive effects are
maintained during long term therapy. After withdrawal of therapy, blood pressure
gradually returns toward baseline. Rebound hypertension has not been observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The blood pressure lowering effects of
irbesartan and thiazide-type diuretics are additive. In patients not adequately
controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide
(12.5&nbsp;mg) to irbesartan once daily results in a further placebo-adjusted blood
pressure reduction at trough of 7-10/3-6&nbsp;mm&nbsp;Hg (systolic/diastolic).</span></p>

<p class=EMEABodyText><span lang=EN-GB>The efficacy of Karvea is not influenced
by age or gender. As is the case with other medicinal products that affect the
renin-angiotensin system, black hypertensive patients have notably less
response to irbesartan monotherapy. When irbesartan is administered
concomitantly with a low dose of hydrochlorothiazide (e.g.&nbsp;12.5&nbsp;mg
daily), the antihypertensive response in black patients approaches that of
white patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>There is no clinically important effect
on serum uric acid or urinary uric acid secretion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Reduction of blood pressure with
0.5&nbsp;mg/kg (low), 1.5&nbsp;mg/kg (medium) and 4.5&nbsp;mg/kg (high) target
titrated doses of irbesartan was evaluated in 318&nbsp;hypertensive or at risk
(diabetic, family history of hypertension) children and adolescents aged 6 to
16&nbsp;years over a three week period. At the end of the three weeks the mean reduction
from baseline in the primary efficacy variable, trough seated systolic blood
pressure (SeSBP) was 11.7&nbsp;mmHg (low dose), 9.3&nbsp;mmHg (medium dose),
13.2&nbsp;mmHg (high dose). No significant difference was apparent between
these doses. Adjusted mean change of trough seated diastolic blood pressure
(SeDBP) was as follows: 3.8&nbsp;mmHg (low dose), 3.2&nbsp;mmHg (medium dose),
5.6&nbsp;mmHg (high dose). Over a subsequent two week period where patients
were re-randomized to either active medicinal product or placebo, patients on
placebo had increases of 2.4 and 2.0&nbsp;mmHg in SeSBP and SeDBP compared to
+0.1 and -0.3&nbsp;mmHg changes respectively in those on all doses of
irbesartan (see section&nbsp;4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hypertension
and type&nbsp;2 diabetes with renal disease</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>The Irbesartan Diabetic Nephropathy
Trial (IDNT) shows that irbesartan decreases the progression of renal disease
in patients with chronic renal insufficiency and overt proteinuria. IDNT was a
double blind, controlled, morbidity and mortality trial comparing Karvea,
amlodipine and placebo. In 1,715&nbsp;hypertensive patients with type&nbsp;2 diabetes,
proteinuria &#8805;&nbsp;900&nbsp;mg/day and serum creatinine ranging from
1.0-3.0&nbsp;mg/dl, the long-term effects (mean&nbsp;2.6&nbsp;years) of Karvea
on the progression of renal disease and all-cause mortality were examined.
Patients were titrated from 75&nbsp;mg to a maintenance dose of 300&nbsp;mg Karvea</span><span
lang=EN-GB style='font-family:"Times",serif'>, from 2.5&nbsp;mg to 10&nbsp;mg
amlodipine, or placebo</span><span lang=EN-GB> as tolerated. Patients in all
treatment groups typically received between&nbsp;2 and 4&nbsp;antihypertensive
agents (e.g., diuretics, beta&nbsp;blockers, alpha&nbsp;blockers) to reach a
predefined blood pressure goal of &#8804;&nbsp;135/85&nbsp;mmHg or a
10&nbsp;mmHg reduction in systolic pressure if baseline was
&gt;&nbsp;160&nbsp;mmHg. Sixty per cent (60%) of patients in the placebo group
reached this target blood pressure whereas this figure was 76% and 78% in the
irbesartan and amlodipine groups respectively. Irbesartan significantly reduced
the relative risk in the primary combined endpoint of doubling serum
creatinine, end-stage renal disease (ESRD) or all-cause mortality. Approximately
33% of patients in the irbesartan group reached the primary renal composite
endpoint compared to 39% and 41% in the placebo and amlodipine groups [20%
relative risk reduction versus placebo (p&nbsp;=&nbsp;0.024) and 23% relative
risk reduction compared to amlodipine (p&nbsp;=&nbsp;0.006)]. When the
individual components of the primary endpoint were analysed, no effect in all
cause mortality was observed, while a positive trend in the reduction in ESRD
and a significant reduction in doubling of serum creatinine were observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>Subgroups
consisting of gender, race, age, duration of diabetes, baseline blood pressure,
serum creatinine, and albumin excretion rate were assessed for treatment
effect. In the female and black subgroups which represented 32% and 26% of the
overall study population respectively, a renal benefit was not evident, </span>although
the confidence intervals do not exclude it. As for the secondary endpoint of
fatal and non-fatal cardiovascular events, there was no difference among the
three groups in the overall population, although an increased incidence of
non-fatal MI was seen for women and a decreased incidence of non-fatal MI was
seen in males in the irbesartan group versus the placebo-based regimen. An
increased incidence of non-fatal MI and stroke was seen in females in the
irbesartan-based regimen versus the amlodipine-based regimen, while
hospitalization due to heart failure was reduced in the overall population.
However, no proper explanation for these findings in women has been identified.</p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The study of the Effects of Irbesartan
on Microalbuminuria in Hypertensive Patients with type&nbsp;2 Diabetes Mellitus
(IRMA&nbsp;2) shows that irbesartan 300&nbsp;mg delays progression to overt
proteinuria in patients with microalbuminuria. IRMA&nbsp;2 was a
placebo-controlled double blind morbidity study in 590&nbsp;patients with
type&nbsp;2 diabetes, microalbuminuria (30-300&nbsp;mg/day) and normal renal
function (serum creatinine&nbsp;&#8804;&nbsp;1.5&nbsp;mg/dl in males and
&lt;&nbsp;1.1&nbsp;mg/dl in females). The study examined the long-term effects
(2&nbsp;years) of Karvea on the progression to clinical (overt) proteinuria
(urinary albumin excretion rate (UAER) &gt;&nbsp;300&nbsp;mg/day, and an
increase in UAER of at least 30% from baseline). The predefined blood pressure
goal was &#8804;&nbsp;135/85&nbsp;mmHg. Additional antihypertensive agents
(excluding ACE inhibitors, angiotensin&nbsp;II receptor antagonists and
dihydropyridine calcium blockers) were added as needed to help achieve the
blood pressure goal. While similar blood pressure was achieved in all treatment
groups, fewer subjects in the irbesartan 300&nbsp;mg group (5.2%) than in the
placebo (14.9%) or in the irbesartan 150&nbsp;mg group (9.7%) reached the
endpoint of overt proteinuria, demonstrating a 70% relative risk reduction
versus placebo (p&nbsp;=&nbsp;0.0004) for the higher dose. An accompanying
improvement in the glomerular filtration rate (GFR) was not observed during the
first three months of treatment. The slowing in the progression to clinical
proteinuria was evident as early as three months and continued over the
2&nbsp;year period. Regression to normoalbuminuria (&lt;&nbsp;30&nbsp;mg/day)
was more frequent in the Karvea&nbsp;300&nbsp;mg group (34%) than in the placebo
group (21%).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS)</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Two large randomised, controlled trials
(ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global
Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))
have examined the use of the combination of an ACE-inhibitor with an
angiotensin II receptor blocker. ONTARGET was a study conducted in patients
with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes
mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study
in patients with type 2 diabetes mellitus and diabetic nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>These studies have shown no significant
beneficial effect on renal and/or cardiovascular outcomes and mortality, while
an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as
compared to monotherapy was observed. Given their similar pharmacodynamic
properties, these results are also relevant for other ACE-inhibitors and
angiotensin II receptor blockers.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ACE-inhibitors and angiotensin II
receptor blockers should therefore not be used concomitantly in patients with
diabetic nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ALTITUDE (Aliskiren Trial in Type 2
Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed
to test the benefit of adding aliskiren to a standard therapy of an
ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2
diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
The study was terminated early because of an increased risk of adverse
outcomes. Cardiovascular death and stroke were both numerically more frequent
in the aliskiren group than in the placebo group and adverse events and serious
adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)
were more frequently reported in the aliskiren group than in the placebo group.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.2 Pharmacokinetic properties</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>After
oral administration, irbesartan is well absorbed: studies of absolute
bioavailability gave values of approximately 60-80%. Concomitant food intake
does not significantly influence the bioavailability of irbesartan. </span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Plasma
protein binding is approximately 96%, with negligible binding to cellular blood
components. The volume of distribution is 53&nbsp;-&nbsp;93&nbsp;litres. </span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Following
oral or intravenous administration of <sup><span style='position:relative;
top:-1.0pt'>14</span></sup>C irbesartan, 80-85% of the circulating plasma
radioactivity is attributable to unchanged irbesartan. Irbesartan is
metabolised by the liver via glucuronide conjugation and oxidation. The major
circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In&nbsp;vitro</i>
studies indicate that irbesartan is primarily oxidised by the
cytochrome&nbsp;P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Linearity / non-linearity</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan exhibits linear and dose
proportional pharmacokinetics over the dose range of 10&nbsp;to 600&nbsp;mg. A
less than proportional increase in oral absorption at doses beyond 600&nbsp;mg
(twice the maximal recommended dose) was observed; the mechanism for this is
unknown. Peak plasma concentrations are attained at
1.5&nbsp;-&nbsp;2&nbsp;hours after oral administration. The total body and
renal clearance are 157&nbsp;-&nbsp;176&nbsp;and 3&nbsp;-&nbsp;3.5&nbsp;ml/min,
respectively. The terminal elimination half-life of irbesartan is
11&nbsp;-&nbsp;15&nbsp;hours. Steady-state plasma concentrations are attained
within 3&nbsp;days after initiation of a once-daily dosing regimen. Limited
accumulation of irbesartan (&lt;&nbsp;20%) is observed in plasma upon repeated
once-daily dosing. In a study, somewhat higher plasma concentrations of
irbesartan were observed in female hypertensive patients. However, there was no
difference in the half-life and accumulation of irbesartan. No dosage
adjustment is necessary in female patients. Irbesartan AUC and C<span
class=EMEASubscript>max</span> values were also somewhat greater in older subjects
(&#8805;&nbsp;65&nbsp;years) than those of young subjects
(18&nbsp;-&nbsp;40&nbsp;years). However the terminal half-life was not
significantly altered. No dosage adjustment is necessary in older people.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Elimination</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan and its metabolites are eliminated
by both biliary and renal pathways. After either oral or IV administration of <sup><span
style='position:relative;top:-1.0pt'>14</span></sup>C irbesartan, about 20% of
the radioactivity is recovered in the urine, and the remainder in the faeces.
Less than 2% of the dose is excreted in the urine as unchanged irbesartan.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>The pharmacokinetics of irbesartan were
evaluated in 23&nbsp;hypertensive children after the administration of single
and multiple daily doses of irbesartan (2&nbsp;mg/kg) up to a maximum daily
dose of 150&nbsp;mg for four weeks. Of those 23 children, 21 were evaluable for
comparison of pharmacokinetics with adults (twelve children over 12&nbsp;years,
nine children between 6 and 12 years). Results showed that C<span
class=EMEASubscript>max</span>, AUC and clearance rates were comparable to
those observed in adult patients receiving 150&nbsp;mg irbesartan daily. A
limited accumulation of irbesartan (18%) in plasma was observed upon repeated
once daily dosing.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients with renal impairment or
those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan
are not significantly altered. Irbesartan is not removed by haemodialysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hepatic impairment</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients with mild to moderate
cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly
altered. </span></p>

<p class=EMEABodyText><span lang=EN-GB>Studies have not been performed in
patients with severe hepatic impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.3<i> </i>Preclinical safety data</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>There was
no evidence of abnormal systemic or target organ toxicity at clinically
relevant doses. In non-clinical safety studies, high doses of irbesartan
(&#8805;&nbsp;250&nbsp;mg/kg/day in rats and &#8805;&nbsp;100&nbsp;mg/kg/day in
macaques) caused a reduction of red blood cell parameters (erythrocytes,
haemoglobin, haematocrit). At very high doses (&#8805;&nbsp;500&nbsp;mg/kg/day)
degenerative changes in the kidney (such as interstitial nephritis, tubular
distension, basophilic tubules, increased plasma concentrations of urea and
creatinine) were induced by irbesartan in the rat and the macaque and are
considered secondary to the hypotensive effects of the medicinal product which
led to decreased renal perfusion. Furthermore, irbesartan induced
hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at
&#8805;&nbsp;90&nbsp;mg/kg/day, in macaques at &#8805;&nbsp;10&nbsp;mg/kg/day).
All of these changes were considered to be caused by the pharmacological action
of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/
hypertrophy of the renal juxtaglomerular cells does not appear to have any
relevance.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>There was no evidence of mutagenicity,
clastogenicity or carcinogenicity.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Fertility and reproductive performance
were not affected in studies of male and female rats even at oral doses of
irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including
mortality at the highest dose. No significant effects on the number of corpora
lutea, implants, or live foetuses were observed. Irbesartan did not affect
survival, development, or reproduction of offspring. Studies in animals
indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.
Irbesartan is excreted in the milk of lactating rats.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Animal studies with irbesartan showed
transient toxic effects (increased renal pelvic cavitation, hydroureter or
subcutaneous oedema) in rat foetuses, which were resolved after birth. In
rabbits, abortion or early resorption were noted at doses causing significant
maternal toxicity, including mortality. No teratogenic effects were observed in
the rat or rabbit.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.1 List of excipients</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Tablet
core:</span></p>

<p class=EMEABodyText><span lang=IT>Lactose monohydrate</span></p>

<p class=EMEABodyText><span lang=IT>Microcrystalline cellulose</span></p>

<p class=EMEABodyText><span lang=IT>Croscarmellose sodium</span></p>

<p class=EMEABodyText><span lang=IT>Hypromellose</span></p>

<p class=EMEABodyText><span lang=IT>Silicon dioxide</span></p>

<p class=EMEABodyText><span lang=IT>Magnesium stearate.</span></p>

<p class=EMEABodyText><span lang=IT>&nbsp;</span></p>

<p class=EMEABodyText><span lang=IT>Film-coating:</span></p>

<p class=EMEABodyText><span lang=IT>Lactose monohydrate</span></p>

<p class=EMEABodyText><span lang=IT>Hypromellose</span></p>

<p class=EMEABodyText><span lang=IT>Titanium dioxide</span></p>

<p class=EMEABodyText><span lang=IT>Macrogol 3000</span></p>

<p class=EMEABodyText><span lang=IT>Carnauba wax.</span></p>

<p class=EMEABodyText><span lang=IT>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.2 Incompatibilities</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not applicable.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.3 Shelf life</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>3&nbsp;years.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.4 Special precautions for storage</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>6.5 Nature
and contents of container</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 14&nbsp;film-coated tablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 28&nbsp;film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 30</span><span lang=EN-GB>
film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 56&nbsp;film-coated tablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 84&nbsp;film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 90</span><span lang=EN-GB>
film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 98&nbsp;film-coated tablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 56&nbsp;x&nbsp;1&nbsp;film-coated tablet in PVC/PVDC/Aluminium
perforated unit dose blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.6 Special precautions for disposal</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=FR>7. MARKETING AUTHORISATION HOLDER</span></p>

<p class=EMEAHeading1><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=FR>8. MARKETING AUTHORISATION NUMBERS</span></p>

<p class=EMEAHeading1><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=SL>EU/1/97/049/021-025<br>
EU/1/97/049/032<br>
EU/1/97/049/035<br>
EU/1/97/049/038</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>9. DATE OF FIRST AUTHORISATION /
RENEWAL OF THE AUTHORISATION</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Date of first authorisation: 27 August
1997<br>
Date of latest renewal: 27 August 2007</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency
http://www.ema.europa.eu</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;300&nbsp;mg film-coated
tablets.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Each film-coated tablet contains 300&nbsp;mg
of irbesartan.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Excipient with known effect</span></u><span
lang=EN-GB>: 102.00&nbsp;mg of lactose monohydrate per film-coated tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For the full list of excipients, see
section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Film-coated
tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB>White to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2873 engraved
on the other side.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>4. CLINICAL PARTICULARS</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.1 Therapeutic indications</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Karvea is
indicated in adults for the treatment of essential hypertension.</span></p>

<p class=EMEABodyText><span lang=EN-GB>It is also indicated for the treatment
of renal disease in adult patients with hypertension and type&nbsp;2 diabetes
mellitus as part of an antihypertensive medicinal product regimen (see sections
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.2 Posology and method of
administration</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>The usual
recommended initial and maintenance dose is 150&nbsp;mg once daily, with or
without food. Karvea at a dose of 150&nbsp;mg once daily generally provides a
better 24&nbsp;hour blood pressure control than 75&nbsp;mg. However, initiation
of therapy with 75&nbsp;mg could be considered, particularly in haemodialysed
patients and in the elderly over 75&nbsp;years.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients insufficiently controlled
with 150&nbsp;mg once daily, the dose of Karvea can be increased to
300&nbsp;mg, or other antihypertensive agents can be added (see sections 4.3,
4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as
hydrochlorothiazide has been shown to have an additive effect with Karvea (see
section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In hypertensive type&nbsp;2 diabetic
patients, therapy should be initiated at 150&nbsp;mg irbesartan once daily and
titrated up to 300&nbsp;mg once daily as the preferred maintenance dose for
treatment of renal disease.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The demonstration of renal benefit of Karvea
in hypertensive type&nbsp;2 diabetic patients is based on studies where
irbesartan was used in addition to other antihypertensive agents, as needed, to
reach target blood pressure (see sections 4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Special Populations</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No dosage adjustment is necessary in
patients with impaired renal function. A lower starting dose (75&nbsp;mg)
should be considered for patients undergoing haemodialysis (see section 4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No dosage adjustment is necessary in
patients with mild to moderate hepatic impairment. There is no clinical
experience in patients with severe hepatic impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Older people</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Although consideration should be given
to initiating therapy with 75&nbsp;mg in patients over 75&nbsp;years of age,
dosage adjustment is not usually necessary forolder people.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Paediatric population</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of Karvea in
children aged 0 to 18 has not been established. Currently available data are
described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can
be made.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Method of Administration</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.3 Contraindications</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Second and third trimesters of pregnancy
(see sections&nbsp;4.4 and&nbsp;4.6).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The concomitant use of Karvea with
aliskiren-containing products is contraindicated in patients with diabetes
mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60
ml/min/1.73m<sup>2</sup>) (see sections 4.5 and 5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.4 Special warnings and precautions
for use</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Intravascular
volume depletion</span></u><span lang=EN-GB>: symptomatic hypotension,
especially after the first dose, may occur in patients who are volume and/or
sodium depleted by vigorous diuretic therapy, dietary salt restriction,
diarrhoea or vomiting. Such conditions should be corrected before the
administration of Karvea.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renovascular hypertension</span></u><span
lang=EN-GB>: there is an increased risk of severe hypotension and renal
insufficiency when patients with bilateral renal artery stenosis or stenosis of
the artery to a single functioning kidney are treated with medicinal products
that affect the renin-angiotensin-aldosterone system. While this is not
documented with Karvea, a similar effect should be anticipated with angiotensin-II
receptor antagonists.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renal impairment and kidney
transplantation</span></u><span lang=EN-GB>: when Karvea is used in patients
with impaired renal function, a periodic monitoring of potassium and creatinine
serum levels is recommended. There is no experience regarding the administration
of Karvea in patients with a recent kidney transplantation.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hypertensive patients with
type&nbsp;2 diabetes and renal disease</span></u><span lang=EN-GB>:</span><span
lang=EN-GB style='layout-grid-mode:line'> the effects of irbesartan both on
renal and cardiovascular events were not uniform across all subgroups, in an
analysis carried out in the study with patients with advanced renal disease. In
particular, they appeared less favourable in women and non-white subjects (see
section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS</span></u><span lang=EN-GB>): there
is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor
blockers or aliskiren increases the risk of hypotension, hyperkalaemia and
decreased renal function (including acute renal failure). Dual blockade of RAAS
through the combined use of ACE-inhibitors, angiotensin II receptor blockers or
aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual
blockade therapy is considered absolutely necessary, this should only occur
under specialist supervision and subject to frequent close monitoring of renal
function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II
receptor blockers should not be used concomitantly in patients with diabetic
nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hyperkalaemia</span></u><span
lang=EN-GB>: as with other medicinal products that affect the renin-angiotensin-aldosterone
system, hyperkalaemia may occur during the treatment with Karvea, especially in
the presence of renal impairment, overt proteinuria due to diabetic renal
disease, and/or heart failure. Close monitoring of serum potassium in patients
at risk is recommended (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hypoglycaemia</span></u><span
lang=EN-GB>: Karvea may induce hypoglycaemia, particularly in diabetic patients.
In patients treated with insulin or antidiabetics an appropriate blood glucose
monitoring should be considered; a dose adjustment of insulin or antidiabetics may
be required when indicated (see section 4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Lithium</span></u><span lang=EN-GB>:
the combination of lithium and Karvea is not recommended (see
section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Aortic and mitral valve stenosis,
obstructive hypertrophic cardiomyopathy</span></u><span lang=EN-GB>: as with
other vasodilators, special caution is indicated in patients suffering from aortic
or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Primary aldosteronism</span></u><span
lang=EN-GB>: patients with primary aldosteronism generally will not respond to
antihypertensive medicinal products acting through inhibition of the
renin-angiotensin system. Therefore, the use of Karvea is not recommended.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>General</span></u><span lang=EN-GB>:
in patients whose vascular tone and renal function depend predominantly on the
activity of the renin-angiotensin-aldosterone system (e.g.&nbsp;patients with
severe congestive heart failure or underlying renal disease, including renal
artery stenosis), treatment with angiotensin<b> </b>converting enzyme
inhibitors or angiotensin-II receptor antagonists that affect this system has
been associated with acute hypotension, azotaemia, oliguria, or rarely acute
renal failure (see section 4.5). As with any antihypertensive agent, excessive
blood pressure decrease in patients with ischaemic cardiopathy or ischaemic
cardiovascular disease could result in a myocardial infarction or stroke.</span></p>

<p class=EMEABodyText><span lang=EN-GB>As observed for angiotensin converting
enzyme inhibitors, irbesartan and the other angiotensin antagonists are
apparently less effective in lowering blood pressure in black people than in
non-blacks, possibly because of higher prevalence of low-renin states in the
black hypertensive population (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Pregnancy:</span></u><span
lang=EN-GB> angiotensin&nbsp;II Receptor Antagonists (AIIRAs) should not be
initiated during pregnancy. </span><span lang=EN-GB>Unless continued AIIRA
therapy is considered essential, patients planning pregnancy should be changed
to alternative antihypertensive treatments which have an established safety
profile for use in pregnancy. When pregnancy is diagnosed, treatment with </span><span
lang=EN-GB>AIIRAs</span><span lang=EN-GB> should be stopped immediately, and,
if appropriate, alternative therapy should be started (see sections&nbsp;4.3
and&nbsp;4.6).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u><span
lang=EN-GB>: irbesartan has been studied in paediatric populations aged 6 to 16
years old but the current data are insufficient to support an extension of the
use in children until further data become available (see sections&nbsp;4.8, 5.1
and&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients</span></u><span lang=FR>:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;300 mg film-coated tablet contains
lactose. Patients with rare hereditary problems of galactose intolerance, total
lactase deficiency or glucose-galactose malabsorption should not take this
medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;300 mg film-coated tablet contains
sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that
is to say essentially sodium-free.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.5 Interaction with other medicinal
products and other forms of interaction</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Diuretics and other antihypertensive
agents</span></u><span lang=EN-GB>: other antihypertensive agents may increase
the hypotensive effects of irbesartan; however Karvea has been safely
administered with other antihypertensive agents, such as beta-blockers,
long-acting calcium channel blockers, and thiazide diuretics. Prior treatment
with high dose diuretics may result in volume depletion and a risk of
hypotension when initiating therapy with Karvea (see section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Aliskiren-containing products or
ACE-inhibitors</span></u><span lang=EN-GB>: clinical trial data has shown that
dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the
combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren
is associated with a higher frequency of adverse events such as hypotension,
hyperkalaemia and decreased renal function (including acute renal failure)
compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and
5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Potassium supplements and
potassium-sparing diuretics</span></u><span lang=EN-GB>:<i> </i>based on
experience with the use of other medicinal products that affect the
renin-angiotensin system, concomitant use of potassium-sparing diuretics,
potassium supplements, salt substitutes containing potassium or other medicinal
products that may increase serum potassium levels (e.g.&nbsp;heparin) may lead
to increases in serum potassium and is, therefore, not recommended (see
section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Lithium</span></u><span lang=EN-GB>:<i>
</i>reversible increases in serum lithium concentrations and toxicity have been
reported during concomitant administration of lithium with angiotensin converting
enzyme inhibitors. Similar effects have been very rarely reported with
irbesartan so far. Therefore, this combination is not recommended (see
section&nbsp;4.4). If the combination proves necessary, careful monitoring of
serum lithium levels is recommended.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><u><span lang=EN-GB>Non-steroidal anti-inflammatory drugs</span></u><span
lang=EN-GB>: <span style='color:black'>when angiotensin&nbsp;II antagonists are
administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.
selective COX-2 inhibitors, acetylsalicylic acid (&gt;&nbsp;3&nbsp;g/day) and
non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>As with ACE inhibitors,
concomitant use of angiotensin&nbsp;II antagonists and NSAIDs may lead to an
increased risk of worsening of renal function, including possible acute renal
failure, and an increase in serum potassium, especially in patients with poor
pre-existing renal function. The combination should be administered with
caution, especially in the elderly. Patients should be adequately hydrated and
consideration should be given to monitoring renal function after initiation of
concomitant therapy, and periodically thereafter.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Repaglinide:</span></u><span
lang=EN-GB style='color:black'> irbesartan has the potential to inhibit OATP1B1.
In a clinical study, it was reported that irbesartan increased the C<sub>max</sub>
and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3&#8209;fold,
respectively, when administered 1 hour before repaglinide. In another study, no
relevant pharmacokinetic interaction was reported, when the two drugs were
co-administered. Therefore, dose adjustment of antidiabetic treatment such as
repaglinide may be required (see section 4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Additional information on irbesartan
interactions</span></u><span lang=EN-GB>: <span style='color:black'>in clinical
studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.
Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation.
No significant pharmacokinetic or pharmacodynamic interactions were observed when
irbesartan was coadministered with warfarin, a medicinal product metabolised by
CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the
pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of
digoxin was not altered by coadministration of irbesartan.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.6 Fertility, pregnancy and
lactation</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEABodyText style='border:none;padding:0in'><span lang=EN-GB>The use
of AIIRAs is not recommended during the first trimester of pregnancy (see section&nbsp;4.4).
The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy
(see sections&nbsp;4.3 and&nbsp;4.4).</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Epidemiological evidence regarding the
risk of teratogenicity following exposure to ACE inhibitors during the first
trimester of pregnancy has not been conclusive; however a small increase in risk
cannot be excluded. Whilst there is no controlled epidemiological data on the
risk with Angiotensin&nbsp;II Receptor Antagonists (AIIRAs), similar risks may
exist for this class of drugs. Unless continued AIIRA therapy is considered
essential, patients planning pregnancy should be changed to alternative
antihypertensive treatments which have an established safety profile for use in
pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped
immediately, and, if appropriate, alternative therapy should be started.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Exposure to AIIRA therapy during the
second and third trimesters is known to induce human foetotoxicity (decreased
renal function, oligohydramnios, skull ossification retardation) and neonatal
toxicity (renal failure, hypotension, hyperkalaemia). (See section&nbsp;5.3).</span></p>

<p class=EMEABodyText><span lang=EN-GB>Should exposure to AIIRAs have occurred
from the second trimester of pregnancy, ultrasound check of renal function and
skull is recommended.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Infants whose mothers have taken AIIRAs
should be closely observed for hypotension (see sections&nbsp;4.3 and&nbsp;4.4).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Because no information is available
regarding the use of Karvea during breast-feeding, Karvea is not recommended
and alternative treatments with better established safety profiles during breast-feeding
are preferable, especially while nursing a newborn or preterm infant.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>It is unknown whether irbesartan or its
metabolites are excreted in human milk. </span></p>

<p class=EMEABodyText><span lang=EN-GB>Available pharmacodynamic/toxicological
data in rats have shown excretion of irbesartan or its metabolites in milk (for
details see 5.3).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=EN-GB>Fertility</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText>Irbesartan had no effect upon fertility of treated rats
and their offspring up to the dose levels inducing the first signs of parental
toxicity (see section 5.3). </p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.7 Effects on ability to drive and
use machines</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Based on
its pharmacodynamic properties, irbesartan is unlikely to affect the ability to
drive and use machines. When driving vehicles or operating machines, it should
be taken into account that dizziness or weariness may occur during treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.8 Undesirable effects</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In placebo-controlled trials in patients
with hypertension, the overall incidence of adverse events did not differ
between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation
due to any clinical or laboratory adverse event was less frequent for irbesartan-treated
patients (3.3%) than for placebo-treated patients (4.5%). The incidence of
adverse events was not related to dose (in the recommended dose range), gender,
age, race, or duration of treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In diabetic hypertensive patients with
microalbuminuria and normal renal function, orthostatic dizziness and
orthostatic hypotension were reported in 0.5% of the patients (i.e.,&nbsp;uncommon)
but in excess of placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The following table presents the adverse
drug reactions that were reported in placebo-controlled trials in which
1,965&nbsp;hypertensive patients received irbesartan. Terms marked with a star
(*) refer to the adverse reactions that were additionally reported in &gt; 2%
of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria
and in excess of placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The frequency of adverse reactions
listed below is defined using the following convention:</span></p>

<p class=EMEABodyText><span lang=EN-GB>very common (&#8805;&nbsp;1/10); common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare
(&lt;&nbsp;1/10,000). Within each frequency grouping, undesirable effects are
presented in order of decreasing seriousness.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Adverse reactions additionally reported
from postmarketing experience are also listed. These adverse reactions are derived
from spontaneous reports.</span></p>

<p class=EMEABodyText><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Blood
and lymphatic system disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: anaemia, thrombocytopenia</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Immune
system disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hypersensitivity reactions such as angioedema, rash, urticaria,
anaphylactic reaction, anaphylactic shock</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Metabolism
and nutrition disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hyperkalaemia, hypoglycaemia</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Nervous
system disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Common: dizziness, orthostatic
dizziness*</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not known: vertigo, headache</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Ear
and labyrinth disorder</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: tinnitus</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Cardiac
disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: tachycardia</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Vascular
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: orthostatic
hypotension*</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: flushing</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Respiratory,
thoracic and mediastinal disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: cough</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Gastrointestinal
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: nausea/vomiting</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: diarrhoea,
dyspepsia/heartburn</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not known: dysgeusia</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Hepatobiliary
disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: jaundice</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: hepatitis, abnormal liver function</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Skin
and subcutaneous tissue disorders</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
known: leukocytoclastic vasculitis</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Musculoskeletal
and connective tissue disorders </span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Common: musculoskeletal pain*</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Not known: arthralgia, myalgia (in some cases associated with
increased plasma creatine kinase levels), muscle cramps</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Renal
and urinary disorders</span></u></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in;page-break-after:
avoid'><span lang=EN-GB>Not known:  impaired renal function including
cases of renal failure in patients at risk (see section&nbsp;4.4)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='text-align:justify;page-break-after:avoid'><u><span
lang=EN-GB>Reproductive system and breast disorders</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: sexual dysfunction</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>General
disorders and administration site conditions</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common: fatigue</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon: chest
pain</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Investigations</span></u></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Very common: Hyperkalaemia* occurred more often in diabetic
patients treated with irbesartan than with placebo. In diabetic hypertensive
patients with microalbuminuria and normal renal function, hyperkalaemia
(&#8805;&nbsp;5.5&nbsp;mEq/L) occurred in 29.4% of the patients in the irbesartan
300&nbsp;mg group and 22% of the patients in the placebo group. In diabetic
hypertensive patients with chronic renal insufficiency and overt proteinuria,
hyperkalaemia (&#8805;&nbsp;5.5&nbsp;mEq/L) occurred in 46.3% of the patients
in the irbesartan group and 26.3% of the patients in the placebo group.</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-1.0in'><span
lang=EN-GB>Common: significant increases in plasma creatine kinase were
commonly observed (1.7%) in irbesartan treated subjects. None of these
increases were associated with identifiable clinical musculoskeletal events.<br>
In 1.7% of hypertensive patients with advanced diabetic renal disease treated
with irbesartan, a decrease in haemoglobin*, which was not clinically
significant, has been observed.</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>I</span><span lang=EN-GB>n a randomised
trial of 318&nbsp;hypertensive children and adolescents aged 6 to 16&nbsp;years,
the following adverse reactions occurred in the 3-week double-blind phase:
headache (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the
26-week open-label period of this trial the most frequent laboratory abnormalities
observed were creatinine increases (6.5%) and elevated CK values in 2% of child
recipients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Reporting of suspected adverse
reactions </span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Reporting suspected adverse reactions
after authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:silver'>the national reporting system listed in Appendix V.</span>
</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.9 Overdose</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Experience
in adults exposed to doses of up to 900&nbsp;mg/day for 8&nbsp;weeks revealed
no toxicity. The most likely manifestations of overdose are expected to be hypotension
and tachycardia; bradycardia might also occur from overdose. No specific
information is available on the treatment of overdose with Karvea. The patient
should be closely monitored, and the treatment should be symptomatic and
supportive. Suggested measures include induction of emesis and/or gastric
lavage. Activated charcoal may be useful in the treatment of overdose.
Irbesartan is not removed by haemodialysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.1 Pharmacodynamic properties</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Pharmacotherapeutic group:
Angiotensin-II antagonists, plain.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ATC&nbsp;code: C09C&nbsp;A04.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Mechanism of action</span></u><b><span
lang=EN-GB> </span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan is a potent, orally active,
selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is
expected to block all actions of angiotensin-II mediated by the AT<sub>1</sub>
receptor, regardless of the source or route of synthesis of angiotensin-II. The
selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results
in increases in plasma renin levels and angiotensin-II levels, and a decrease
in plasma aldosterone concentration. Serum potassium levels are not
significantly affected by irbesartan alone at the recommended doses. Irbesartan
does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II
and also degrades bradykinin into inactive metabolites. Irbesartan does not
require metabolic activation for its activity.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><u><span lang=EN-GB style='font-weight:normal'>Clinical
efficacy</span></u></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hypertension</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan lowers blood pressure with
minimal change in heart rate. The decrease in blood pressure is dose-related
for once a day doses with a tendency towards plateau at doses above
300&nbsp;mg. Doses of 150-300&nbsp;mg once daily lower supine or seated blood
pressures at trough (i.e.&nbsp;24&nbsp;hours after dosing) by an average of 8-13/5-8&nbsp;mm&nbsp;Hg
(systolic/diastolic) greater than those associated with placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Peak reduction of blood pressure is
achieved within 3-6&nbsp;hours after administration and the blood pressure
lowering effect is maintained for at least 24&nbsp;hours. At 24&nbsp;hours the
reduction of blood pressure was 60-70% of the corresponding peak diastolic and
systolic responses at the recommended doses. Once daily dosing with 150&nbsp;mg
produced trough and mean 24&nbsp;hour responses similar to twice daily dosing
on the same total dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The blood pressure lowering effect of Karvea
is evident within 1-2&nbsp;weeks, with the maximal effect occurring by 4-6&nbsp;weeks
after start of therapy. The antihypertensive effects are maintained during long
term therapy. After withdrawal of therapy, blood pressure gradually returns toward
baseline. Rebound hypertension has not been observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The blood pressure lowering effects of
irbesartan and thiazide-type diuretics are additive. In patients not adequately
controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide
(12.5&nbsp;mg) to irbesartan once daily results in a further placebo-adjusted
blood pressure reduction at trough of 7-10/3-6&nbsp;mm&nbsp;Hg
(systolic/diastolic).</span></p>

<p class=EMEABodyText><span lang=EN-GB>The efficacy of Karvea is not influenced
by age or gender. As is the case with other medicinal products that affect the
renin-angiotensin system, black hypertensive patients have notably less response
to irbesartan monotherapy. When irbesartan is administered concomitantly with a
low dose of hydrochlorothiazide (e.g.&nbsp;12.5&nbsp;mg daily), the antihypertensive
response in black patients approaches that of white patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>There is no clinically important effect
on serum uric acid or urinary uric acid secretion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Reduction of blood pressure with
0.5&nbsp;mg/kg (low), 1.5&nbsp;mg/kg (medium) and 4.5&nbsp;mg/kg (high) target
titrated doses of irbesartan was evaluated in 318&nbsp;hypertensive or at risk (diabetic,
family history of hypertension) children and adolescents aged 6 to
16&nbsp;years over a three week period. At the end of the three weeks the mean
reduction from baseline in the primary efficacy variable, trough seated systolic
blood pressure (SeSBP) was 11.7&nbsp;mmHg (low dose), 9.3&nbsp;mmHg (medium
dose), 13.2&nbsp;mmHg (high dose). No significant difference was apparent
between these doses. Adjusted mean change of trough seated diastolic blood
pressure (SeDBP) was as follows: 3.8&nbsp;mmHg (low dose), 3.2&nbsp;mmHg (medium
dose), 5.6&nbsp;mmHg (high dose). Over a subsequent two week period where
patients were re-randomized to either active medicinal product or placebo,
patients on placebo had increases of 2.4 and 2.0&nbsp;mmHg in SeSBP and SeDBP
compared to +0.1 and -0.3&nbsp;mmHg changes respectively in those on all doses
of irbesartan (see section&nbsp;4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hypertension
and type&nbsp;2 diabetes with renal disease</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>The Irbesartan Diabetic Nephropathy
Trial (IDNT) shows that irbesartan decreases the progression of renal disease
in patients with chronic renal insufficiency and overt proteinuria. IDNT was a
double blind, controlled, morbidity and mortality trial comparing Karvea,
amlodipine and placebo. In 1,715&nbsp;hypertensive patients with type&nbsp;2
diabetes, proteinuria &#8805;&nbsp;900&nbsp;mg/day and serum creatinine ranging
from 1.0-3.0&nbsp;mg/dl, the long-term effects (mean&nbsp;2.6&nbsp;years) of Karvea
on the progression of renal disease and all-cause mortality were examined. Patients
were titrated from 75&nbsp;mg to a maintenance dose of 300&nbsp;mg Karvea</span><span
lang=EN-GB style='font-family:"Times",serif'>, from 2.5&nbsp;mg to 10&nbsp;mg
amlodipine, or placebo</span><span lang=EN-GB> as tolerated. Patients in all
treatment groups typically received between&nbsp;2 and 4&nbsp;antihypertensive
agents (e.g., diuretics, beta&nbsp;blockers, alpha&nbsp;blockers) to reach a
predefined blood pressure goal of &#8804;&nbsp;135/85&nbsp;mmHg or a
10&nbsp;mmHg reduction in systolic pressure if baseline was
&gt;&nbsp;160&nbsp;mmHg. Sixty per cent (60%) of patients in the placebo group
reached this target blood pressure whereas this figure was 76% and 78% in the
irbesartan and amlodipine groups respectively. Irbesartan significantly reduced
the relative risk in the primary combined endpoint of doubling serum
creatinine, end-stage renal disease (ESRD) or all-cause mortality.
Approximately 33% of patients in the irbesartan group reached the primary renal
composite endpoint compared to 39% and 41% in the placebo and amlodipine groups
[20% relative risk reduction versus placebo (p&nbsp;=&nbsp;0.024) and 23%
relative risk reduction compared to amlodipine (p&nbsp;=&nbsp;0.006)]. When the
individual components of the primary endpoint were analysed, no effect in all
cause mortality was observed, while a positive trend in the reduction in ESRD
and a significant reduction in doubling of serum creatinine were observed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>Subgroups
consisting of gender, race, age, duration of diabetes, baseline blood pressure,
serum creatinine, and albumin excretion rate were assessed for treatment
effect. In the female and black subgroups which represented 32% and 26% of the
overall study population respectively, a renal benefit was not evident, </span>although
the confidence intervals do not exclude it. As for the secondary endpoint of
fatal and non-fatal cardiovascular events, there was no difference among the
three groups in the overall population, although an increased incidence of
non-fatal MI was seen for women and a decreased incidence of non-fatal MI was
seen in males in the irbesartan group versus the placebo-based regimen. An
increased incidence of non-fatal MI and stroke was seen in females in the
irbesartan-based regimen versus the amlodipine-based regimen, while
hospitalization due to heart failure was reduced in the overall population.
However, no proper explanation for these findings in women has been identified.</p>

<p class=EMEABodyText><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The study of the Effects of Irbesartan
on Microalbuminuria in Hypertensive Patients with type&nbsp;2 Diabetes Mellitus
(IRMA&nbsp;2) shows that irbesartan 300&nbsp;mg delays progression to overt
proteinuria in patients with microalbuminuria. IRMA&nbsp;2 was a
placebo-controlled double blind morbidity study in 590&nbsp;patients with type&nbsp;2
diabetes, microalbuminuria (30-300&nbsp;mg/day) and normal renal function
(serum creatinine&nbsp;&#8804;&nbsp;1.5&nbsp;mg/dl in males and
&lt;&nbsp;1.1&nbsp;mg/dl in females). The study examined the long-term effects
(2&nbsp;years) of Karvea on the progression to clinical (overt) proteinuria
(urinary albumin excretion rate (UAER) &gt;&nbsp;300&nbsp;mg/day, and an
increase in UAER of at least 30% from baseline). The predefined blood pressure
goal was &#8804;&nbsp;135/85&nbsp;mmHg. Additional antihypertensive agents
(excluding ACE inhibitors, angiotensin&nbsp;II receptor antagonists and dihydropyridine
calcium blockers) were added as needed to help achieve the blood pressure goal.
While similar blood pressure was achieved in all treatment groups, fewer
subjects in the irbesartan 300&nbsp;mg group (5.2%) than in the placebo (14.9%)
or in the irbesartan 150&nbsp;mg group (9.7%) reached the endpoint of overt
proteinuria, demonstrating a 70% relative risk reduction versus placebo
(p&nbsp;=&nbsp;0.0004) for the higher dose. An accompanying improvement in the
glomerular filtration rate (GFR) was not observed during the first three months
of treatment. The slowing in the progression to clinical proteinuria was
evident as early as three months and continued over the 2&nbsp;year period.
Regression to normoalbuminuria (&lt;&nbsp;30&nbsp;mg/day) was more frequent in
the Karvea&nbsp;300&nbsp;mg group (34%) than in the placebo group (21%).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS)</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Two large randomised, controlled trials
(ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global
Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))
have examined the use of the combination of an ACE-inhibitor with an
angiotensin II receptor blocker. ONTARGET was a study conducted in patients
with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes
mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study
in patients with type 2 diabetes mellitus and diabetic nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>These studies have shown no significant
beneficial effect on renal and/or cardiovascular outcomes and mortality, while
an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as
compared to monotherapy was observed. Given their similar pharmacodynamic
properties, these results are also relevant for other ACE-inhibitors and angiotensin
II receptor blockers.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ACE-inhibitors and angiotensin II
receptor blockers should therefore not be used concomitantly in patients with
diabetic nephropathy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>ALTITUDE (Aliskiren Trial in Type 2
Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed
to test the benefit of adding aliskiren to a standard therapy of an
ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2
diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
The study was terminated early because of an increased risk of adverse
outcomes. Cardiovascular death and stroke were both numerically more frequent
in the aliskiren group than in the placebo group and adverse events and serious
adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)
were more frequently reported in the aliskiren group than in the placebo group.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.2 Pharmacokinetic properties</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>After
oral administration, irbesartan is well absorbed: studies of absolute
bioavailability gave values of approximately 60-80%. Concomitant food intake
does not significantly influence the bioavailability of irbesartan. </span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Plasma
protein binding is approximately 96%, with negligible binding to cellular blood
components. The volume of distribution is 53&nbsp;-&nbsp;93&nbsp;litres. </span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Following
oral or intravenous administration of <sup><span style='position:relative;
top:-1.0pt'>14</span></sup>C irbesartan, 80-85% of the circulating plasma
radioactivity is attributable to unchanged irbesartan. Irbesartan is
metabolised by the liver via glucuronide conjugation and oxidation. The major
circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In&nbsp;vitro</i>
studies indicate that irbesartan is primarily oxidised by the
cytochrome&nbsp;P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Linarity / non-linearity</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan exhibits linear and dose
proportional pharmacokinetics over the dose range of 10&nbsp;to 600&nbsp;mg. A
less than proportional increase in oral absorption at doses beyond 600&nbsp;mg
(twice the maximal recommended dose) was observed; the mechanism for this is
unknown. Peak plasma concentrations are attained at
1.5&nbsp;-&nbsp;2&nbsp;hours after oral administration. The total body and
renal clearance are 157&nbsp;-&nbsp;176&nbsp;and 3&nbsp;-&nbsp;3.5&nbsp;ml/min,
respectively. The terminal elimination half-life of irbesartan is
11&nbsp;-&nbsp;15&nbsp;hours. Steady-state plasma concentrations are attained
within 3&nbsp;days after initiation of a once-daily dosing regimen. Limited
accumulation of irbesartan (&lt;&nbsp;20%) is observed in plasma upon repeated
once-daily dosing. In a study, somewhat higher plasma concentrations of
irbesartan were observed in female hypertensive patients. However, there was no
difference in the half-life and accumulation of irbesartan. No dosage
adjustment is necessary in female patients. Irbesartan AUC and C<span
class=EMEASubscript>max</span> values were also somewhat greater in older subjects
(&#8805;&nbsp;65&nbsp;years) than those of young subjects
(18&nbsp;-&nbsp;40&nbsp;years). However the terminal half-life was not
significantly altered. No dosage adjustment is necessary in older people.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Elimination</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Irbesartan and its metabolites are
eliminated by both biliary and renal pathways. After either oral or IV
administration of <sup><span style='position:relative;top:-1.0pt'>14</span></sup>C
irbesartan, about 20% of the radioactivity is recovered in the urine, and the
remainder in the faeces. Less than 2% of the dose is excreted in the urine as
unchanged irbesartan.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>The pharmacokinetics of irbesartan were
evaluated in 23&nbsp;hypertensive children after the administration of single
and multiple daily doses of irbesartan (2&nbsp;mg/kg) up to a maximum daily
dose of 150&nbsp;mg for four weeks. Of those 23 children, 21 were evaluable for
comparison of pharmacokinetics with adults (twelve children over 12&nbsp;years,
nine children between 6 and 12 years). Results showed that C<span
class=EMEASubscript>max</span>, AUC and clearance rates were comparable to
those observed in adult patients receiving 150&nbsp;mg irbesartan daily. A
limited accumulation of irbesartan (18%) in plasma was observed upon repeated
once daily dosing.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients with renal impairment or
those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan
are not significantly altered. Irbesartan is not removed by haemodialysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Hepatic impairment</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients with mild to moderate
cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly
altered. </span></p>

<p class=EMEABodyText><span lang=EN-GB>Studies have not been performed in
patients with severe hepatic impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.3<i> </i>Preclinical safety data</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>There was
no evidence of abnormal systemic or target organ toxicity at clinically
relevant doses. In non-clinical safety studies, high doses of irbesartan
(&#8805;&nbsp;250&nbsp;mg/kg/day in rats and &#8805;&nbsp;100&nbsp;mg/kg/day in
macaques) caused a reduction of red blood cell parameters (erythrocytes,
haemoglobin, haematocrit). At very high doses (&#8805;&nbsp;500&nbsp;mg/kg/day)
degenerative changes in the kidney (such as interstitial nephritis, tubular
distension, basophilic tubules, increased plasma concentrations of urea and
creatinine) were induced by irbesartan in the rat and the macaque and are
considered secondary to the hypotensive effects of the medicinal product which
led to decreased renal perfusion. Furthermore, irbesartan induced
hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &#8805;&nbsp;90&nbsp;mg/kg/day,
in macaques at &#8805;&nbsp;10&nbsp;mg/kg/day). All of these changes were
considered to be caused by the pharmacological action of irbesartan. For
therapeutic doses of irbesartan in humans, the hyperplasia/ hypertrophy of the
renal juxtaglomerular cells does not appear to have any relevance.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>There was no evidence of mutagenicity,
clastogenicity or carcinogenicity.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Fertility and reproductive performance
were not affected in studies of male and female rats even at oral doses of
irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including
mortality at the highest dose. No significant effects on the number of corpora
lutea, implants, or live foetuses were observed. Irbesartan did not affect
survival, development, or reproduction of offspring. Studies in animals
indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.
Irbesartan is excreted in the milk of lactating rats.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Animal studies with irbesartan showed
transient toxic effects (increased renal pelvic cavitation, hydroureter or
subcutaneous oedema) in rat foetuses, which were resolved after birth. In
rabbits, abortion or early resorption were noted at doses causing significant
maternal toxicity, including mortality. No teratogenic effects were observed in
the rat or rabbit.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.1 List of excipients</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Tablet
core:</span></p>

<p class=EMEABodyText><span lang=IT>Lactose monohydrate</span></p>

<p class=EMEABodyText><span lang=IT>Microcrystalline cellulose</span></p>

<p class=EMEABodyText><span lang=IT>Croscarmellose sodium</span></p>

<p class=EMEABodyText><span lang=IT>Hypromellose</span></p>

<p class=EMEABodyText><span lang=IT>Silicon dioxide</span></p>

<p class=EMEABodyText><span lang=IT>Magnesium stearate.</span></p>

<p class=EMEABodyText><span lang=IT>&nbsp;</span></p>

<p class=EMEABodyText><span lang=IT>Film-coating:</span></p>

<p class=EMEABodyText><span lang=IT>Lactose monohydrate</span></p>

<p class=EMEABodyText><span lang=IT>Hypromellose</span></p>

<p class=EMEABodyText><span lang=IT>Titanium dioxide</span></p>

<p class=EMEABodyText><span lang=IT>Macrogol 3000</span></p>

<p class=EMEABodyText><span lang=IT>Carnauba wax.</span></p>

<p class=EMEABodyText><span lang=IT>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.2 Incompatibilities</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not applicable.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.3 Shelf life</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>3&nbsp;years.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.4 Special precautions for storage</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>6.5 Nature
and contents of container</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 14&nbsp;film-coated tablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 28&nbsp;film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 30</span><span lang=EN-GB>
film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 56&nbsp;film-coated tablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 84&nbsp;film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 90</span><span lang=EN-GB>
film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cartons of 98&nbsp;film-coated tablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 56&nbsp;x&nbsp;1&nbsp;film-coated tablet in PVC/PVDC/Aluminium
perforated unit dose blisters.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.6 Special precautions for disposal</span></p>

<p class=EMEAHeading2><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=FR>7. MARKETING AUTHORISATION HOLDER</span></p>

<p class=EMEAHeading1><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=FR>8. MARKETING AUTHORISATION NUMBERS</span></p>

<p class=EMEAHeading1><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=SL>EU/1/97/049/026-030<br>
EU/1/97/049/033<br>
EU/1/97/049/036<br>
EU/1/97/049/039</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>9. DATE OF FIRST AUTHORISATION /
RENEWAL OF THE AUTHORISATION</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Date of first authorisation: 27 August
1997<br>
Date of latest renewal: 27 August 2007</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency
http://www.ema.europa.eu</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>ANNEX II</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle align=left style='margin-left:85.0pt;text-align:left;
text-indent:-35.3pt'><span lang=EN-GB>A. MANUFACTURERS RESPONSIBLE FOR
BATCH RELEASE</span></p>

<p class=EMEATitle align=left style='margin-left:85.0pt;text-align:left;
text-indent:-35.3pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle align=left style='margin-left:85.0pt;text-align:left;
text-indent:-35.3pt'><span lang=EN-GB>B. CONDITIONS OR RESTRICTIONS
REGARDING SUPPLY AND USE</span></p>

<p class=EMEATitle align=left style='margin-left:85.0pt;text-align:left;
text-indent:-35.3pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle align=left style='margin-left:85.0pt;text-align:left;
text-indent:-35.3pt'><span lang=EN-GB>C. OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle align=left style='margin-left:85.0pt;text-align:left;
text-indent:-35.3pt'><span lang=EN-GB>D. CONDITIONS OR RESTRICTIONS WITH
REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1><span lang=EN-GB>A. MANUFACTURERS RESPONSIBLE FOR
BATCH RELEASE</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Name and address of the manufacturers
responsible for batch release</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>Sanofi Winthrop Industrie<br>
1 rue de la Vierge<br>
Ambars &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex<br>
France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>Sanofi Winthrop Industrie<br>
30-36 Avenue Gustave Eiffel, BP 7166<br>
F-37071 Tours Cedex 2<br>
France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>Chinoin Private Co. Ltd.<br>
Lvai u.5.<br>
2112 Veresegyhaz<br>
Hungary</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=IT>SANOFI-AVENTIS, S.A.</span></p>

<p class=EMEABodyText><span lang=IT>Ctra. C-35 (La Batlloria-Hostalric), km.
63.09</span></p>

<p class=EMEABodyText><span lang=EN-GB>17404 Riells i Viabrea (Girona) - Spain</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The printed package leaflet of the
medicinal product must state the name and address of the manufacturer
responsible for the release of the concerned batch.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>B. CONDITIONS OR RESTRICTIONS
REGARDING SUPPLY AND USE</span><span lang=EN-GB style='font-weight:normal'> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Medicinal product subject to medical
prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
AUTHORISATION</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText style='margin-left:64.35pt;text-indent:-64.35pt;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic Safety Update Reports (PSURs)</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><a name="_Hlk37090071"><span style='font-family:"TimesNewRomanPSMT",serif;
color:black'>The requirements for submission o</span></a><span
style='font-family:"TimesNewRomanPSMT",serif'>f PSURs</span><span lang=EN-GB>
for this medicinal product are set out in the list of Union reference dates
(EURD list) provided for under Article 107c(7) of Directive 2001/83</span><span
lang=EN-GB>/EC</span><span lang=EN-GB> and any subsequent updates published on
the European medicines web-portal.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><b><span lang=EN-GB>D. CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='margin-left:64.35pt;text-indent:-64.35pt'><a
name="_BPDC_LN_INS_1002"></a><span lang=EN-GB style='font-family:Symbol;
color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Not applicable.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>ANNEX III</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>A. LABELLING</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING </span></p>

<p class=EMEATitlePAC><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Karvea&nbsp;75&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Each
tablet contains: irbesartan 75&nbsp;mg</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Excipients:
also contains lactose monohydrate. See leaflet for further information.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>14&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>28&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>56&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>56&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>98&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Oral use.
Read the package leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Keep out
of the sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>8. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Do not
store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris&nbsp;-&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>EU/1/97/049/010
- 14&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/001 -
28&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/002 -
56&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/013 -
56&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>EU/1/97/049/003
- 98&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>13. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>16. Information in Braille</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea 75&nbsp;mg</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB style='font-weight:
normal'>PC: </span></p>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB style='font-weight:
normal'>SN:</span></p>

<p class=EMEABodyText><span lang=EN-GB>NN:</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;75&nbsp;mg&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. NAME OF THE MARKETING
AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>sanofi-aventis groupe</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=FR>3. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=FR>EXP</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. Other</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
style='background:silver'>14&nbsp;-&nbsp;28&nbsp;-&nbsp;56&nbsp;-&nbsp;98&nbsp;tablets:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Mon<br>
Tue<br>
Wed<br>
Thu<br>
Fri<br>
Sat<br>
Sun</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>56&nbsp;x&nbsp;1&nbsp;tablets:</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING </span></p>

<p class=EMEATitlePAC><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Karvea&nbsp;150&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Each
tablet contains: irbesartan 150&nbsp;mg</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Excipients:
also contains lactose monohydrate. See leaflet for further information.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>14&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>28&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>56&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>56&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>98&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Oral use.
Read the package leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Keep out
of the sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>8. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Do not
store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>EU/1/97/049/011
- 14&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/004 -
28&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/005 -
56&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/014 -
56&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>EU/1/97/049/006
- 98&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>13. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>16. Information in Braille</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea 150&nbsp;mg</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB style='font-weight:
normal'>PC: </span></p>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB style='font-weight:
normal'>SN:</span></p>

<p class=EMEABodyText><span lang=EN-GB>NN:</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS
OR STRIPS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;150&nbsp;mg&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. NAME OF THE MARKETING
AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>sanofi-aventis groupe</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=FR>3. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=FR>EXP</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. Other</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
style='background:silver'>14&nbsp;-&nbsp;28&nbsp;-&nbsp;56&nbsp;-&nbsp;98&nbsp;tablets:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Mon<br>
Tue<br>
Wed<br>
Thu<br>
Fri<br>
Sat<br>
Sun</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>56&nbsp;x&nbsp;1&nbsp;tablets:</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING </span></p>

<p class=EMEATitlePAC><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Karvea&nbsp;300&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Each
tablet contains: irbesartan 300&nbsp;mg</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Excipients:
also contains lactose monohydrate. See leaflet for further information.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>14&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>28&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>56&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>56&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>98&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Oral use.
Read the package leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Keep out
of the sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>8. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Do not
store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>EU/1/97/049/012
- 14&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/007 -
28&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/008 -
56&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/015 -
56&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>EU/1/97/049/009
- 98&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>13. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>16. Information in Braille</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea 300&nbsp;mg</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB style='font-weight:
normal'>PC: </span></p>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB style='font-weight:
normal'>SN:</span></p>

<p class=EMEABodyText><span lang=EN-GB>NN:</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;300&nbsp;mg&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. NAME OF THE MARKETING AUTHORISATION
HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>sanofi-aventis groupe</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=FR>3. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=FR>EXP</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. Other</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
style='background:silver'>14&nbsp;-&nbsp;28&nbsp;-&nbsp;56&nbsp;-&nbsp;98&nbsp;tablets:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Mon<br>
Tue<br>
Wed<br>
Thu<br>
Fri<br>
Sat<br>
Sun</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>56&nbsp;x&nbsp;1&nbsp;tablets:</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING
</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;75&nbsp;mg film-coated tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Each
tablet contains: irbesartan 75&nbsp;mg</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Excipients:
also contains lactose monohydrate. See leaflet for further information.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>14&nbsp;tablets<br>
28&nbsp;tablets<br>
30&nbsp;tablets<br>
56&nbsp;tablets<br>
56&nbsp;x&nbsp;1&nbsp;tablets<br>
84&nbsp;tablets<br>
90&nbsp;tablets<br>
98&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Oral use. Read the package leaflet
before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Keep out
of the sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>8. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Do not store
above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>EU/1/97/049/016
- 14&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/017 -
28&nbsp;tablets<br>
EU/1/97/049/034 - 30&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/018 -
56&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/019 -
56&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=SL style='background:silver'>EU/1/97/049/031 -
84</span><span lang=FR style='background:silver'>&nbsp;tablets<br>
EU/1/97/049/037 - 90&nbsp;tablets</span></p>

<p class=EMEABodyText><span style='background:silver'>EU/1/97/049/020 - 98</span><span
lang=EN-GB style='background:silver'>&nbsp;tablets</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>13. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>16. information in braille</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea 75&nbsp;mg</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB style='font-weight:
normal'>PC: </span></p>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB style='font-weight:
normal'>SN:</span></p>

<p class=EMEABodyText><span lang=EN-GB>NN:</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;75&nbsp;mg tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. NAME OF THE MARKETING
AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>sanofi-aventis groupe</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=FR>3. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=FR>EXP</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. OTher</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span style='background:
silver'>14&nbsp;-&nbsp;28&nbsp;-&nbsp;56&nbsp;-&nbsp;84&nbsp;-&nbsp;98&nbsp;</span><span
lang=LT style='background:silver'>tablets:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Mon<br>
Tue<br>
Wed<br>
Thu<br>
Fri<br>
Sat<br>
Sun</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>30&nbsp;-&nbsp;56&nbsp;x&nbsp;1&nbsp;-&nbsp;90&nbsp;tablets:</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING </span></p>

<p class=EMEATitlePAC><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;150&nbsp;mg film-coated
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Each
tablet contains: irbesartan 150&nbsp;mg</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Excipients:
also contains lactose monohydrate. See leaflet for further information.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>14&nbsp;tablets<br>
28&nbsp;tablets<br>
30&nbsp;tablets<br>
56&nbsp;tablets<br>
56&nbsp;x&nbsp;1&nbsp;tablets<br>
84&nbsp;tablets<br>
90&nbsp;tablets<br>
98&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Oral use. Read the package leaflet
before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Keep out
of the sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>8. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Do not
store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>EU/1/97/049/021
- 14&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/022 -
28&nbsp;tablets<br>
EU/1/97/049/035 - 30&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/023 -
56&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/024 -
56&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=SL style='background:silver'>EU/1/97/049/032 -
84</span><span lang=FR style='background:silver'>&nbsp;tablets<br>
EU/1/97/049/038 - 90&nbsp;tablets</span></p>

<p class=EMEABodyText><span style='background:silver'>EU/1/97/049/025 - 98</span><span
lang=EN-GB style='background:silver'>&nbsp;tablets</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>13. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>16. information in braille</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea 150&nbsp;mg</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB style='font-weight:
normal'>PC: </span></p>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB style='font-weight:
normal'>SN:</span></p>

<p class=EMEABodyText><span lang=EN-GB>NN:</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;150&nbsp;mg tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. NAME OF THE MARKETING
AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>sanofi-aventis groupe</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=FR>3. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=FR>EXP</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. OTher</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span style='background:
silver'>14&nbsp;-&nbsp;28&nbsp;-&nbsp;56&nbsp;-&nbsp;84&nbsp;-&nbsp;98&nbsp;</span><span
lang=LT style='background:silver'>tablets:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Mon<br>
Tue<br>
Wed<br>
Thu<br>
Fri<br>
Sat<br>
Sun</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>30&nbsp;-&nbsp;56&nbsp;x&nbsp;1&nbsp;-&nbsp;90&nbsp;tablets:</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING </span></p>

<p class=EMEATitlePAC><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;300&nbsp;mg film-coated
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Each
tablet contains: irbesartan 300&nbsp;mg</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Excipients:
also contains lactose monohydrate. See leaflet for further information.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. PHARMACEUTICAL FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>14&nbsp;tablets<br>
28&nbsp;tablets<br>
30&nbsp;tablets<br>
56&nbsp;tablets<br>
56&nbsp;x&nbsp;1&nbsp;tablets<br>
84&nbsp;tablets<br>
90&nbsp;tablets<br>
98&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Oral use. Read the package leaflet
before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Keep out
of the sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>8. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Do not
store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>EU/1/97/049/026
- 14&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/027 -
28&nbsp;tablets<br>
EU/1/97/049/036 - 30&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/028 -
56&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=FR style='background:silver'>EU/1/97/049/029 -
56&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=SL style='background:silver'>EU/1/97/049/033 -
84</span><span lang=FR style='background:silver'>&nbsp;tablets<br>
EU/1/97/049/039 - 90&nbsp;tablets</span></p>

<p class=EMEABodyText><span style='background:silver'>EU/1/97/049/030 - 98</span><span
lang=EN-GB style='background:silver'>&nbsp;tablets</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>13. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>16. information in braille</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea 300&nbsp;mg</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB style='font-weight:
normal'>PC: </span></p>

<p class=EMEATitlePAC style='border:none'><span lang=EN-GB style='font-weight:
normal'>SN:</span></p>

<p class=EMEABodyText><span lang=EN-GB>NN:</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;300&nbsp;mg tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. NAME OF THE MARKETING AUTHORISATION
HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>sanofi-aventis groupe</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=FR>3. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=FR>EXP</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. OTher</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span style='background:
silver'>14&nbsp;-&nbsp;28&nbsp;-&nbsp;56&nbsp;-&nbsp;84&nbsp;-&nbsp;98&nbsp;</span><span
lang=LT style='background:silver'>tablets:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Mon<br>
Tue<br>
Wed<br>
Thu<br>
Fri<br>
Sat<br>
Sun</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>30&nbsp;-&nbsp;56&nbsp;x&nbsp;1&nbsp;-&nbsp;90&nbsp;tablets:</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText align=center style='text-align:center'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=EMEATitle><span lang=EN-GB>Karvea&nbsp;75&nbsp;mg tablets</span></p>

<p class=EMEATitle><span lang=EN-GB style='font-weight:normal'>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Read all of this leaflet carefully before
you start taking this medicine because it contains important information for
you.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>If you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><u><span lang=EN-GB>What is in this leaflet</span></u></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>1. What Karvea is and what it is used for</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>2. What you need to know before you take Karvea</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>3. How to take Karvea</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4. Possible side effects</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>5. How to store Karvea</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>1. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>What
Karvea is and what it is used for</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea belongs to a group of medicines
known as angiotensin-II receptor antagonists. Angiotensin-II is a substance
produced in the body which binds to receptors in blood vessels causing them to
tighten. This results in an increase in blood pressure. Karvea prevents the
binding of angiotensin-II to these receptors, causing the blood vessels to
relax and the blood pressure to lower. Karvea slows the decrease of kidney
function in patients with high blood pressure and type&nbsp;2 diabetes.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is used in adult patients</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>to treat high blood pressure (<i>essential hypertension</i>)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>to protect the kidney in patients with high blood pressure,
type&nbsp;2 diabetes and laboratory evidence of impaired kidney function.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>2. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>What
you need to know before you take Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Do not take Karvea</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>allergic</b> to irbesartan or any other ingredients of
this medicine (listed in section 6)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>more than 3 months pregnant</b>. (It is also better to
avoid Karvea in early pregnancy  see pregnancy section)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>if you have diabetes or impaired kidney function </span></b><span
lang=EN-GB>and you are treated with a blood pressure lowering medicine
containing aliskiren. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Warning and precautions</span></p>

<p class=EMEAHeading3><span lang=EN-GB style='font-weight:normal'>Talk to your
doctor before taking Karvea and</span><span lang=EN-GB> if any of the following
apply to you:</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you get <b>excessive vomiting or diarrhoea</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you suffer from <b>kidney problems</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you suffer from <b>heart problems</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>if you receive Karvea for <b>diabetic kidney disease</b>. In this
case your doctor may perform regular blood tests, especially for measuring blood
potassium levels in case of poor kidney function</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>if you develop <b>low blood sugar levels</b> (symptoms may include
sweating, weakness, hunger, dizziness, trembling, headache, flushing or
paleness, numbness, having a fast, pounding heart beat), particularly if you
are being treated for diabetes.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>going to have an operation</b> (surgery) or <b>be
given anaesthetics</b></span></p>

<p class=EMEABodyTextIndent style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking any of the following medicines
used to treat high blood pressure:</span></p>

<p class=EMEABodyTextIndent style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB>an ACE-inhibitor (for example enalapril, lisinopril,
ramipril), in particular if you have diabetes-related kidney problems.</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB>aliskiren</span></p>

<p class=EMEABodyText><span lang=EN-GB>Your doctor may check your kidney
function, blood pressure, and the amount of electrolytes (e.g. potassium) in
your blood at regular intervals.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>See also information under the heading
Do not take Karvea.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>You must tell your doctor if you think
you are (<u>or might become</u>) pregnant. Karvea is not recommended in early
pregnancy, and must not be taken if you are more than 3&nbsp;months pregnant,
as it may cause serious harm to your baby if used at that stage (see pregnancy
section).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Children and adolescents</span></p>

<p class=EMEABodyText>This medicinal product should not be used in children and
adolescents because the safety and efficacy have not&nbsp;yet been&nbsp;fully
established.</p>

<p class=EMEAHeading3><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Other medicines and Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor or pharmacist if you are
taking, have recently taken or might take any other medicines.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Your doctor may need to change your dose
and/or to take other precautions:</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you are taking an ACE-inhibitor or aliskiren
(see also information under the headings Do not take Karvea and Warnings and
precautions).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>You may need to have blood checks if
you take:</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>potassium supplements</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>salt substitutes containing potassium</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>potassium-sparing medicines (such as certain diuretics)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>medicines containing lithium</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>repaglinide (medication used for lowering blood sugar levels)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you take certain painkillers, called
non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Karvea with food and drink</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea can be taken with or without
food.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Pregnancy and breast-feeding</span></p>

<p class=EMEAHeading2><span lang=EN-GB>Pregnancy</span></p>

<p class=EMEABodyText><span lang=EN-GB>You must tell your doctor if you think
you are (<u>or might become</u>) pregnant. Your doctor will normally advise you
to stop taking Karvea before you become pregnant or as soon as you know you are
pregnant and will advise you to take another medicine instead of Karvea. Karvea
is not recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if used after
the third month of pregnancy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>Breast-feeding</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor if you are
breast-feeding or about to start breast-feeding. Karvea is not recommended for
mothers who are breast-feeding, and your doctor may choose another treatment
for you if you wish to breast-feed, especially if your baby is newborn, or was
born prematurely.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Driving and using machines</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is unlikely to affect your
ability to drive or use machines. However, occasionally dizziness or weariness
may occur during treatment of high blood pressure. If you experience these,
talk to your doctor before attempting to drive or use machines.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Karvea contains lactose</span></b><span
lang=EN-GB>. If you have been told by your doctor that you have an intolerance
to some sugars (e.g. lactose), contact your doctor before taking this medicinal
product.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Karvea contains sodium. </span></b><span
lang=EN-GB>This medicine contains less than 1 mmol sodium (23 mg) per tablet,
that is to say essentially sodium-free.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>3. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>How
to take Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Always take this medicine exactly as
your doctor has told you. Check with your doctor or pharmacist if you are not
sure.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Method of administration</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is for <b>oral use</b>. Swallow the
tablets with a sufficient amount of fluid (e.g. one glass of water). You can
take Karvea with or without food. Try to take your daily dose at about the same
time each day. It is important that you continue to take Karvea until your
doctor tells you otherwise.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Patients with high blood pressure</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>The usual
dose is 150&nbsp;mg once a day (two tablets a day). The dose may later be
increased to 300&nbsp;mg (four tablets a day) once daily depending on blood
pressure response.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Patients with high blood pressure and type&nbsp;2 diabetes with kidney
disease</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>In patients
with high blood pressure and type&nbsp;2 diabetes, 300&nbsp;mg (four tablets a
day) once daily is the preferred maintenance dose for the treatment of
associated kidney disease.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The doctor may advise a lower dose,
especially when starting treatment in certain patients such as those on <b>haemodialysis</b>,
or those <b>over the age of 75&nbsp;years.</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The maximal blood pressure lowering
effect should be reached 4-6&nbsp;weeks after beginning treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Use in children and adolescents</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea should not be given to children
under 18&nbsp;years of age. If a child swallows some tablets, contact your
doctor immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>If you take more Karvea than you should</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you accidentally take too many
tablets, contact your doctor immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>If you forget to take Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you accidentally miss a daily dose,
just take the next dose as normal. Do not take a double dose to make up for a
forgotten dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>4. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>Possible
side effects</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Like all medicines, this medicine can
cause side effects, although not everybody gets them.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Some of these effects may be serious and
may require medical attention.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>As with similar medicines, rare cases of
allergic skin reactions (rash, urticaria), as well as localised swelling of the
face, lips and/or tongue have been reported in patients taking irbesartan. If
you get any of these symptoms or get short of breath, <b>stop taking Karvea and
contact your doctor immediately.</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The frequency of the side effects listed
below is defined using the following convention:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Very common: </span><span lang=EN-GB>may
affect more than 1 in 10 people</span></p>

<p class=EMEABodyText><span lang=EN-GB>Common: may affect up to 1 in 10 people</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: may affect up to 1 in 100
people</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Side
effects reported in clinical studies for patients treated with Karvea were:</span></p>

<p class=EMEABodyTextIndent style='page-break-after:avoid'><span lang=EN-GB
style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Very common (</span><span lang=EN-GB>may affect
more than 1 in 10 people)</span><span lang=EN-GB>: if you suffer from high
blood pressure and type&nbsp;2 diabetes with kidney disease, blood tests may
show an increased level of potassium.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='page-break-after:avoid'><span lang=EN-GB
style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Common (</span><span lang=EN-GB>may affect up to
1 10 people)</span><span lang=EN-GB>: dizziness, feeling sick/vomiting, fatigue
and blood tests may show raised levels of an enzyme that measures the muscle
and heart function (creatine kinase enzyme). In patients with high blood
pressure and type&nbsp;2 diabetes with kidney disease, dizziness when getting up
from a lying or sitting position, low blood pressure when getting up from a
lying or sitting position, pain in joints or muscles and decreased levels of a
protein in the red blood cells (haemoglobin) were also reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Uncommon (</span><span lang=EN-GB>may affect up to 1 in 100 people)</span><span
lang=EN-GB>: heart rate increased, flushing, cough, diarrhoea,
indigestion/heartburn, sexual dysfunction (problems with sexual performance),
chest pain.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Some undesirable effects have been
reported since marketing of Karvea. Undesirable effects where the frequency is
not known are: feeling of spinning, headache, taste disturbance, ringing in the
ears, </span><span lang=EN-GB>muscle cramps, </span><span lang=EN-GB>pain in
joints and muscles, </span><span lang=EN-GB>decreased number of red blood cells
(anaemia  symptoms may include tiredness, headaches, being short of breath
when exercising, dizziness and looking pale),</span><span lang=EN-GB> reduced
number of platelets, abnormal liver function, increased blood potassium levels,
impaired kidney function, inflammation of small blood vessels</span><span
lang=EN-GB> </span><span lang=EN-GB>mainly affecting the skin</span><span
lang=EN-GB> (a condition known as leukocytoclastic vasculitis),</span><span
lang=EN-GB> severe allergic reactions (anaphylactic shock)</span><span
lang=EN-GB> and </span><span lang=EN-GB>low blood sugar levels. Uncommon cases of
jaundice (yellowing of the skin and/or whites of the eyes) have also been
reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Reporting of side effects</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>If you get any side effects, talk to
your doctor or pharmacist. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span></span><span
class=MsoHyperlink><span lang=ES-TRAD style='background:silver;text-decoration:
none'>Appendix V</span></span><span lang=EN-GB>. By reporting side effects you
can help provide more information on the safety of this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>5. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>How
to store Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the carton and on the blister after EXP. The expiry
date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away of
medicines you no longer use. These measures will help protect the environment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>6. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>Contents
of the pack and other information</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>What Karvea contains</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>The active substance is irbesartan. Each tablet of Karvea&nbsp;75&nbsp;mg
contains 75&nbsp;mg irbesartan.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>The other ingredients are microcrystalline cellulose, croscarmellose
sodium, lactose monohydrate, magnesium stearate, colloidal hydrated silica,
pregelatinised maize starch, and poloxamer&nbsp;188. Please see section 2 Karvea
contains lactose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>What Karvea looks like and contents of
the pack</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;75&nbsp;mg tablets are white
to off-white, biconvex, and oval-shaped with a heart debossed on one side and
the number&nbsp;2771 engraved on the other side.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;75&nbsp;mg tablets are
supplied in blister packs of 14, 28, 56 or 98&nbsp;tablets. Unidose blister
packs of 56&nbsp;x&nbsp;1&nbsp;tablet for delivery in hospitals are also
available.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=FR>Marketing Authorisation Holder:</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris&nbsp;-&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=FR>Manufacturer:</span></p>

<p class=EMEAAddress><span lang=FR>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
1, rue de la Vierge<br>
Ambars &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex&nbsp;-&nbsp;France</span></p>

<p class=EMEAAddress><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
30-36&nbsp;Avenue Gustave Eiffel, BP&nbsp;7166<br>
F-37071&nbsp;Tours&nbsp;Cedex&nbsp;2&nbsp;-&nbsp;France</span></p>

<p class=EMEAAddress><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For any information about this medicinal
product, please contact the local representative of the Marketing Authorisation
Holder.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Belgi/</span></b><b><span lang=CS>Belgique</span></b><b><span
  lang=MT>/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='layout-grid-mode:line'>Sanofi
  Belgium</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tl/Tel: <span style='layout-grid-mode:
  line'>+32 (0)2 710 54 00</span></span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=CS>UAB sanofi-aventis Lietuva</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +370 5 2755224</span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Bulgaria EOOD</span></p>
  <p class=MsoNormal><span lang=BG>&#1058;&#1077;&#1083;</span><span lang=IT>.</span><span
  lang=BG>: +</span><span lang=IT>359 (0)2</span><span lang=IT> 970 53 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-LU>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='layout-grid-mode:line'>Sanofi
  Belgium </span></p>
  <p class=MsoNormal><span lang=FR-LU>Tl/Tel: </span><span lang=FR-BE
  style='layout-grid-mode:line'>+32 (0)2 710 54 00 (</span><span lang=FR-BE>Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=HU>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>&#268;esk republika</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis, s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +420 233 086 111</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=CS>SANOFI-AVENTIS Zrt.</span></p>
  <p class=MsoNormal><span lang=CS>Tel.: +36 1 </span><span lang=HU>505 0050</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Danmark</span></b></p>
  <p class=MsoNormal><span lang=CS>Sanofi A/S</span></p>
  <p class=MsoNormal><span lang=CS>Tlf: +45 45 16 70 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +39 02 39394275</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=CS>Sanofi-Aventis Deutschland GmbH</span></p>
  <p class=MsoNormal><span lang=CS>Tel: 0800 52 52 010</span></p>
  <p class=MsoNormal><span lang=CS>Tel. aus dem Ausland: +49 69 305 21 131</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Nederland</span></b></p>
  <p class=MsoNormal><span lang=CS>Genzyme Europe B.V.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +31 20 245 4000</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis Estonia O</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +372 627 34 88</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Norge</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis Norge AS</span></p>
  <p class=MsoNormal><span lang=CS>Tlf: +47 67 10 71 00</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis AEBE</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;</span><span lang=CS>: +30
  210 900 16 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE>sanofi-aventis GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +43 1 80 185  0</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espaa</span></b></p>
  <p class=MsoNormal><span lang=PT>sanofi-aventis, S.A.</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +34 93 485 94 00</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Polska</span></b></p>
  <p class=MsoNormal><span lang=SV>sanofi-aventis Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=FR>Tel.: +48 22&nbsp;280 00 00</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>sanofi-aventis France</span></p>
  <p class=MsoNormal><span lang=PT>Tl: 0 800 222 555</span></p>
  <p class=MsoNormal><span lang=PT>Appel depuis ltranger : +33 1 57 63 23 23</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT>Sanofi - Produtos Farmacuticos, Lda</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +351 21 35 89 400</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=IT>sanofi-aventis Croatia d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +385 1 600 34 00</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Romnia</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Romania SRL</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +40 </span><span lang=IT>(0) 21 317 31
  36</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>Ireland</span></b></p>
  <p class=MsoNormal><span lang=FR>sanofi-aventis Ireland Ltd. T/A SANOFI</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +353 (0) 1 403 56 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis d.o.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +386 1 560 48 00</span></p>
  <p class=MsoNormal><span lang=SK>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS>sland</span></b></p>
  <p class=MsoNormal><span lang=CS>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Smi</span><span lang=CS>: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Slovensk republika</span></b></p>
  <p class=MsoNormal><span lang=SK>sanofi-</span><span lang=CS>aventis Slovakia
  </span><span lang=SK>s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +</span><span lang=SK>421 2 </span><span
  lang=EN-GB>33 100 100</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=IT>Tel</span><span lang=CS>: 800 536389</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Oy</span></p>
  <p class=MsoNormal><span lang=IT>Puh/Tel: +358 (0) 201 200 300</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=FR>sanofi-aventis Cyprus Ltd.</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: +</span><span lang=FR>357
  22 871600</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal><span lang=SV>Sanofi AB</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +46 (0)8 634 50 00</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT>sanofi-aventis Latvia SIA</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +371 67 33 24 51</span></p>
  <p class=MsoNormal><span lang=LV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=SV>Sanofi</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +44 (0) 845 372 7101</span></p>
  <p class=MsoNormal><span lang=LV>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu/</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText align=center style='text-align:center'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=EMEATitle><span lang=EN-GB>Karvea&nbsp;150&nbsp;mg tablets</span></p>

<p class=EMEATitle><span lang=EN-GB style='font-weight:normal'>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>If you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><u><span lang=EN-GB>What is in this leaflet</span></u></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>1. What Karvea is and what it is used for</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>2. What you need to know before you take Karvea</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>3. How to take Karvea</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4. Possible side effects</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>5. How to store Karvea</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>1. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>What
Karvea is and what it is used for</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea belongs to a group of medicines
known as angiotensin-II receptor antagonists. Angiotensin-II is a substance
produced in the body which binds to receptors in blood vessels causing them to
tighten. This results in an increase in blood pressure. Karvea prevents the
binding of angiotensin-II to these receptors, causing the blood vessels to
relax and the blood pressure to lower. Karvea slows the decrease of kidney
function in patients with high blood pressure and type&nbsp;2 diabetes.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is used in adult patients</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>to treat high blood pressure (<i>essential hypertension</i>)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>to protect the kidney in patients with high blood pressure,
type&nbsp;2 diabetes and laboratory evidence of impaired kidney function.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>2. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>What
you need to know before you take Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Do not take Karvea</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>allergic</b> to irbesartan or any other ingredients of
this medicine (listed in section 6)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>more than 3 months pregnant</b>. (It is also better to
avoid Karvea in early pregnancy  see pregnancy section)</span></p>

<p class=EMEABodyTextIndent style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>if you have diabetes or impaired kidney
function </span></b><span lang=EN-GB>and you are treated with a blood pressure
lowering medicine containing aliskiren. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Warning and precautions</span></p>

<p class=EMEAHeading3><span lang=EN-GB style='font-weight:normal'>Talk to your
doctor before taking Karvea and</span><span lang=EN-GB> if any of the following
apply to you:</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you get <b>excessive vomiting or diarrhoea</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you suffer from <b>kidney problems</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you suffer from <b>heart problems</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>if you receive Karvea for <b>diabetic kidney disease</b>. In this
case your doctor may perform regular blood tests, especially for measuring
blood potassium levels in case of poor kidney function</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>if you develop <b>low blood sugar levels</b> (symptoms may include
sweating, weakness, hunger, dizziness, trembling, headache, flushing or
paleness, numbness, having a fast, pounding heart beat), particularly if you
are being treated for diabetes.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>going to have an operation</b> (surgery) or <b>be
given anaesthetics</b></span></p>

<p class=EMEABodyTextIndent style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking any of the following medicines
used to treat high blood pressure:</span></p>

<p class=EMEABodyTextIndent style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB>an ACE-inhibitor (for example enalapril,
lisinopril, ramipril), in particular if you have diabetes-related kidney
problems.</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB>aliskiren</span></p>

<p class=EMEABodyText><span lang=EN-GB>Your doctor may check your kidney
function, blood pressure, and the amount of electrolytes (e.g. potassium) in
your blood at regular intervals.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>See also information under the heading
Do not take Karvea.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>You must tell your doctor if you think
you are (<u>or might become</u>) pregnant. Karvea is not recommended in early
pregnancy, and must not be taken if you are more than 3&nbsp;months pregnant,
as it may cause serious harm to your baby if used at that stage (see pregnancy
section).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Children and adolescents</span></p>

<p class=EMEABodyText>This medicinal product should not be used in children and
adolescents because the safety and efficacy have not&nbsp;yet been&nbsp;fully
established.</p>

<p class=EMEAHeading3><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Other medicines and Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor or pharmacist if you
are taking, have recently taken or might take any other medicines.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Your doctor may need to change your dose
and/or to take other precautions:</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you are taking an ACE-inhibitor or
aliskiren (see also information under the headings Do not take Karvea and
Warnings and precautions).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>You may need to have blood checks if
you take:</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>potassium supplements</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>salt substitutes containing potassium</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>potassium-sparing medicines (such as certain diuretics)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>medicines containing lithium</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>repaglinide (medication used for lowering blood sugar levels)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you take certain painkillers, called
non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Karvea with food and drink</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea can be taken with or without
food.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Pregnancy and breast-feeding</span></p>

<p class=EMEAHeading2><span lang=EN-GB>Pregnancy</span></p>

<p class=EMEABodyText><span lang=EN-GB>You must tell your doctor if you think
you are (<u>or might become</u>) pregnant. Your doctor will normally advise you
to stop taking Karvea before you become pregnant or as soon as you know you are
pregnant and will advise you to take another medicine instead of Karvea. Karvea
is not recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if used after
the third month of pregnancy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>Breast-feeding</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor if you are
breast-feeding or about to start breast-feeding. Karvea is not recommended for
mothers who are breast-feeding, and your doctor may choose another treatment
for you if you wish to breast-feed, especially if your baby is newborn, or was
born prematurely.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Driving and using machines</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is unlikely to affect your
ability to drive or use machines. However, occasionally dizziness or weariness
may occur during treatment of high blood pressure. If you experience these,
talk to your doctor before attempting to drive or use machines.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Karvea contains lactose</span></b><span
lang=EN-GB>. If you have been told by your doctor that you have an intolerance
to some sugars (e.g. lactose), contact your doctor before taking this medicinal
product.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Karvea contains sodium. </span></b><span
lang=EN-GB>This medicine contains less than 1 mmol sodium (23 mg) per tablet,
that is to say essentially sodium-free.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>3. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>How
to take Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Always take this medicine exactly as
your doctor has told you. Check with your doctor or pharmacist if you are not
sure.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Method of administration</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is for <b>oral use</b>. Swallow
the tablets with a sufficient amount of fluid (e.g. one glass of water). You
can take Karvea with or without food. Try to take your daily dose at about the
same time each day. It is important that you continue to take Karvea until your
doctor tells you otherwise.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Patients with high blood pressure</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>The usual
dose is 150&nbsp;mg once a day. The dose may later be increased to 300&nbsp;mg
(two tablets a day) once daily depending on blood pressure response.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Patients with high blood pressure and type&nbsp;2 diabetes with
kidney disease</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>In patients
with high blood pressure and type&nbsp;2 diabetes, 300&nbsp;mg (two tablets a
day) once daily is the preferred maintenance dose for the treatment of
associated kidney disease.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The doctor may advise a lower dose,
especially when starting treatment in certain patients such as those on <b>haemodialysis</b>,
or those <b>over the age of 75&nbsp;years.</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The maximal blood pressure lowering
effect should be reached 4-6&nbsp;weeks after beginning treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Use in children and adolescents</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea should not be given to children
under 18&nbsp;years of age. If a child swallows some tablets, contact your
doctor immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>If you take more Karvea than you should</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you accidentally take too many
tablets, contact your doctor immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>If you forget to take Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you accidentally miss a daily dose,
just take the next dose as normal. Do not take a double dose to make up for a
forgotten dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>4. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>Possible
side effects</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Like all medicines, this medicine can
cause side effects, although not everybody gets them.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Some of these effects may be serious and
may require medical attention.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>As with similar medicines, rare cases of
allergic skin reactions (rash, urticaria), as well as localised swelling of the
face, lips and/or tongue have been reported in patients taking irbesartan. If
you get any of these symptoms or get short of breath, <b>stop taking Karvea and
contact your doctor immediately.</b></span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The frequency of the side effects listed
below is defined using the following convention:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Very common: </span><span lang=EN-GB>may
affect more than 1 in 10 people</span></p>

<p class=EMEABodyText><span lang=EN-GB>Common: may affect up to 1 in 10 people</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: may affect up to 1 in 100
people</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Side
effects reported in clinical studies for patients treated with Karvea were:</span></p>

<p class=EMEABodyTextIndent style='page-break-after:avoid'><span lang=EN-GB
style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Very common (</span><span lang=EN-GB>may affect
more than 1 in 10 people)</span><span lang=EN-GB>: if you suffer from high
blood pressure and type&nbsp;2 diabetes with kidney disease, blood tests may
show an increased level of potassium.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='page-break-after:avoid'><span lang=EN-GB
style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Common (</span><span lang=EN-GB>may affect up to
1 10 people)</span><span lang=EN-GB>: dizziness, feeling sick/vomiting, fatigue
and blood tests may show raised levels of an enzyme that measures the muscle
and heart function (creatine kinase enzyme). In patients with high blood
pressure and type&nbsp;2 diabetes with kidney disease, dizziness when getting
up from a lying or sitting position, low blood pressure when getting up from a
lying or sitting position, pain in joints or muscles and decreased levels of a
protein in the red blood cells (haemoglobin) were also reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Uncommon (</span><span lang=EN-GB>may affect up to 1 in 100 people)</span><span
lang=EN-GB>: heart rate increased, flushing, cough, diarrhoea,
indigestion/heartburn, sexual dysfunction (problems with sexual performance),
chest pain.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Some undesirable effects have been reported
since marketing of Karvea. Undesirable effects where the frequency is not known
are: feeling of spinning, headache, taste disturbance, ringing in the ears, </span><span
lang=EN-GB>muscle cramps, </span><span lang=EN-GB>pain in joints and muscles, </span><span
lang=EN-GB>decreased number of red blood cells (anaemia  symptoms may include
tiredness, headaches, being short of breath when exercising, dizziness and
looking pale), </span><span lang=EN-GB>reduced number of platelets, abnormal
liver function, increased blood potassium levels, impaired kidney function,
inflammation of small blood vessels</span><span lang=EN-GB> </span><span
lang=EN-GB>mainly affecting the skin</span><span lang=EN-GB> (a condition known
as leukocytoclastic vasculitis),</span><span lang=EN-GB> </span>severe allergic
reactions (anaphylactic shock) <span lang=EN-GB>and </span><span lang=EN-GB>low
blood sugar levels. Uncommon cases of jaundice (yellowing of the skin and/or
whites of the eyes) have also been reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Reporting of side effects</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>If you get any side effects, talk to
your doctor or pharmacist. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span></span><span
class=MsoHyperlink><span lang=ES-TRAD style='background:silver;text-decoration:
none'>Appendix V</span></span><span lang=EN-GB>. By reporting side effects you
can help provide more information on the safety of this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>5. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>How
to store Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not use this medicine after the
expiry date which is stated on the carton and on the blister after EXP. The
expiry date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away of
medicines you no longer use. These measures will help protect the environment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>6. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>Contents
of the pack and other information</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>What Karvea contains</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>The active substance is irbesartan. Each tablet of Karvea&nbsp;150&nbsp;mg
contains 150&nbsp;mg irbesartan.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>The other ingredients are microcrystalline cellulose, croscarmellose
sodium, lactose monohydrate, magnesium stearate, colloidal hydrated silica,
pregelatinised maize starch, and poloxamer&nbsp;188. </span>Please see section
2 Karvea contains lactose.</p>

<p class=EMEABodyTextIndent><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>What Karvea looks like and contents of
the pack</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;150&nbsp;mg tablets are
white to off-white, biconvex, and oval-shaped with a heart debossed on one side
and the number&nbsp;2772 engraved on the other side.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;150&nbsp;mg tablets are
supplied in blister packs of 14, 28, 56 or 98&nbsp;tablets. Unidose blister
packs of 56&nbsp;x&nbsp;1&nbsp;tablet for delivery in hospitals are also
available.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=FR>Marketing Authorisation Holder:</span></p>

<p class=EMEAAddress><span lang=FR>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=FR>Manufacturer:</span></p>

<p class=EMEAAddress><span lang=FR>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
1, rue de la Vierge<br>
Ambars &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex&nbsp;-&nbsp;France</span></p>

<p class=EMEAAddress><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
30-36&nbsp;Avenue Gustave Eiffel, BP&nbsp;7166<br>
F-37071&nbsp;Tours&nbsp;Cedex&nbsp;2&nbsp;-&nbsp;France</span></p>

<p class=EMEAAddress><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>CHINOIN PRIVATE CO. LTD.<br>
Lvai u.5.<br>
2112 Veresegyhz&nbsp;-&nbsp;Hungary</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For any information about this medicinal
product, please contact the local representative of the Marketing Authorisation
Holder.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Belgi/</span></b><b><span lang=CS>Belgique</span></b><b><span
  lang=MT>/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='layout-grid-mode:line'>Sanofi Belgium</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tl/Tel: <span style='layout-grid-mode:
  line'>+32 (0)2 710 54 00</span></span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=CS>UAB sanofi-aventis Lietuva</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +370 5 2755224</span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Bulgaria EOOD</span></p>
  <p class=MsoNormal><span lang=BG>&#1058;&#1077;&#1083;</span><span lang=IT>.</span><span
  lang=BG>: +</span><span lang=IT>359 (0)2</span><span lang=IT> 970 53 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-LU>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='layout-grid-mode:line'>Sanofi
  Belgium </span></p>
  <p class=MsoNormal><span lang=FR-LU>Tl/Tel: </span><span lang=FR-BE
  style='layout-grid-mode:line'>+32 (0)2 710 54 00 (</span><span lang=FR-BE>Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=HU>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>&#268;esk republika</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis, s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +420 233 086 111</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=CS>SANOFI-AVENTIS Zrt.</span></p>
  <p class=MsoNormal><span lang=CS>Tel.: +36 1 </span><span lang=HU>505 0050</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Danmark</span></b></p>
  <p class=MsoNormal><span lang=CS>Sanofi A/S</span></p>
  <p class=MsoNormal><span lang=CS>Tlf: +45 45 16 70 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +39 02 39394275</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=CS>Sanofi-Aventis Deutschland GmbH</span></p>
  <p class=MsoNormal><span lang=CS>Tel: 0800 52 52 010</span></p>
  <p class=MsoNormal><span lang=CS>Tel. aus dem Ausland: +49 69 305 21 131</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Nederland</span></b></p>
  <p class=MsoNormal><span lang=CS>Genzyme Europe B.V.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +31 20 245 4000</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis Estonia O</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +372 627 34 88</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Norge</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis Norge AS</span></p>
  <p class=MsoNormal><span lang=CS>Tlf: +47 67 10 71 00</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis AEBE</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;</span><span lang=CS>: +30
  210 900 16 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE>sanofi-aventis GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +43 1 80 185  0</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espaa</span></b></p>
  <p class=MsoNormal><span lang=PT>sanofi-aventis, S.A.</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +34 93 485 94 00</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Polska</span></b></p>
  <p class=MsoNormal><span lang=SV>sanofi-aventis Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=FR>Tel.: +48 22&nbsp;280 00 00</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>sanofi-aventis France</span></p>
  <p class=MsoNormal><span lang=PT>Tl: 0 800 222 555</span></p>
  <p class=MsoNormal><span lang=PT>Appel depuis ltranger : +33 1 57 63 23 23</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT>Sanofi - Produtos Farmacuticos, Lda</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +351 21 35 89 400</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=IT>sanofi-aventis Croatia d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +385 1 600 34 00</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Romnia</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Romania SRL</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +40 </span><span lang=IT>(0) 21 317 31
  36</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>Ireland</span></b></p>
  <p class=MsoNormal><span lang=FR>sanofi-aventis Ireland Ltd. T/A SANOFI</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +353 (0) 1 403 56 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis d.o.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +386 1 560 48 00</span></p>
  <p class=MsoNormal><span lang=SK>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS>sland</span></b></p>
  <p class=MsoNormal><span lang=CS>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Smi</span><span lang=CS>: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Slovensk republika</span></b></p>
  <p class=MsoNormal><span lang=SK>sanofi-</span><span lang=CS>aventis Slovakia
  </span><span lang=SK>s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +</span><span lang=SK>421 2 </span><span
  lang=EN-GB>33 100 100</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=IT>Tel</span><span lang=CS>: 800 536389</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Oy</span></p>
  <p class=MsoNormal><span lang=IT>Puh/Tel: +358 (0) 201 200 300</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=FR>sanofi-aventis Cyprus Ltd.</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: +</span><span lang=FR>357
  22 871600</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal><span lang=SV>Sanofi AB</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +46 (0)8 634 50 00</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT>sanofi-aventis Latvia SIA</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +371 67 33 24 51</span></p>
  <p class=MsoNormal><span lang=LV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=SV>Sanofi</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +44 (0) 845 372 7101</span></p>
  <p class=MsoNormal><span lang=LV>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu/</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText align=center style='text-align:center'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=EMEATitle><span lang=EN-GB>Karvea&nbsp;300&nbsp;mg tablets</span></p>

<p class=EMEATitle><span lang=EN-GB style='font-weight:normal'>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>If you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><u><span lang=EN-GB>What is in this leaflet</span></u></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>1. What Karvea is and what it is used for</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>2. What you need to know before you take Karvea</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>3. How to take Karvea</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4. Possible side effects</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>5. How to store Karvea</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>1. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>What
Karvea is and what it is used for</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea belongs to a group of medicines
known as angiotensin-II receptor antagonists. Angiotensin-II is a substance
produced in the body which binds to receptors in blood vessels causing them to
tighten. This results in an increase in blood pressure. Karvea prevents the
binding of angiotensin-II to these receptors, causing the blood vessels to
relax and the blood pressure to lower. Karvea slows the decrease of kidney
function in patients with high blood pressure and type&nbsp;2 diabetes.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is used in adult patients</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>to treat high blood pressure (<i>essential hypertension</i>)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>to protect the kidney in patients with high blood pressure,
type&nbsp;2 diabetes and laboratory evidence of impaired kidney function.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>2. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>What
you need to know before you take Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Do not take Karvea</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>allergic</b> to irbesartan or any other ingredients of
this medicine (listed in section 6)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>more than 3 months pregnant</b>. (It is also better to
avoid Karvea in early pregnancy  see pregnancy section)</span></p>

<p class=EMEABodyTextIndent style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>if you have diabetes or impaired kidney </span></b><span
lang=EN-GB>function and you are treated with a blood pressure lowering medicine
containing aliskiren.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Warning and precautions</span></p>

<p class=EMEAHeading3><span lang=EN-GB style='font-weight:normal'>Talk to your
doctor before taking Karvea and</span><span lang=EN-GB> if any of the following
apply to you:</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you get <b>excessive vomiting or diarrhoea</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you suffer from <b>kidney problems</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you suffer from <b>heart problems</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>if you receive Karvea for <b>diabetic kidney disease</b>. In this
case your doctor may perform regular blood tests, especially for measuring
blood potassium levels in case of poor kidney function</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>if you develop <b>low blood sugar levels</b> (symptoms may include
sweating, weakness, hunger, dizziness, trembling, headache, flushing or
paleness, numbness, having a fast, pounding heart beat), particularly if you
are being treated for diabetes.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>going to have an operation</b> (surgery) or <b>be
given anaesthetics</b></span></p>

<p class=EMEABodyTextIndent style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking any of the following medicines
used to treat high blood pressure:</span></p>

<p class=EMEABodyTextIndent style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB>an ACE-inhibitor (for example enalapril,
lisinopril, ramipril), in particular if you have diabetes-related kidney
problems.</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB>aliskiren</span></p>

<p class=EMEABodyText><span lang=EN-GB>Your doctor may check your kidney
function, blood pressure, and the amount of electrolytes (e.g. potassium) in
your blood at regular intervals.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>See also information under the heading
Do not take Karvea.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>You must tell your doctor if you think
you are (<u>or might become</u>) pregnant. Karvea is not recommended in early
pregnancy, and must not be taken if you are more than 3&nbsp;months pregnant,
as it may cause serious harm to your baby if used at that stage (see pregnancy
section).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Children and adolescents</span></p>

<p class=EMEABodyText>This medicinal product should not be used in children and
adolescents because the safety and efficacy have not&nbsp;yet been&nbsp;fully
established.</p>

<p class=EMEAHeading3><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Other medicines and Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor or pharmacist if you
are taking, have recently taken or might take any other medicines.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Your doctor may need to change your dose
and/or to take other precautions:</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you are taking an ACE-inhibitor or
aliskiren (see also information under the headings Do not take Karvea and
Warnings and precautions).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>You may need to have blood checks if
you take:</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>potassium supplements</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>salt substitutes containing potassium</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>potassium-sparing medicines (such as certain diuretics)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>medicines containing lithium</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>repaglinide (medication used for lowering blood sugar levels)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you take certain painkillers, called
non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Karvea with food and drink</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea can be taken with or without
food.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Pregnancy and breast-feeding</span></p>

<p class=EMEAHeading2><span lang=EN-GB>Pregnancy</span></p>

<p class=EMEABodyText><span lang=EN-GB>You must tell your doctor if you think
you are (<u>or might become</u>) pregnant. Your doctor will normally advise you
to stop taking Karvea before you become pregnant or as soon as you know you are
pregnant and will advise you to take another medicine instead of Karvea. Karvea
is not recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if used after
the third month of pregnancy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>Breast-feeding</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor if you are
breast-feeding or about to start breast-feeding. Karvea is not recommended for
mothers who are breast-feeding, and your doctor may choose another treatment
for you if you wish to breast-feed, especially if your baby is newborn, or was
born prematurely.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Driving and using machines</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is unlikely to affect your
ability to drive or use machines. However, occasionally dizziness or weariness
may occur during treatment of high blood pressure. If you experience these,
talk to your doctor before attempting to drive or use machines.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Karvea contains lactose</span></b><span
lang=EN-GB>. If you have been told by your doctor that you have an intolerance
to some sugars (e.g. lactose), contact your doctor before taking this medicinal
product.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Karvea contains sodium. </span></b><span
lang=EN-GB>This medicine contains less than 1 mmol sodium (23 mg) per tablet,
that is to say essentially sodium-free.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>3. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>How
to take Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Always take this medicine exactly as
your doctor has told you. Check with your doctor or pharmacist if you are not
sure.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Method of administration</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is for <b>oral use</b>. Swallow
the tablets with a sufficient amount of fluid (e.g. one glass of water). You
can take Karvea with or without food. Try to take your daily dose at about the
same time each day. It is important that you continue to take Karvea until your
doctor tells you otherwise.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Patients with high blood pressure</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>The usual
dose is 150&nbsp;mg once a day. The dose may later be increased to 300&nbsp;mg
once daily depending on blood pressure response.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Patients with high blood pressure and type&nbsp;2 diabetes with
kidney disease</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>In patients
with high blood pressure and type&nbsp;2 diabetes, 300&nbsp;mg once daily is
the preferred maintenance dose for the treatment of associated kidney disease.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The doctor may advise a lower dose,
especially when starting treatment in certain patients such as those on <b>haemodialysis</b>,
or those <b>over the age of 75&nbsp;years.</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The maximal blood pressure lowering
effect should be reached 4-6&nbsp;weeks after beginning treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Use in children and adolescents</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea should not be given to children
under 18&nbsp;years of age. If a child swallows some tablets, contact your
doctor immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>If you take more Karvea than you should</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you accidentally take too many
tablets, contact your doctor immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>If you forget to take Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you accidentally miss a daily dose,
just take the next dose as normal. Do not take a double dose to make up for a
forgotten dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>4. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>Possible
side effects</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Like all medicines, this medicine can
cause side effects, although not everybody gets them.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Some of these effects may be serious and
may require medical attention.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>As with similar medicines, rare cases of
allergic skin reactions (rash, urticaria), as well as localised swelling of the
face, lips and/or tongue have been reported in patients taking irbesartan. If
you get any of these symptoms or get short of breath, <b>stop taking Karvea and
contact your doctor immediately.</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The frequency of the side effects listed
below is defined using the following convention:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Very common: </span><span lang=EN-GB>may
affect more than 1 in 10 people</span></p>

<p class=EMEABodyText><span lang=EN-GB>Common: may affect up to 1 in 10 people</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: may affect up to 1 in 100
people</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Side effects reported in clinical
studies for patients treated with Karvea were:</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Very common (</span><span lang=EN-GB>may affect more than 1 in 10
people)</span><span lang=EN-GB>: if you suffer from high blood pressure and
type&nbsp;2 diabetes with kidney disease, blood tests may show an increased
level of potassium.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Common (</span><span lang=EN-GB>may affect up to 1 10 people)</span><span
lang=EN-GB>: dizziness, feeling sick/vomiting, fatigue and blood tests may show
raised levels of an enzyme that measures the muscle and heart function
(creatine kinase enzyme). In patients with high blood pressure and type&nbsp;2
diabetes with kidney disease, dizziness when getting up from a lying or sitting
position, low blood pressure when getting up from a lying or sitting position,
pain in joints or muscles and decreased levels of a protein in the red blood
cells (haemoglobin) were also reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Uncommon (</span><span lang=EN-GB>may affect up to 1 in 100 people)</span><span
lang=EN-GB>: heart rate increased, flushing, cough, diarrhoea, indigestion/heartburn,
sexual dysfunction (problems with sexual performance), chest pain.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Some undesirable effects have been reported
since marketing of Karvea. Undesirable effects where the frequency is not known
are: feeling of spinning, headache, taste disturbance, ringing in the ears, </span><span
lang=EN-GB>muscle cramps, </span><span lang=EN-GB>pain in joints and muscles, </span><span
lang=EN-GB>decreased number of red blood cells (anaemia  symptoms may include
tiredness, headaches, being short of breath when exercising, dizziness and
looking pale), </span><span lang=EN-GB>reduced number of platelets, abnormal liver
function, increased blood potassium levels, impaired kidney function, inflammation
of small blood vessels</span><span lang=EN-GB> </span><span lang=EN-GB>mainly
affecting the skin</span><span lang=EN-GB> (a condition known as
leukocytoclastic vasculitis),</span><span lang=EN-GB> </span>severe allergic
reactions (anaphylactic shock) <span lang=EN-GB>and </span><span lang=EN-GB>low
blood sugar levels. Uncommon cases of jaundice (yellowing of the skin and/or
whites of the eyes) have also been reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Reporting of side effects</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>If you get any side effects, talk to
your doctor or pharmacist. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span></span><span
class=MsoHyperlink><span lang=ES-TRAD style='background:silver;text-decoration:
none'>Appendix V</span></span><span lang=EN-GB>. By reporting side effects you
can help provide more information on the safety of this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>5. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>How
to store Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not use this medicine after the
expiry date which is stated on the carton and on the blister after EXP. The expiry
date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away of
medicines you no longer use. These measures will help protect the environment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>6. </span><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif;text-transform:none'>Contents
of the pack and other information</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>What Karvea contains</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>The active substance is irbesartan. Each tablet of Karvea&nbsp;300&nbsp;mg
contains 300&nbsp;mg irbesartan.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>The other ingredients are microcrystalline cellulose, croscarmellose
sodium, lactose monohydrate, magnesium stearate, colloidal hydrated silica,
pregelatinised maize starch, and poloxamer&nbsp;188. </span>Please see section
2 Karvea contains lactose.</p>

<p class=EMEABodyTextIndent><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>What Karvea looks like and contents of
the pack</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;300&nbsp;mg tablets are
white to off-white, biconvex, and oval-shaped with a heart debossed on one side
and the number&nbsp;2773 engraved on the other side.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;300&nbsp;mg tablets are
supplied in blister packs of 14, 28, 56 or 98&nbsp;tablets. Unidose blister
packs of 56&nbsp;x&nbsp;1&nbsp;tablet for delivery in hospitals are also
available.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=FR>Marketing Authorisation Holder:</span></p>

<p class=EMEAAddress><span lang=FR-BE>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris</span><span lang=FR>&nbsp;</span><span lang=FR-BE>-&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR-BE>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=FR>Manufacturer:</span></p>

<p class=EMEAAddress><span lang=FR-BE>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
1, rue de la Vierge<br>
Ambars &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex&nbsp;-&nbsp;France</span></p>

<p class=EMEAAddress><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
30-36&nbsp;Avenue Gustave Eiffel, BP&nbsp;7166<br>
F-37071&nbsp;Tours&nbsp;Cedex&nbsp;2&nbsp;-&nbsp;France</span></p>

<p class=EMEAAddress><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>CHINOIN PRIVATE CO. LTD.<br>
Lvai u.5.<br>
2112 Veresegyhz&nbsp;-&nbsp;Hungary</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For any information about this medicinal
product, please contact the local representative of the Marketing Authorisation
Holder.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Belgi/</span></b><b><span lang=CS>Belgique</span></b><b><span
  lang=MT>/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='layout-grid-mode:line'>Sanofi Belgium</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tl/Tel: <span style='layout-grid-mode:
  line'>+32 (0)2 710 54 00</span></span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=CS>UAB sanofi-aventis Lietuva</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +370 5 2755224</span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Bulgaria EOOD</span></p>
  <p class=MsoNormal><span lang=BG>&#1058;&#1077;&#1083;</span><span lang=IT>.</span><span
  lang=BG>: +</span><span lang=IT>359 (0)2</span><span lang=IT> 970 53 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-LU>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='layout-grid-mode:line'>Sanofi
  Belgium </span></p>
  <p class=MsoNormal><span lang=FR-LU>Tl/Tel: </span><span lang=FR-BE
  style='layout-grid-mode:line'>+32 (0)2 710 54 00 (</span><span lang=FR-BE>Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=HU>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>&#268;esk republika</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis, s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +420 233 086 111</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=CS>SANOFI-AVENTIS Zrt.</span></p>
  <p class=MsoNormal><span lang=CS>Tel.: +36 1 </span><span lang=HU>505 0050</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Danmark</span></b></p>
  <p class=MsoNormal><span lang=CS>Sanofi A/S</span></p>
  <p class=MsoNormal><span lang=CS>Tlf: +45 45 16 70 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +39 02 39394275</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=CS>Sanofi-Aventis Deutschland GmbH</span></p>
  <p class=MsoNormal><span lang=CS>Tel: 0800 52 52 010</span></p>
  <p class=MsoNormal><span lang=CS>Tel. aus dem Ausland: +49 69 305 21 131</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Nederland</span></b></p>
  <p class=MsoNormal><span lang=CS>Genzyme Europe B.V.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +31 20 245 4000</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis Estonia O</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +372 627 34 88</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Norge</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis Norge AS</span></p>
  <p class=MsoNormal><span lang=CS>Tlf: +47 67 10 71 00</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis AEBE</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;</span><span lang=CS>: +30
  210 900 16 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE>sanofi-aventis GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +43 1 80 185  0</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espaa</span></b></p>
  <p class=MsoNormal><span lang=PT>sanofi-aventis, S.A.</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +34 93 485 94 00</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Polska</span></b></p>
  <p class=MsoNormal><span lang=SV>sanofi-aventis Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=FR>Tel.: +48 22&nbsp;280 00 00</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>sanofi-aventis France</span></p>
  <p class=MsoNormal><span lang=PT>Tl: 0 800 222 555</span></p>
  <p class=MsoNormal><span lang=PT>Appel depuis ltranger : +33 1 57 63 23 23</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT>Sanofi - Produtos Farmacuticos, Lda</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +351 21 35 89 400</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=IT>sanofi-aventis Croatia d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +385 1 600 34 00</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Romnia</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Romania SRL</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +40 </span><span lang=IT>(0) 21 317 31
  36</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>Ireland</span></b></p>
  <p class=MsoNormal><span lang=FR>sanofi-aventis Ireland Ltd. T/A SANOFI</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +353 (0) 1 403 56 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis d.o.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +386 1 560 48 00</span></p>
  <p class=MsoNormal><span lang=SK>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS>sland</span></b></p>
  <p class=MsoNormal><span lang=CS>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Smi</span><span lang=CS>: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Slovensk republika</span></b></p>
  <p class=MsoNormal><span lang=SK>sanofi-</span><span lang=CS>aventis Slovakia
  </span><span lang=SK>s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +</span><span lang=SK>421 2 </span><span
  lang=EN-GB>33 100 100</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=IT>Tel: </span><span lang=CS>800 536389</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Oy</span></p>
  <p class=MsoNormal><span lang=IT>Puh/Tel: +358 (0) 201 200 300</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=FR>sanofi-aventis Cyprus Ltd.</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: +</span><span lang=FR>357
  22 871600</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal><span lang=SV>Sanofi AB</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +46 (0)8 634 50 00</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT>sanofi-aventis Latvia SIA</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +371 67 33 24 51</span></p>
  <p class=MsoNormal><span lang=LV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=SV>Sanofi</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +44 (0) 845 372 7101</span></p>
  <p class=MsoNormal><span lang=LV>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu/</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText align=center style='text-align:center'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=EMEABodyText align=center style='text-align:center'><b><span
lang=EN-GB>Karvea</span></b><span lang=EN-GB>&nbsp;<b>75</b>&nbsp;<b>mg
film-coated tablets</b></span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>If you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><u><span lang=EN-GB>What is in this leaflet</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>1. What Karvea is and what it is
used for</span></p>

<p class=EMEABodyText><span lang=EN-GB>2. What you need to know before
you take Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>3. How to take Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>4. Possible side effects</span></p>

<p class=EMEABodyText><span lang=EN-GB>5. How to store Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>6. Contents of the pack and other
information</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>1. What Karvea is and what it is used for</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea belongs to a group of medicines
known as angiotensin-II receptor antagonists. Angiotensin-II is a substance
produced in the body which binds to receptors in blood vessels causing them to
tighten. This results in an increase in blood pressure. Karvea prevents the
binding of angiotensin-II to these receptors, causing the blood vessels to
relax and the blood pressure to lower. Karvea slows the decrease of kidney
function in patients with high blood pressure and type&nbsp;2 diabetes.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is used in adult patients</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>to treat high blood pressure (<i>essential hypertension</i>)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>to protect the kidney in patients with high blood pressure,
type&nbsp;2 diabetes and laboratory evidence of impaired kidney function.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>2. </span><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;text-transform:none'>What you
need to know before you take</span><span lang=EN-GB> </span><span lang=EN-GB
style='text-transform:none'>Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Do not take Karvea</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>allergic</b> to irbesartan or any other ingredients of
this medicine (listed in section 6)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>more than 3&nbsp;months pregnant</b>. (It is also
better to avoid Karvea in early pregnancy  see pregnancy section)</span></p>

<p class=EMEABodyTextIndent style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>if you have diabetes or impaired kidney
function </span></b><span lang=EN-GB>and you are treated with a blood pressure
lowering medicine containing aliskiren. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Warnings and precautions</span></p>

<p class=EMEAHeading3><span lang=EN-GB style='font-weight:normal'>Talk to your
doctor before taking Karvea</span><span lang=EN-GB> </span><span lang=EN-GB
style='font-weight:normal'>and </span><span lang=EN-GB>if any of the following
apply to you:</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you get <b>excessive vomiting or diarrhoea</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you suffer from <b>kidney problems</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you suffer from <b>heart problems</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>if you receive Karvea for <b>diabetic kidney disease</b>. In this
case your doctor may perform regular blood tests, especially for measuring
blood potassium levels in case of poor kidney function</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>if you develop <b>low blood sugar levels</b> (symptoms may include
sweating, weakness, hunger, dizziness, trembling, headache, flushing or
paleness, numbness, having a fast, pounding heart beat), particularly if you
are being treated for diabetes.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>going to have an operation</b> (surgery) or <b>be
given anaesthetics</b></span></p>

<p class=EMEABodyTextIndent style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking any of the following medicines
used to treat high blood pressure:</span></p>

<p class=EMEABodyTextIndent style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB>an ACE-inhibitor (for example enalapril,
lisinopril, ramipril), in particular if you have diabetes-related kidney
problems.</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB>aliskiren</span></p>

<p class=EMEABodyText><span lang=EN-GB>Your doctor may check your kidney
function, blood pressure, and the amount of electrolytes (e.g. potassium) in
your blood at regular intervals.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>See also information under the heading
Do not take Karvea.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>You must tell your doctor if you think
you are (<u>or might become</u>) pregnant. Karvea is not recommended in early
pregnancy, and must not be taken if you are more than 3&nbsp;months pregnant,
as it may cause serious harm to your baby if used at that stage (see pregnancy
section).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>Children and adolescents</span></p>

<p class=EMEABodyText>This medicinal product should not be used in children and
adolescents because the safety and efficacy have not&nbsp;yet been&nbsp;fully
established.</p>

<p class=EMEAHeading3><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Other medicines and Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor or pharmacist if you
are taking, have recently taken or might take any other medicines.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Your doctor may need to change your dose
and/or to take other precautions:</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you are taking an ACE-inhibitor or
aliskiren (see also information under the headings Do not take Karvea and
Warnings and precautions).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>You may need to have blood checks if
you take:</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>potassium supplements</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>salt substitutes containing potassium</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>potassium-sparing medicines (such as certain diuretics)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>medicines containing lithium</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>repaglinide (medication used for lowering blood sugar levels)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you take certain painkillers, called
non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Karvea with food and drink</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea can be taken with or without
food.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Pregnancy and breast-feeding</span></p>

<p class=EMEAHeading2><span lang=EN-GB>Pregnancy</span></p>

<p class=EMEABodyText><span lang=EN-GB>You must tell your doctor if you think
you are (<u>or might become</u>) pregnant. Your doctor will normally advise you
to stop taking Karvea before you become pregnant or as soon as you know you are
pregnant and will advise you to take another medicine instead of Karvea. Karvea
is not recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if used after
the third month of pregnancy.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEAHeading2><span lang=EN-GB>Breast-feeding</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor if you are
breast-feeding or about to start breast-feeding. Karvea is not recommended for
mothers who are breast-feeding, and your doctor may choose another treatment
for you if you wish to breast-feed, especially if your baby is newborn, or was
born prematurely.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Driving and using machines</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is unlikely to affect your
ability to drive or use machines. However, occasionally dizziness or weariness
may occur during treatment of high blood pressure. If you experience these,
talk to your doctor before attempting to drive or use machines.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Karvea contains lactose</span></b><span
lang=EN-GB>. If you have been told by your doctor that you have an intolerance
to some sugars (e.g. lactose), contact your doctor before taking this medicinal
product.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Karvea contains sodium. </span></b><span
lang=EN-GB>This medicine contains less than 1 mmol sodium (23 mg) per tablet,
that is to say essentially sodium-free.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>3. How to take Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Always take this medicine exactly as
your doctor has told you. Check with your doctor or pharmacist if you are not
sure.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Method of administration</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is for <b>oral use</b>. Swallow
the tablets with a sufficient amount of fluid (e.g. one glass of water). You
can take Karvea with or without food. Try to take your daily dose at about the
same time each day. It is important that you continue to take Karvea until your
doctor tells you otherwise.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Patients with high blood pressure</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>The usual
dose is 150&nbsp;mg once a day (two tablets a day). The dose may later be
increased to 300&nbsp;mg (four tablets a day) once daily depending on blood pressure
response.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Patients with high blood pressure and type&nbsp;2 diabetes with kidney
disease</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>In patients
with high blood pressure and type&nbsp;2 diabetes, 300&nbsp;mg (four tablets a
day) once daily is the preferred maintenance dose for the treatment of
associated kidney disease.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The doctor may advise a lower dose,
especially when starting treatment in certain patients such as those on <b>haemodialysis</b>,
or those <b>over the age of 75&nbsp;years.</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The maximal blood pressure lowering
effect should be reached 4-6&nbsp;weeks after beginning treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Use in children and adolescents</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea should not be given to children
under 18&nbsp;years of age. If a child swallows some tablets, contact your
doctor immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>If you take more Karvea than you should:</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you accidentally take too many tablets,
contact your doctor immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>If you forget to take Karvea:</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you accidentally miss a daily dose,
just take the next dose as normal. Do not take a double dose to make up for a
forgotten dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>4. Possible side effects</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Like all medicines, this medicine can
cause side effects, although not everybody gets them.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Some of these effects may be serious and
may require medical attention.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>As with similar medicines, rare cases of
allergic skin reactions (rash, urticaria), as well as localised swelling of the
face, lips and/or tongue have been reported in patients taking irbesartan. If
you get any of these symptoms or get short of breath, <b>stop taking Karvea and
contact your doctor immediately.</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The frequency of the side effects listed
below is defined using the following convention:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Very common: </span><span lang=EN-GB>may
affect more than 1 in 10 people</span></p>

<p class=EMEABodyText><span lang=EN-GB>Common: may affect up to 1 in 10 people</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: may affect up to 1 in 100
people</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Side effects reported in clinical
studies for patients treated with Karvea were:</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Very common (</span><span lang=EN-GB>may affect more than 1 in 10
people)</span><span lang=EN-GB>: if you suffer from high blood pressure and
type&nbsp;2 diabetes with kidney disease, blood tests may show an increased
level of potassium.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Common (</span><span lang=EN-GB>may affect up to 1 10 people)</span><span
lang=EN-GB>: dizziness, feeling sick/vomiting, fatigue and blood tests may show
raised levels of an enzyme that measures the muscle and heart function
(creatine kinase enzyme). In patients with high blood pressure and type&nbsp;2
diabetes with kidney disease, dizziness when getting up from a lying or sitting
position, low blood pressure when getting up from a lying or sitting position,
pain in joints or muscles and decreased levels of a protein in the red blood
cells (haemoglobin) were also reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Uncommon (</span><span lang=EN-GB>may affect up to 1 in 100 people)</span><span
lang=EN-GB>: heart rate increased, flushing, cough, diarrhoea,
indigestion/heartburn, sexual dysfunction (problems with sexual performance),
chest pain.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Some undesirable effects have been reported
since marketing of Karvea. Undesirable effects where the frequency is not known
are: feeling of spinning, headache, taste disturbance, ringing in the ears, </span><span
lang=EN-GB>muscle cramps, </span><span lang=EN-GB>pain in joints and muscles, </span><span
lang=EN-GB>decreased number of red blood cells (anaemia  symptoms may include
tiredness, headaches, being short of breath when exercising, dizziness and
looking pale), </span><span lang=EN-GB>reduced number of platelets, abnormal
liver function, increased blood potassium levels, impaired kidney function,
inflammation of small blood vessels</span><span lang=EN-GB> </span><span
lang=EN-GB>mainly affecting the skin</span><span lang=EN-GB> (a condition known
as leukocytoclastic vasculitis),</span><span lang=EN-GB> </span>severe allergic
reactions (anaphylactic shock) <span lang=EN-GB>and </span><span lang=EN-GB>low
blood sugar levels. Uncommon cases of jaundice (yellowing of the skin and/or
whites of the eyes) have also been reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Reporting of side effects</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>If you get any side effects, talk to
your doctor or pharmacist. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span></span><span
class=MsoHyperlink><span lang=ES-TRAD style='background:silver;text-decoration:
none'>Appendix V</span></span><span lang=EN-GB>. By reporting side effects you
can help provide more information on the safety of this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>5. How to store Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not use this medicine after the
expiry date which is stated on the carton and on the blister after EXP. The
expiry date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines
you no longer use. These measures will help protect the environment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>6. Contents of the pack and other information</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>What Karvea contains</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>The active substance is irbesartan. Each tablet of Karvea&nbsp;75&nbsp;mg
contains 75&nbsp;mg irbesartan.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>The other ingredients are lactose monohydrate, microcrystalline
cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium
stearate, titanium dioxide, macrogol 3000, carnauba wax. </span>Please see
section 2 Karvea contains lactose.</p>

<p class=EMEABodyTextIndent><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>What Karvea looks like and contents of
the pack</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;75&nbsp;mg film-coated
tablets are white to off-white, biconvex, and oval-shaped with a heart debossed
on one side and the number&nbsp;2871 engraved on the other side.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;75&nbsp;mg film-coated
tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or
98&nbsp;film-coated tablets. Unidose blister packs of
56&nbsp;x&nbsp;1&nbsp;film-coated tablet for delivery in hospitals are also
available.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=FR>Marketing Authorisation Holder:</span></p>

<p class=EMEAAddress><span lang=FR-BE>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris</span><span lang=FR-BE> </span><span lang=FR-BE>-&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR-BE>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=FR>Manufacturer:</span></p>

<p class=EMEAAddress><span lang=FR-BE>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
1, rue de la Vierge<br>
Ambars &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex&nbsp;-&nbsp;France</span></p>

<p class=EMEAAddress><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
30-36&nbsp;Avenue Gustave Eiffel, BP&nbsp;7166<br>
F-37071&nbsp;Tours&nbsp;Cedex&nbsp;2&nbsp;-&nbsp;France</span></p>

<p class=EMEAAddress><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For any information about this medicinal
product, please contact the local representative of the Marketing Authorisation
Holder.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Belgi/</span></b><b><span lang=CS>Belgique</span></b><b><span
  lang=MT>/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='layout-grid-mode:line'>Sanofi
  Belgium</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tl/Tel: <span style='layout-grid-mode:
  line'>+32 (0)2 710 54 00</span></span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=CS>UAB sanofi-aventis Lietuva</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +370 5 2755224</span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Bulgaria EOOD</span></p>
  <p class=MsoNormal><span lang=BG>&#1058;&#1077;&#1083;</span><span lang=IT>.</span><span
  lang=BG>: +</span><span lang=IT>359 (0)2</span><span lang=IT> 970 53 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-LU>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='layout-grid-mode:line'>Sanofi Belgium
  </span></p>
  <p class=MsoNormal><span lang=FR-LU>Tl/Tel: </span><span lang=FR-BE
  style='layout-grid-mode:line'>+32 (0)2 710 54 00 (</span><span lang=FR-BE>Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=HU>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>&#268;esk republika</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis, s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +420 233 086 111</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=CS>SANOFI-AVENTIS Zrt.</span></p>
  <p class=MsoNormal><span lang=CS>Tel.: +36 1 </span><span lang=HU>505 0050</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Danmark</span></b></p>
  <p class=MsoNormal><span lang=CS>Sanofi A/S</span></p>
  <p class=MsoNormal><span lang=CS>Tlf: +45 45 16 70 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +39 02 39394275</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=CS>Sanofi-Aventis Deutschland GmbH</span></p>
  <p class=MsoNormal><span lang=CS>Tel: 0800 52 52 010</span></p>
  <p class=MsoNormal><span lang=CS>Tel. aus dem Ausland: +49 69 305 21 131</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Nederland</span></b></p>
  <p class=MsoNormal><span lang=CS>Genzyme Europe B.V.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +31 20 245 4000</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis Estonia O</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +372 627 34 88</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Norge</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis Norge AS</span></p>
  <p class=MsoNormal><span lang=CS>Tlf: +47 67 10 71 00</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis AEBE</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;</span><span lang=CS>: +30
  210 900 16 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE>sanofi-aventis GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +43 1 80 185  0</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espaa</span></b></p>
  <p class=MsoNormal><span lang=PT>sanofi-aventis, S.A.</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +34 93 485 94 00</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Polska</span></b></p>
  <p class=MsoNormal><span lang=SV>sanofi-aventis Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=FR>Tel.: +48 22&nbsp;280 00 00</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>sanofi-aventis France</span></p>
  <p class=MsoNormal><span lang=PT>Tl: 0 800 222 555</span></p>
  <p class=MsoNormal><span lang=PT>Appel depuis ltranger : +33 1 57 63 23 23</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT>Sanofi - Produtos Farmacuticos, Lda</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +351 21 35 89 400</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=IT>sanofi-aventis Croatia d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +385 1 600 34 00</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Romnia </span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Romania SRL</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +40 </span><span lang=IT>(0) 21 317 31
  36</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>Ireland</span></b></p>
  <p class=MsoNormal><span lang=FR>sanofi-aventis Ireland Ltd. T/A SANOFI</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +353 (0) 1 403 56 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis d.o.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +386 1 560 48 00</span></p>
  <p class=MsoNormal><span lang=SK>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS>sland</span></b></p>
  <p class=MsoNormal><span lang=CS>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Smi</span><span lang=CS>: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Slovensk republika</span></b></p>
  <p class=MsoNormal><span lang=SK>sanofi-</span><span lang=CS>aventis Slovakia
  </span><span lang=SK>s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +</span><span lang=SK>421 2 </span><span
  lang=EN-GB>33 100 100</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=FR>Tel: 800 536389</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Oy</span></p>
  <p class=MsoNormal><span lang=IT>Puh/Tel: +358 (0) 201 200 300</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=FR>sanofi-aventis Cyprus Ltd.</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: +</span><span lang=FR>357
  22 871600</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal><span lang=SV>Sanofi AB</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +46 (0)8 634 50 00</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT>sanofi-aventis Latvia SIA</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +371 67 33 24 51</span></p>
  <p class=MsoNormal><span lang=LV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=SV>Sanofi</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +44 (0) 845 372 7101</span></p>
  <p class=MsoNormal><span lang=LV>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu/</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText align=center style='text-align:center'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=EMEABodyText align=center style='text-align:center'><b><span
lang=EN-GB>Karvea</span></b><span lang=EN-GB>&nbsp;<b>150</b>&nbsp;<b>mg
film-coated tablets</b></span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>If you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><u><span lang=EN-GB>What is in this leaflet</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>1. What Karvea is and what it is
used for</span></p>

<p class=EMEABodyText><span lang=EN-GB>2. What you need to know before
you take Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>3. How to take Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>4. Possible side effects</span></p>

<p class=EMEABodyText><span lang=EN-GB>5. How to store Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>6. Contents of the pack and other
information</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>1. What Karvea is and what it is used for</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea belongs to a group of medicines
known as angiotensin-II receptor antagonists. Angiotensin-II is a substance
produced in the body which binds to receptors in blood vessels causing them to
tighten. This results in an increase in blood pressure. Karvea prevents the
binding of angiotensin-II to these receptors, causing the blood vessels to
relax and the blood pressure to lower. Karvea slows the decrease of kidney
function in patients with high blood pressure and type&nbsp;2 diabetes.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is used in adult patients</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>to treat high blood pressure (<i>essential hypertension</i>)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>to protect the kidney in patients with high blood pressure,
type&nbsp;2 diabetes and laboratory evidence of impaired kidney function.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>2.  <span style='text-transform:
uppercase'>What you need to know before you take Karvea</span>Do not take
Karvea</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>allergic</b>to irbesartan or any other ingredients of this
medicine (listed in section 6)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>more than 3&nbsp;months pregnant</b>. (It is also
better to avoid Karvea in early pregnancy  see pregnancy section)</span></p>

<p class=EMEABodyTextIndent style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>if you have diabetes or impaired kidney
function</span></b><span lang=EN-GB> and you are treated with a blood pressure
lowering medicine containing aliskiren.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Warnings and precautions</span></p>

<p class=EMEAHeading3><span lang=EN-GB style='font-weight:normal'>Talk to your
doctor before taking Karvea</span><span lang=EN-GB> </span><span lang=EN-GB
style='font-weight:normal'>and </span><span lang=EN-GB>if any of the following
apply to you:</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you get <b>excessive vomiting or diarrhoea</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you suffer from <b>kidney problems</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you suffer from <b>heart problems</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>if you receive Karvea for <b>diabetic kidney disease</b>. In this
case your doctor may perform regular blood tests, especially for measuring
blood potassium levels in case of poor kidney function</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>if you develop <b>low blood sugar levels</b> (symptoms may include
sweating, weakness, hunger, dizziness, trembling, headache, flushing or
paleness, numbness, having a fast, pounding heart beat), particularly if you
are being treated for diabetes.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>going to have an operation</b> (surgery) or <b>be
given anaesthetics</b></span></p>

<p class=EMEABodyTextIndent style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking any of the following medicines
used to treat high blood pressure:</span></p>

<p class=EMEABodyTextIndent style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB>an ACE-inhibitor (for example enalapril,
lisinopril, ramipril), in particular if you have diabetes-related kidney
problems.</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB>aliskiren</span></p>

<p class=EMEABodyText><span lang=EN-GB>Your doctor may check your kidney
function, blood pressure, and the amount of electrolytes (e.g. potassium) in
your blood at regular intervals.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>See also information under the heading
Do not take Karvea.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>You must tell your doctor if you think
you are (<u>or might become</u>) pregnant. Karvea is not recommended in early
pregnancy, and must not be taken if you are more than 3&nbsp;months pregnant,
as it may cause serious harm to your baby if used at that stage (see pregnancy
section).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>Children and adolescents</span></p>

<p class=EMEABodyText>This medicinal product should not be used in children and
adolescents because the safety and efficacy have not&nbsp;yet been&nbsp;fully
established.</p>

<p class=EMEAHeading3><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Other medicines and Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor or pharmacist if you
are taking, have recently taken or might take any other medicines.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Your doctor may need to change your dose
and/or to take other precautions:</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you are taking an ACE-inhibitor or aliskiren
(see also information under the headings Do not take Karvea and Warnings and
precautions).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>You may need to have blood checks if
you take:</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>potassium supplements</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>salt substitutes containing potassium</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>potassium-sparing medicines (such as certain diuretics)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>medicines containing lithium</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>repaglinide (medication used for lowering blood sugar levels)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you take certain painkillers, called
non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Karvea with food and drink</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea can be taken with or without
food.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Pregnancy and breast-feeding</span></p>

<p class=EMEAHeading2><span lang=EN-GB>Pregnancy</span></p>

<p class=EMEABodyText><span lang=EN-GB>You must tell your doctor if you think
you are (<u>or might become</u>) pregnant. Your doctor will normally advise you
to stop taking Karvea before you become pregnant or as soon as you know you are
pregnant and will advise you to take another medicine instead of Karvea. Karvea
is not recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if used after
the third month of pregnancy.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEAHeading2><span lang=EN-GB>Breast-feeding</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor if you are
breast-feeding or about to start breast-feeding. Karvea is not recommended for
mothers who are breast-feeding, and your doctor may choose another treatment
for you if you wish to breast-feed, especially if your baby is newborn, or was
born prematurely.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Driving and using machines</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is unlikely to affect your
ability to drive or use machines. However, occasionally dizziness or weariness
may occur during treatment of high blood pressure. If you experience these,
talk to your doctor before attempting to drive or use machines.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Karvea contains lactose</span></b><span
lang=EN-GB>. If you have been told by your doctor that you have an intolerance
to some sugars (e.g. lactose), contact your doctor before taking this medicinal
product.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Karvea contains sodium. </span></b><span
lang=EN-GB>This medicine contains less than 1 mmol sodium (23 mg) per tablet,
that is to say essentially sodium-free.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>3. How to take Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Always take this medicine exactly as
your doctor has told you. Check with your doctor or pharmacist if you are not
sure.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Method of administration</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is for <b>oral use</b>. Swallow
the tablets with a sufficient amount of fluid (e.g. one glass of water). You
can take Karvea with or without food. Try to take your daily dose at about the
same time each day. It is important that you continue to take Karvea until your
doctor tells you otherwise.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Patients with high blood pressure</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>The usual
dose is 150&nbsp;mg once a day. The dose may later be increased to 300&nbsp;mg
(two tablets a day) once daily depending on blood pressure response.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Patients with high blood pressure and type&nbsp;2 diabetes with
kidney disease</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>In patients
with high blood pressure and type&nbsp;2 diabetes, 300&nbsp;mg (two tablets a
day) once daily is the preferred maintenance dose for the treatment of
associated kidney disease.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The doctor may advise a lower dose,
especially when starting treatment in certain patients such as those on <b>haemodialysis</b>,
or those <b>over the age of 75&nbsp;years.</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The maximal blood pressure lowering
effect should be reached 4-6&nbsp;weeks after beginning treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Use in children and adolescents</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea should not be given to children
under 18&nbsp;years of age. If a child swallows some tablets, contact your
doctor immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>If you take more Karvea than you should:</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you accidentally take too many
tablets, contact your doctor immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>If you forget to take Karvea:</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you accidentally miss a daily dose,
just take the next dose as normal. Do not take a double dose to make up for a
forgotten dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>4. Possible side effects</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Like all medicines, this medicine can
cause side effects, although not everybody gets them.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Some of these effects may be serious and
may require medical attention.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>As with similar medicines, rare cases of
allergic skin reactions (rash, urticaria), as well as localised swelling of the
face, lips and/or tongue have been reported in patients taking irbesartan. If
you get any of these symptoms or get short of breath, <b>stop taking Karvea and
contact your doctor immediately.</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The frequency of the side effects listed
below is defined using the following convention:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Very common: </span><span lang=EN-GB>may
affect more than 1 in 10 people</span></p>

<p class=EMEABodyText><span lang=EN-GB>Common: may affect up to 1 in 10 people</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: may affect up to 1 in 100
people</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Side effects reported in clinical
studies for patients treated with Karvea were:</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Very common (</span><span lang=EN-GB>may affect more than 1 in 10
people)</span><span lang=EN-GB>: if you suffer from high blood pressure and
type&nbsp;2 diabetes with kidney disease, blood tests may show an increased
level of potassium.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Common (</span><span lang=EN-GB>may affect up to 1 10 people)</span><span
lang=EN-GB>: dizziness, feeling sick/vomiting, fatigue and blood tests may show
raised levels of an enzyme that measures the muscle and heart function
(creatine kinase enzyme). In patients with high blood pressure and type&nbsp;2
diabetes with kidney disease, dizziness when getting up from a lying or sitting
position, low blood pressure when getting up from a lying or sitting position,
pain in joints or muscles and decreased levels of a protein in the red blood
cells (haemoglobin) were also reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Uncommon (</span><span lang=EN-GB>may affect up to 1 in 100 people)</span><span
lang=EN-GB>: heart rate increased, flushing, cough, diarrhoea,
indigestion/heartburn, sexual dysfunction (problems with sexual performance),
chest pain.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Some undesirable effects have been reported
since marketing of Karvea. Undesirable effects where the frequency is not known
are: feeling of spinning, headache, taste disturbance, ringing in the ears, </span><span
lang=EN-GB>muscle cramps, </span><span lang=EN-GB>pain in joints and muscles, </span><span
lang=EN-GB>decreased number of red blood cells (anaemia  symptoms may include
tiredness, headaches, being short of breath when exercising, dizziness and
looking pale), </span><span lang=EN-GB>reduced number of platelets, abnormal
liver function, increased blood potassium levels, impaired kidney function,
inflammation of small blood vessels</span><span lang=EN-GB> </span><span
lang=EN-GB>mainly affecting the skin</span><span lang=EN-GB> (a condition known
as leukocytoclastic vasculitis),</span><span lang=EN-GB> </span>severe allergic
reactions (anaphylactic shock) <span lang=EN-GB>and </span><span lang=EN-GB>low
blood sugar levels. Uncommon cases of jaundice (yellowing of the skin and/or
whites of the eyes) have also been reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Reporting of side effects</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>If you get any side effects, talk to
your doctor or pharmacist. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span></span><span
class=MsoHyperlink><span lang=ES-TRAD style='background:silver;text-decoration:
none'>Appendix V</span></span><span lang=EN-GB>. By reporting side effects you
can help provide more information on the safety of this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>5. How to store Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not use this medicine after the
expiry date which is stated on the carton and on the blister after EXP. The
expiry date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines
you no longer use. These measures will help protect the environment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>6. Contents of the pack and other information</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>What Karvea contains</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>The active substance is irbesartan. Each tablet of Karvea&nbsp;150&nbsp;mg
contains 150&nbsp;mg irbesartan.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>The other ingredients are lactose monohydrate, microcrystalline
cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium
stearate, titanium dioxide, macrogol 3000, carnauba wax. </span>Please see
section 2 Karvea contains lactose.</p>

<p class=EMEABodyTextIndent><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>What Karvea looks like and contents of
the pack</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;150&nbsp;mg film-coated
tablets are white to off-white, biconvex, and oval-shaped with a heart debossed
on one side and the number&nbsp;2872 engraved on the other side.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;150&nbsp;mg film-coated
tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or
98&nbsp;film-coated tablets. Unidose blister packs of
56&nbsp;x&nbsp;1&nbsp;film-coated tablet for delivery in hospitals are also
available.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=FR>Marketing Authorisation Holder:</span></p>

<p class=EMEAAddress><span lang=FR-BE>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris</span><span lang=FR>&nbsp;</span><span lang=FR-BE>-&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR-BE>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=FR>Manufacturer:</span></p>

<p class=EMEAAddress><span lang=FR-BE>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
1, rue de la Vierge<br>
Ambars &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex&nbsp;-&nbsp;France</span></p>

<p class=EMEAAddress><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
30-36&nbsp;Avenue Gustave Eiffel, BP&nbsp;7166<br>
F-37071&nbsp;Tours&nbsp;Cedex&nbsp;2&nbsp;-&nbsp;France</span></p>

<p class=EMEAAddress><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>CHINOIN PRIVATE CO. LTD.<br>
Lvai u.5.<br>
2112 Veresegyhz&nbsp;-&nbsp;Hungary</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=IT>SANOFI-AVENTIS, S.A.</span></p>

<p class=EMEABodyText><span lang=IT>Ctra. C-35 (La Batlloria-Hostalric), km.
63.09</span></p>

<p class=EMEABodyText><span lang=EN-GB>17404 Riells i Viabrea (Girona)  Spain</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For any information about this medicinal
product, please contact the local representative of the Marketing Authorisation
Holder.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Belgi/</span></b><b><span lang=CS>Belgique</span></b><b><span
  lang=MT>/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='layout-grid-mode:line'>Sanofi
  Belgium</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tl/Tel: <span style='layout-grid-mode:
  line'>+32 (0)2 710 54 00</span></span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=CS>UAB sanofi-aventis Lietuva</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +370 5 2755224</span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Bulgaria EOOD</span></p>
  <p class=MsoNormal><span lang=BG>&#1058;&#1077;&#1083;</span><span lang=IT>.</span><span
  lang=BG>: +</span><span lang=IT>359 (0)2</span><span lang=IT> 970 53 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-LU>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='layout-grid-mode:line'>Sanofi
  Belgium </span></p>
  <p class=MsoNormal><span lang=FR-LU>Tl/Tel: </span><span lang=FR-BE
  style='layout-grid-mode:line'>+32 (0)2 710 54 00 (</span><span lang=FR-BE>Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=HU>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>&#268;esk republika</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis, s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +420 233 086 111</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=CS>SANOFI-AVENTIS Zrt.</span></p>
  <p class=MsoNormal><span lang=CS>Tel.: +36 1 </span><span lang=HU>505 0050</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Danmark</span></b></p>
  <p class=MsoNormal><span lang=CS>Sanofi A/S</span></p>
  <p class=MsoNormal><span lang=CS>Tlf: +45 45 16 70 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +39 02 39394275</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=CS>Sanofi-Aventis Deutschland GmbH</span></p>
  <p class=MsoNormal><span lang=CS>Tel: 0800 52 52 010</span></p>
  <p class=MsoNormal><span lang=CS>Tel. aus dem Ausland: +49 69 305 21 131</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Nederland</span></b></p>
  <p class=MsoNormal><span lang=CS>Genzyme Europe B.V.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +31 20 245 4000</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis Estonia O</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +372 627 34 88</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Norge</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis Norge AS</span></p>
  <p class=MsoNormal><span lang=CS>Tlf: +47 67 10 71 00</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis AEBE</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;</span><span lang=CS>: +30
  210 900 16 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE>sanofi-aventis GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +43 1 80 185  0</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espaa</span></b></p>
  <p class=MsoNormal><span lang=PT>sanofi-aventis, S.A.</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +34 93 485 94 00</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Polska</span></b></p>
  <p class=MsoNormal><span lang=SV>sanofi-aventis Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=FR>Tel.: +48 22&nbsp;280 00 00</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>sanofi-aventis France</span></p>
  <p class=MsoNormal><span lang=PT>Tl: 0 800 222 555</span></p>
  <p class=MsoNormal><span lang=PT>Appel depuis ltranger : +33 1 57 63 23 23</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT>Sanofi - Produtos Farmacuticos, Lda</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +351 21 35 89 400</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=IT>sanofi-aventis Croatia d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +385 1 600 34 00</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL>Romnia</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Romania SRL</span></p>
  <p class=MsoNormal><span lang=PL>Tel: +40 </span><span lang=FR>(0) 21 317 31
  36</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>Ireland</span></b></p>
  <p class=MsoNormal><span lang=FR>sanofi-aventis Ireland Ltd. T/A SANOFI</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +353 (0) 1 403 56 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis d.o.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +386 1 560 48 00</span></p>
  <p class=MsoNormal><span lang=SK>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS>sland</span></b></p>
  <p class=MsoNormal><span lang=CS>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Smi</span><span lang=CS>: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Slovensk republika</span></b></p>
  <p class=MsoNormal><span lang=SK>sanofi-</span><span lang=CS>aventis Slovakia
  </span><span lang=SK>s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +</span><span lang=SK>421 2 </span><span
  lang=IT>33 100 100</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal><span lang=CS>Sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: 800 536389</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Oy</span></p>
  <p class=MsoNormal><span lang=IT>Puh/Tel: +358 (0) 201 200 300</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=FR>sanofi-aventis Cyprus Ltd.</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: +</span><span lang=FR>357
  22 871600</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal><span lang=SV>Sanofi AB</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +46 (0)8 634 50 00</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal><span lang=SV>sanofi-aventis Latvia SIA</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +371 67 33 24 51</span></p>
  <p class=MsoNormal><span lang=LV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=SV>Sanofi</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +44 (0) 845 372 7101</span></p>
  <p class=MsoNormal><span lang=LV>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu/</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText align=center style='text-align:center'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=EMEABodyText align=center style='text-align:center'><b><span
lang=EN-GB>Karvea</span></b><span lang=EN-GB>&nbsp;<b>300</b>&nbsp;<b>mg
film-coated tablets</b></span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB>irbesartan</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>If you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><u><span lang=EN-GB>What is in this leaflet</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>1. What Karvea is and what it is
used for</span></p>

<p class=EMEABodyText><span lang=EN-GB>2. What you need to know before
you take Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>3. How to take Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>4. Possible side effects</span></p>

<p class=EMEABodyText><span lang=EN-GB>5. How to store Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>6. Contents of the pack and other
information</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>1. What Karvea is and what it is used for</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea belongs to a group of medicines
known as angiotensin-II receptor antagonists. Angiotensin-II is a substance
produced in the body which binds to receptors in blood vessels causing them to
tighten. This results in an increase in blood pressure. Karvea prevents the
binding of angiotensin-II to these receptors, causing the blood vessels to
relax and the blood pressure to lower. Karvea slows the decrease of kidney
function in patients with high blood pressure and type&nbsp;2 diabetes.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is used in adult patients</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>to treat high blood pressure (<i>essential hypertension</i>)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>to protect the kidney in patients with high blood pressure,
type&nbsp;2 diabetes and laboratory evidence of impaired kidney function.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>2. </span><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;text-transform:none'>What you
need to know before you take</span><span lang=EN-GB> </span><span lang=EN-GB
style='text-transform:none'>Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Do not take Karvea</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>allergic</b> to irbesartan or any other ingredients of
this medicine (listed in section 6)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>more than 3&nbsp;months pregnant</b>. (It is also
better to avoid Karvea in early pregnancy  see pregnancy section)</span></p>

<p class=EMEABodyTextIndent style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>if you have diabetes or impaired kidney
function</span></b><span lang=EN-GB> and you are treated with a blood pressure
lowering medicine containing aliskiren.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Warnings and precautions</span></p>

<p class=EMEAHeading3><span lang=EN-GB style='font-weight:normal'>Talk to your
doctor before taking Karvea</span><span lang=EN-GB> </span><span lang=EN-GB
style='font-weight:normal'>and </span><span lang=EN-GB>if any of the following
apply to you:</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you get <b>excessive vomiting or diarrhoea</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you suffer from <b>kidney problems</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you suffer from <b>heart problems</b></span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>if you receive Karvea for <b>diabetic kidney disease</b>. In this
case your doctor may perform regular blood tests, especially for measuring
blood potassium levels in case of poor kidney function</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>if you develop <b>low blood sugar levels</b> (symptoms may include
sweating, weakness, hunger, dizziness, trembling, headache, flushing or
paleness, numbness, having a fast, pounding heart beat), particularly if you
are being treated for diabetes.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>if you are <b>going to have an operation</b> (surgery) or <b>be
given anaesthetics</b></span></p>

<p class=EMEABodyTextIndent style='margin-left:27.5pt;text-indent:-27.5pt'><a
name="_BPDC_LN_INS_1001"></a><span lang=EN-GB style='font-family:Wingdings;
color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>if you are taking any of the following medicines used to treat high
blood pressure:</span></p>

<p class=EMEABodyTextIndent style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB>an ACE-inhibitor (for example enalapril,
lisinopril, ramipril), in particular if you have diabetes-related kidney
problems.</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB>aliskiren</span></p>

<p class=EMEABodyText><span lang=EN-GB>Your doctor may check your kidney
function, blood pressure, and the amount of electrolytes (e.g. potassium) in
your blood at regular intervals.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>See also information under the heading
Do not take Karvea.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>You must tell your doctor if you think
you are (<u>or might become</u>) pregnant. Karvea is not recommended in early
pregnancy, and must not be taken if you are more than 3&nbsp;months pregnant,
as it may cause serious harm to your baby if used at that stage (see pregnancy
section).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>Children and adolescents</span></p>

<p class=EMEABodyText>This medicinal product should not be used in children and
adolescents because the safety and efficacy have not&nbsp;yet been&nbsp;fully
established.</p>

<p class=EMEAHeading3><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Other medicines and Karvea</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor or pharmacist if you
are taking, have recently taken or might take any other medicines.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Your doctor may need to change your dose
and/or to take other precautions:</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you are taking an ACE-inhibitor or aliskiren
(see also information under the headings Do not take Karvea and Warnings and
precautions).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>You may need to have blood checks if
you take:</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>potassium supplements</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>salt substitutes containing potassium</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>potassium-sparing medicines (such as certain diuretics)</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>medicines containing lithium</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>repaglinide (medication used for lowering blood sugar levels)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you take certain painkillers, called
non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Karvea with food and drink</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea can be taken with or without
food.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Pregnancy and breast-feeding</span></p>

<p class=EMEAHeading2><span lang=EN-GB>Pregnancy</span></p>

<p class=EMEABodyText><span lang=EN-GB>You must tell your doctor if you think
you are (<u>or might become</u>) pregnant. Your doctor will normally advise you
to stop taking Karvea before you become pregnant or as soon as you know you are
pregnant and will advise you to take another medicine instead of Karvea. Karvea
is not recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if used after
the third month of pregnancy.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEAHeading2><span lang=EN-GB>Breast-feeding</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor if you are
breast-feeding or about to start breast-feeding. Karvea is not recommended for
mothers who are breast-feeding, and your doctor may choose another treatment
for you if you wish to breast-feed, especially if your baby is newborn, or was
born prematurely.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Driving and using machines</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is unlikely to affect your
ability to drive or use machines. However, occasionally dizziness or weariness
may occur during treatment of high blood pressure. If you experience these,
talk to your doctor before attempting to drive or use machines.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Karvea contains lactose</span></b><span
lang=EN-GB>. If you have been told by your doctor that you have an intolerance
to some sugars (e.g. lactose), contact your doctor before taking this medicinal
product.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Karvea contains sodium. </span></b><span
lang=EN-GB>This medicine contains less than 1 mmol sodium (23 mg) per tablet,
that is to say essentially sodium-free.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>3. How to take Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Always take this medicine exactly as
your doctor has told you. Check with your doctor or pharmacist if you are not
sure.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Method of administration</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea is for <b>oral use</b>. Swallow
the tablets with a sufficient amount of fluid (e.g. one glass of water). You
can take Karvea with or without food. Try to take your daily dose at about the
same time each day. It is important that you continue to take Karvea until your
doctor tells you otherwise.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Patients with high blood pressure</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>The usual
dose is 150&nbsp;mg once a day. The dose may later be increased to 300&nbsp;mg
once daily depending on blood pressure response.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Patients with high blood pressure and type&nbsp;2 diabetes with
kidney disease</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>In patients
with high blood pressure and type&nbsp;2 diabetes, 300&nbsp;mg once daily is
the preferred maintenance dose for the treatment of associated kidney disease.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The doctor may advise a lower dose,
especially when starting treatment in certain patients such as those on <b>haemodialysis</b>,
or those <b>over the age of 75&nbsp;years.</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The maximal blood pressure lowering
effect should be reached 4-6&nbsp;weeks after beginning treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>Use in children and adolescents</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea should not be given to children
under 18&nbsp;years of age. If a child swallows some tablets, contact your
doctor immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>If you take more Karvea than you should:</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you accidentally take too many
tablets, contact your doctor immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>If you forget to take Karvea:</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you accidentally miss a daily dose,
just take the next dose as normal. Do not take a double dose to make up for a
forgotten dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>4. Possible side effects</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Like all medicines, this medicine can
cause side effects, although not everybody gets them.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Some of these effects may be serious and
may require medical attention.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>As with similar medicines, rare cases of
allergic skin reactions (rash, urticaria), as well as localised swelling of the
face, lips and/or tongue have been reported in patients taking irbesartan. If
you get any of these symptoms or get short of breath, <b>stop taking Karvea and
contact your doctor immediately.</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The frequency of the side effects listed
below is defined using the following convention:</span></p>

<p class=EMEABodyText><span lang=EN-GB>Very common: </span><span lang=EN-GB>may
affect more than 1 in 10 people</span></p>

<p class=EMEABodyText><span lang=EN-GB>Common: may affect up to 1 in 10 people</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uncommon: may affect up to 1 in 100
people</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Side effects reported in clinical
studies for patients treated with Karvea were:</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Very common (</span><span lang=EN-GB>may affect more than 1 in 10
people)</span><span lang=EN-GB>: if you suffer from high blood pressure and
type&nbsp;2 diabetes with kidney disease, blood tests may show an increased
level of potassium.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Common (</span><span lang=EN-GB>may affect up to 1 10 people)</span><span
lang=EN-GB>: dizziness, feeling sick/vomiting, fatigue and blood tests may show
raised levels of an enzyme that measures the muscle and heart function
(creatine kinase enzyme). In patients with high blood pressure and type&nbsp;2
diabetes with kidney disease, dizziness when getting up from a lying or sitting
position, low blood pressure when getting up from a lying or sitting position,
pain in joints or muscles and decreased levels of a protein in the red blood
cells (haemoglobin) were also reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Uncommon (</span><span lang=EN-GB>may affect up to 1 in 100 people)</span><span
lang=EN-GB>: heart rate increased, flushing, cough, diarrhoea, indigestion/heartburn,
sexual dysfunction (problems with sexual performance), chest pain.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Some undesirable effects have been reported
since marketing of Karvea. Undesirable effects where the frequency is not known
are: feeling of spinning, headache, taste disturbance, ringing in the ears, </span><span
lang=EN-GB>muscle cramps, </span><span lang=EN-GB>pain in joints and muscles, </span><span
lang=EN-GB>decreased number of red blood cells (anaemia  symptoms may include
tiredness, headaches, being short of breath when exercising, dizziness and
looking pale), </span><span lang=EN-GB>reduced number of platelets, abnormal
liver function, increased blood potassium levels, impaired kidney function, inflammation
of small blood vessels</span><span lang=EN-GB> </span><span lang=EN-GB>mainly
affecting the skin</span><span lang=EN-GB> (a condition known as
leukocytoclastic vasculitis),</span><span lang=EN-GB> </span>severe allergic
reactions (anaphylactic shock) <span lang=EN-GB>and </span><span lang=EN-GB>low
blood sugar levels. Uncommon cases of jaundice (yellowing of the skin and/or
whites of the eyes) have also been reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Reporting of side effects</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>If you get any side effects, talk to
your doctor or pharmacist. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span></span><span
class=MsoHyperlink><span lang=ES-TRAD style='background:silver;text-decoration:
none'>Appendix V</span></span><span lang=EN-GB>. By reporting side effects you
can help provide more information on the safety of this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>5. How to store Karvea</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not use this medicine after the
expiry date which is stated on the carton and on the blister after EXP. The
expiry date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not store above 30C.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines
you no longer use. These measures will help protect the environment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:none'>6. Contents of the pack and other information</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>What Karvea contains</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>The active substance is irbesartan. Each tablet of Karvea&nbsp;300&nbsp;mg
contains 300&nbsp;mg irbesartan.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'> </span><span
lang=EN-GB>The other ingredients are lactose monohydrate, microcrystalline
cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium
stearate, titanium dioxide, macrogol 3000, carnauba wax. </span>Please see
section 2 Karvea contains lactose.</p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>What Karvea looks like and contents of
the pack</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;300&nbsp;mg film-coated
tablets are white to off-white, biconvex, and oval-shaped with a heart debossed
on one side and the number&nbsp;2873 engraved on the other side.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Karvea&nbsp;300&nbsp;mg film-coated
tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or
98&nbsp;film-coated tablets. Unidose blister packs of
56&nbsp;x&nbsp;1&nbsp;film-coated tablet for delivery in hospitals are also
available.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=FR>Marketing Authorisation Holder:</span></p>

<p class=EMEAAddress><span lang=FR-BE>sanofi-aventis groupe<br>
54, rue La Botie<br>
F-75008 Paris</span><span lang=FR-BE> </span><span lang=FR-BE>-&nbsp;France</span></p>

<p class=EMEABodyText><span lang=FR-BE>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=FR>Manufacturer:</span></p>

<p class=EMEAAddress><span lang=FR-BE>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
1, rue de la Vierge<br>
Ambars &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex&nbsp;-&nbsp;France</span></p>

<p class=EMEAAddress><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
30-36&nbsp;Avenue Gustave Eiffel, BP&nbsp;7166<br>
F-37071&nbsp;Tours&nbsp;Cedex&nbsp;2&nbsp;-&nbsp;France</span></p>

<p class=EMEAAddress><span lang=FR>&nbsp;</span></p>

<p class=EMEAAddress><span lang=FR>CHINOIN PRIVATE CO. LTD.<br>
Lvai u.5.<br>
2112 Veresegyhz&nbsp;-&nbsp;Hungary</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=IT>SANOFI-AVENTIS, S.A.</span></p>

<p class=EMEABodyText><span lang=IT>Ctra. C-35 (La Batlloria-Hostalric), km.
63.09</span></p>

<p class=EMEABodyText><span lang=EN-GB>17404 Riells i Viabrea (Girona)  Spain</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For any information about this medicinal
product, please contact the local representative of the Marketing Authorisation
Holder.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Belgi/</span></b><b><span lang=CS>Belgique</span></b><b><span
  lang=MT>/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='layout-grid-mode:line'>Sanofi
  Belgium</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tl/Tel: <span style='layout-grid-mode:
  line'>+32 (0)2 710 54 00</span></span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=CS>UAB sanofi-aventis Lietuva</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +370 5 2755224</span></p>
  <p class=MsoNormal><span lang=FR-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Bulgaria EOOD</span></p>
  <p class=MsoNormal><span lang=BG>&#1058;&#1077;&#1083;</span><span lang=IT>.</span><span
  lang=BG>: +</span><span lang=IT>359 (0)2</span><span lang=IT> 970 53 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-LU>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='layout-grid-mode:line'>Sanofi
  Belgium </span></p>
  <p class=MsoNormal><span lang=FR-LU>Tl/Tel: </span><span lang=FR-BE
  style='layout-grid-mode:line'>+32 (0)2 710 54 00 (</span><span lang=FR-BE>Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=HU>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>&#268;esk republika</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis, s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +420 233 086 111</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=CS>SANOFI-AVENTIS Zrt.</span></p>
  <p class=MsoNormal><span lang=CS>Tel.: +36 1 </span><span lang=HU>505 0050</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Danmark</span></b></p>
  <p class=MsoNormal><span lang=CS>Sanofi A/S</span></p>
  <p class=MsoNormal><span lang=CS>Tlf: +45 45 16 70 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +39 02 39394275</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=CS>Sanofi-Aventis Deutschland GmbH</span></p>
  <p class=MsoNormal><span lang=CS>Tel: 0800 52 52 010</span></p>
  <p class=MsoNormal><span lang=CS>Tel. aus dem Ausland: +49 69 305 21 131</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Nederland</span></b></p>
  <p class=MsoNormal><span lang=CS>Genzyme Europe B.V.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +31 20 245 4000</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis Estonia O</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +372 627 34 88</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>Norge</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis Norge AS</span></p>
  <p class=MsoNormal><span lang=CS>Tlf: +47 67 10 71 00</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis AEBE</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;</span><span lang=CS>: +30
  210 900 16 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE>sanofi-aventis GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +43 1 80 185  0</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espaa</span></b></p>
  <p class=MsoNormal><span lang=PT>sanofi-aventis, S.A.</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +34 93 485 94 00</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Polska</span></b></p>
  <p class=MsoNormal><span lang=SV>sanofi-aventis Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=FR>Tel.: +48 22&nbsp;280 00 00</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>sanofi-aventis France</span></p>
  <p class=MsoNormal><span lang=PT>Tl: 0 800 222 555</span></p>
  <p class=MsoNormal><span lang=PT>Appel depuis ltranger : +33 1 57 63 23 23</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT>Sanofi - Produtos Farmacuticos, Lda</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +351 21 35 89 400</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=IT>sanofi-aventis Croatia d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +385 1 600 34 00</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Romnia</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Romania SRL</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +40 </span><span lang=IT>(0) 21 317 31
  36</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>Ireland</span></b></p>
  <p class=MsoNormal><span lang=FR>sanofi-aventis Ireland Ltd. T/A SANOFI</span></p>
  <p class=MsoNormal><span lang=FR>Tel: +353 (0) 1 403 56 00</span></p>
  <p class=MsoNormal><span lang=CS>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=CS>sanofi-aventis d.o.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +386 1 560 48 00</span></p>
  <p class=MsoNormal><span lang=SK>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS>sland</span></b></p>
  <p class=MsoNormal><span lang=CS>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Smi</span><span lang=CS>: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Slovensk republika</span></b></p>
  <p class=MsoNormal><span lang=SK>sanofi-</span><span lang=CS>aventis Slovakia
  </span><span lang=SK>s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +</span><span lang=SK>421 2 </span><span
  lang=EN-GB>33 100 100</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=IT>Tel: </span><span lang=FR>800 536389</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT>Sanofi Oy</span></p>
  <p class=MsoNormal><span lang=IT>Puh/Tel: +358 (0) 201 200 300</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=FR>sanofi-aventis Cyprus Ltd.</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: +</span><span lang=FR>357
  22 871600</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal><span lang=SV>Sanofi AB</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +46 (0)8 634 50 00</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT>sanofi-aventis Latvia SIA</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +371 67 33 24 51</span></p>
  <p class=MsoNormal><span lang=LV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=SV>Sanofi</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +44 (0) 845 372 7101</span></p>
  <p class=MsoNormal><span lang=LV>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu/</span><span
lang=EN-GB style='font-size:9.0pt;font-family:"Verdana",sans-serif'> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
